U.S. patent application number 13/488628 was filed with the patent office on 2013-02-21 for methods for making fully human bispecific antibodies using a common light chain.
This patent application is currently assigned to Regeneron Pharmaceuticals, Inc.. The applicant listed for this patent is Robert Babb, David R. Buckler, Samuel Davis, Karolina A. Hosiawa, Lynn MacDonald, John McWhirter, Andrew J. Murphy, Sean Stevens. Invention is credited to Robert Babb, David R. Buckler, Samuel Davis, Karolina A. Hosiawa, Lynn MacDonald, John McWhirter, Andrew J. Murphy, Sean Stevens.
Application Number | 20130045492 13/488628 |
Document ID | / |
Family ID | 47712903 |
Filed Date | 2013-02-21 |
United States Patent
Application |
20130045492 |
Kind Code |
A1 |
Babb; Robert ; et
al. |
February 21, 2013 |
Methods For Making Fully Human Bispecific Antibodies Using A Common
Light Chain
Abstract
A genetically modified mouse is provided, wherein the mouse
expresses an immunoglobulin light chain repertoire characterized by
a limited number of light chain variable domains. Mice are provided
that express just one or a few immunoglobulin light chain variable
domains from a limited repertoire in their germline. Methods for
making bispecific antibodies having universal light chains using
mice as described herein, including human light chain variable
regions, are provided. Methods for making human variable regions
suitable for use in multispecific binding proteins, e.g.,
bispecific antibodies, and host cells are provided. Bispecific
antibodies capable of binding first and second antigens are
provided, wherein the first and second antigens are separate
epitopes of a single protein or separate epitopes on two different
proteins are provided.
Inventors: |
Babb; Robert; (River Edge,
NJ) ; McWhirter; John; (Tarrytown, NY) ;
MacDonald; Lynn; (White Plains, NY) ; Stevens;
Sean; (San Francisco, CA) ; Davis; Samuel;
(New York, NY) ; Buckler; David R.; (Chester,
NJ) ; Hosiawa; Karolina A.; (Tarrytown, NY) ;
Murphy; Andrew J.; (Croton-on-Hudson, NY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Babb; Robert
McWhirter; John
MacDonald; Lynn
Stevens; Sean
Davis; Samuel
Buckler; David R.
Hosiawa; Karolina A.
Murphy; Andrew J. |
River Edge
Tarrytown
White Plains
San Francisco
New York
Chester
Tarrytown
Croton-on-Hudson |
NJ
NY
NY
CA
NY
NJ
NY
NY |
US
US
US
US
US
US
US
US |
|
|
Assignee: |
Regeneron Pharmaceuticals,
Inc.
Tarrytown
NY
|
Family ID: |
47712903 |
Appl. No.: |
13/488628 |
Filed: |
June 5, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13412936 |
Mar 6, 2012 |
|
|
|
13488628 |
|
|
|
|
13093156 |
Apr 25, 2011 |
|
|
|
13412936 |
|
|
|
|
13022759 |
Feb 8, 2011 |
|
|
|
13093156 |
|
|
|
|
61302282 |
Feb 8, 2010 |
|
|
|
Current U.S.
Class: |
435/7.92 ;
435/69.6; 436/501 |
Current CPC
Class: |
A01K 2267/01 20130101;
C07K 16/28 20130101; C07K 2317/565 20130101; C07K 2317/76 20130101;
C07K 2317/92 20130101; C07K 2317/31 20130101; A01K 67/0278
20130101; C07K 16/00 20130101; C07K 2317/515 20130101; C07K 2317/56
20130101; A01K 2207/15 20130101; C07K 2317/24 20130101; A01K
2227/105 20130101; A01K 2217/072 20130101; C07K 2319/30 20130101;
C12N 15/8509 20130101; A01K 2217/15 20130101; C07K 2317/21
20130101; C12N 2800/204 20130101; C07K 16/468 20130101; C07K
2317/567 20130101 |
Class at
Publication: |
435/7.92 ;
436/501; 435/69.6 |
International
Class: |
C12P 21/00 20060101
C12P021/00; G01N 21/64 20060101 G01N021/64; G01N 33/566 20060101
G01N033/566 |
Claims
1. A method for making a bispecific antigen-binding protein,
comprising exposing a first mouse that expresses a single human
immunoglobulin light chain to a first antigen of interest that
comprises a first epitope, exposing a second mouse that expresses a
single human immunoglobulin light chain to a second antigen of
interest that comprises a second epitope, allowing the first and
the second mouse to each mount immune responses to the antigens of
interest, identifying in the first mouse a first human heavy chain
variable region that binds the first epitope of the first antigen
of interest, identifying in the second mouse a second human heavy
chain variable region that binds the second epitope of the second
antigen of interest, making a first fully human heavy chain gene
that encodes a first heavy chain that binds the first epitope of
the first antigen of interest, making a second fully human heavy
chain gene that encodes a second heavy chain that binds the second
epitope of the second antigen of interest, expressing the first
heavy chain and the second heavy chain in a cell that expresses a
single fully human light chain to form a bispecific antigen-binding
protein, and isolating the bispecific antigen-binding protein.
2. The method of claim 1, wherein the single fully human light
chain is derived from a rearranged human V.kappa.1-39 or a human
V.kappa.3-20 gene segment.
3. The method of claim 1, wherein (a) the first antigen and the
second antigen are not identical; or (b) the first antigen and the
second antigen are identical, and the first epitope and the second
epitope are not identical.
4. The method of claim 1, wherein the human light chain when paired
with the first heavy chain specifically binds the first epitope of
the first antigen and when paired with the second heavy chain
specifically binds the second epitope of the second antigen.
5. The method of claim 1, wherein the first fully human heavy chain
gene bears an amino acid modification that reduces its affinity to
protein A, and the second fully human heavy chain does not comprise
a modification that reduces its affinity to protein A.
6. The method of claim 5, wherein the modification is selected from
a 95R (EUR 435R), 96F (EUR 436F), and a combination thereof.
7. The method of claim 1, wherein the human light chain of the cell
comprises a germline sequence.
8. A method for making a human bispecific antibody comprising a
step of employing in the bispecific antibody two human heavy chain
variable region sequences of two different B cells a mouse that
expresses a single human light chain variable domain.
9. The method of claim 8, wherein the single human light chain
variable domain comprises a rearranged human V.kappa.1-39 or human
V.kappa.3-20 gene segment.
10. The method of claim 8, wherein in the single human light chain
variable domain further comprises a rearranged human J.kappa.5 or
human J.kappa.1 gene segment.
11. The method of claim 8, wherein the mouse further comprises a
humanized heavy chain locus containing one or more unrearranged
human V.sub.H gene segments, one or more unrearranged human D.sub.H
gene segments, and one or more unrearranged human J.sub.H gene
segments, operably linked to one or more non-human heavy chain
constant region genes.
12. The method of claim 11, wherein the humanized heavy chain locus
comprises 80 unrearranged human V.sub.H gene segments, 27
unrearranged human D.sub.H gene segments and six unrearranged human
J.sub.H gene segments operably linked to one or more mouse heavy
chain constant region genes.
13. The method of claim 12, wherein the one or more human V.sub.H
gene segments comprises human V.sub.H1-2, V.sub.H1-8, V.sub.H1-24,
V.sub.H1-69, V.sub.H2-5, V.sub.H3-7, V.sub.H3-9, V.sub.H3-11,
V.sub.H3-13, V.sub.H3-15, V.sub.H3-20, V.sub.H3-23, V.sub.H3-30,
V.sub.H3-33, V.sub.H3-48, V.sub.H3-53, V.sub.H4-31, V.sub.H4-39,
V.sub.H4-59, V.sub.H5-51, V.sub.H6-1, or a combination thereof.
14. The method of claim 8, wherein the mouse does not contain an
endogenous light chain variable gene segment that is capable of
rearranging to form an immunoglobulin light chain.
15. A method of selecting two human immunoglobulin heavy chain
variable domains for use in a bispecific antibody comprising
immunizing a mouse with an antigen of interest, wherein the mouse
expresses a single human light chain variable domain, and wherein
the two human immunoglobulin heavy chain variable domains
independently associate with the single human light chain variable
domain to bind the antigen of interest.
16. The method of claim 15, wherein the single human light chain
variable domain is derived from a rearranged human V.kappa.1-39
gene segment.
17. The method of claim 16, wherein the single human light chain
variable domain further comprises a rearranged human J.kappa.5 gene
segment.
18. The method of claim 15, wherein the single human light chain
variable domain is derived from a rearranged human V.kappa.3-20
gene segment.
19. The method of claim 18, wherein the single human light chain
variable domain further comprises a rearranged human J.kappa.1 gene
segment.
20. The method of claim 15, wherein the mouse does not contain an
endogenous light chain variable gene segment that is capable of
rearranging to form an immunoglobulin light chain.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Ser. No.
13/412,936 filed Mar. 6, 2012, which is a continuation-in-part of
U.S. Ser. No. 13/093,156 filed Apr. 25, 2011, which is a
continuation-in-part of U.S. Ser. No. 13/022,759 filed Feb. 8,
2011, which is a nonprovisional application of U.S. Provisional
Application Ser. No. 61/302,282, filed Feb. 8, 2010; which
applications are hereby incorporated by reference in their
entirety.
FIELD
[0002] A genetically modified mouse is provided that expresses
antibodies having a common human variable/mouse constant light
chain associated with diverse human variable/mouse constant heavy
chains. A method for making a human bispecific antibody from human
variable region gene sequences of B cells of the mouse is
provided.
BACKGROUND
[0003] Antibodies typically comprise a homodimeric heavy chain
component, wherein each heavy chain monomer is associated with an
identical light chain. Antibodies having a heterodimeric heavy
chain component (e.g., bispecific antibodies) are desirable as
therapeutic antibodies. But making bispecific antibodies having a
suitable light chain component that can satisfactorily associate
with each of the heavy chains of a bispecific antibody has proved
problematic.
[0004] In one approach, a light chain might be selected by
surveying usage statistics for all light chain variable domains,
identifying the most frequently employed light chain in human
antibodies, and pairing that light chain in vitro with the two
heavy chains of differing specificity.
[0005] In another approach, a light chain might be selected by
observing light chain sequences in a phage display library (e.g., a
phage display library comprising human light chain variable region
sequences, e.g., a human scFv library) and selecting the most
commonly used light chain variable region from the library. The
light chain can then be tested on the two different heavy chains of
interest.
[0006] In another approach, a light chain might be selected by
assaying a phage display library of light chain variable sequences
using the heavy chain variable sequences of both heavy chains of
interest as probes. A light chain that associates with both heavy
chain variable sequences might be selected as a light chain for the
heavy chains.
[0007] In another approach, a candidate light chain might be
aligned with the heavy chains' cognate light chains, and
modifications are made in the light chain to more closely match
sequence characteristics common to the cognate light chains of both
heavy chains. If the chances of immunogenicity need to be
minimized, the modifications preferably result in sequences that
are present in known human light chain sequences, such that
proteolytic processing is unlikely to generate a T cell epitope
based on parameters and methods known in the art for assessing the
likelihood of immunogenicity (i.e., in silico as well as wet
assays).
[0008] All of the above approaches rely on in vitro methods that
subsume a number of a priori restraints, e.g., sequence identity,
ability to associate with specific pre-selected heavy chains, etc.
There is a need in the art for compositions and methods that do not
rely on manipulating in vitro conditions, but that instead employ
more biologically sensible approaches to making human
epitope-binding proteins that include a common light chain.
SUMMARY
[0009] Genetically modified mice that express human immunoglobulin
heavy and light chain variable domains, wherein the mice have a
limited light chain variable repertoire, are provided. A biological
system for generating a human light chain variable domain that
associates and expresses with a diverse repertoire of
affinity-matured human heavy chain variable domains is provided.
Methods for making binding proteins comprising immunoglobulin
variable domains are provided, comprising immunizing mice that have
a limited immunoglobulin light chain repertoire with an antigen of
interest, and employing an immunoglobulin variable region gene
sequence of the mouse in a binding protein that specifically binds
the antigen of interest. Methods include methods for making human
immunoglobulin heavy chain variable domains suitable for use in
making multi-specific antigen-binding proteins.
[0010] Genetically engineered mice are provided that select
suitable affinity-matured human immunoglobulin heavy chain variable
domains derived from a repertoire of unrearranged human heavy chain
variable region gene segments, wherein the affinity-matured human
heavy chain variable domains associate and express with a single
human light chain variable domain derived from one human light
chain variable region gene segment. Genetically engineered mice
that present a choice of two human light chain variable region gene
segments are also provided. In various aspects, the one or two gene
segments include human V.kappa.1-39 and human V.kappa.3-20.
[0011] Genetically engineered mice are provided that express a
limited repertoire of human light chain variable domains, or a
single human light chain variable domain, from a limited repertoire
of human light chain variable region gene segments. The mice are
genetically engineered to include a single unrearranged human light
chain variable region gene segment (or two human light chain
variable region gene segments) that rearranges to form a rearranged
human light chain variable region gene (or two rearranged light
chain variable region genes) that express a single light chain (or
that express either or both of two light chains). The rearranged
human light chain variable domains are capable of pairing with a
plurality of affinity-matured human heavy chains selected by the
mice, wherein the heavy chain variable regions specifically bind
different epitopes.
[0012] Genetically engineered mice are provided that express a
limited repertoire of human light chain variable domains, or a
single human light chain variable domain, from a limited repertoire
of human light chain variable region sequences. The mice are
genetically engineered to include a single V/J human light chain
sequence (or two V/J sequences) that express a variable region of a
single light chain (or that express either or both of two variable
regions). A light chain comprising the variable sequence is capable
of pairing with a plurality of affinity-matured human heavy chains
clonally selected by the mice, wherein the heavy chain variable
regions specifically bind different epitopes.
[0013] In one aspect, a genetically modified mouse is provided that
comprises a single human immunoglobulin light chain variable
(V.sub.L) region gene segment that is capable of rearranging with a
human J gene segment (selected from one or a plurality of J.sub.L
segments) and encoding a human V.sub.L domain of an immunoglobulin
light chain. In another aspect, the mouse comprises no more than
two human V.sub.L gene segments, each of which is capable of
rearranging with a human J gene segment (selected from one or a
plurality of J.sub.L segments) and encoding a human V.sub.L domain
of an immunoglobulin light chain.
[0014] In one embodiment, the single human V.sub.L gene segment is
operably linked to a human J.sub.L gene segment selected from
J.kappa.1, J.kappa.2, J.kappa.3, J.kappa.4, and J.kappa.5, wherein
the single human V.sub.L gene segment is capable of rearranging to
form a sequence encoding a light chain variable region gene with
any of the one or more human J.sub.L gene segments.
[0015] In one embodiment, the genetically modified mouse comprises
an immunoglobulin light chain locus that does not comprise an
endogenous mouse V.sub.L gene segment that is capable of
rearranging to form an immunoglobulin light chain gene, wherein the
V.sub.L locus comprises a single human V.sub.L gene segment that is
capable of rearranging to encode a V.sub.L region of a light chain
gene. In a specific embodiment, the human V.sub.L gene segment is a
human V.kappa.1-39J.kappa.5 gene segment or a human
V.kappa.3-20J.kappa.1 gene segment. In one embodiment, the
genetically modified mouse comprises a V.sub.L locus that does not
comprise an endogenous mouse V.sub.L gene segment that is capable
of rearranging to form an immunoglobulin light chain gene, wherein
the V.sub.L locus comprises no more than two human V.sub.L gene
segments that are capable of rearranging to encode a V.sub.L region
of a light chain gene. In a specific embodiment, the no more than 2
human V.sub.L gene segments are a human V.kappa.1-39J.kappa.5 gene
segment and a human V.kappa.3-20J.kappa.1 gene segment.
[0016] In one aspect, a genetically modified mouse is provided that
comprises a single rearranged (V/J) human immunoglobulin light
chain variable (V.sub.L) region (i.e., a V.sub.L/J.sub.L region)
that encodes a human V.sub.L domain of an immunoglobulin light
chain. In another aspect, the mouse comprises no more than two
rearranged human V.sub.L regions that are capable of encoding a
human V.sub.L domain of an immunoglobulin light chain.
[0017] In one embodiment, the V.sub.L region is a rearranged human
V.kappa.1-39/J sequence or a rearranged human V.kappa.3-20/J
sequence. In one embodiment, the human J.sub.L segment of the
rearranged V.sub.L/J.sub.L sequence is selected from J.kappa.1,
J.kappa.2, J.kappa.3, J.kappa..sub.4, and J.kappa.5. In a specific
embodiment, the V.sub.L region is a human V.kappa.1-39J.kappa.5
sequence or a human V.kappa.3-20J.kappa.1 sequence. In a specific
embodiment, the mouse has both a human V.kappa.1-39J.kappa.5
sequence and a human V.kappa.3-20J.kappa.1 sequence.
[0018] In one embodiment, the human V.sub.L gene segment is
operably linked to a human or mouse leader sequence. In one
embodiment, the leader sequence is a mouse leader sequence. In a
specific embodiment, the mouse leader sequence is a mouse
V.kappa.3-7 leader sequence. In a specific embodiment, the leader
sequence is operably linked to an unrearranged human V.sub.L gene
segment. In a specific embodiment, the leader sequence is operably
linked to a rearranged human V.sub.L/J.sub.L sequence.
[0019] In one embodiment, the V.sub.L gene segment is operably
linked to an immunoglobulin promoter sequence. In one embodiment,
the promoter sequence is a human promoter sequence. In a specific
embodiment, the human immunoglobulin promoter is a human
V.kappa.3-15 promoter. In a specific embodiment, the promoter is
operably linked to an unrearranged human V.sub.L gene segment. In a
specific embodiment, the promoter is operably linked to a
rearranged human V.sub.L/J.sub.L sequence.
[0020] In one embodiment, the light chain locus comprises a leader
sequence flanked 5' (with respect to transcriptional direction of a
V.sub.L gene segment) with a human immunoglobulin promoter and
flanked 3' with a human V.sub.L gene segment that rearranges with a
human J segment and encodes a V.sub.L domain of a reverse chimeric
light chain comprising an endogenous mouse light chain constant
region (C.sub.L). In a specific embodiment, the V.sub.L gene
segment is at the mouse V.kappa. locus, and the mouse C.sub.L is a
mouse C.kappa..
[0021] In one embodiment, the light chain locus comprises a leader
sequence flanked 5' (with respect to transcriptional direction of a
V.sub.L gene segment) with a human immunoglobulin promoter and
flanked 3' with a rearranged human V.sub.L region (V.sub.L/J.sub.L
sequence) and encodes a V.sub.L domain of a reverse chimeric light
chain comprising an endogenous mouse light chain constant region
(C.sub.L). In a specific embodiment, the rearranged human
V.sub.L/J.sub.L sequence is at the mouse kappa (.kappa.) locus, and
the mouse C.sub.L is a mouse C.kappa..
[0022] In one embodiment, the V.sub.L locus of the modified mouse
is a .kappa. light chain locus, and the .kappa. light chain locus
comprises a mouse .kappa. intronic enhancer, a mouse .kappa.3'
enhancer, or both an intronic enhancer and a 3' enhancer.
[0023] In one embodiment, the mouse comprises a nonfunctional
immunoglobulin lambda (.lamda.) light chain locus. In a specific
embodiment, the .lamda. light chain locus comprises a deletion of
one or more sequences of the locus, wherein the one or more
deletions renders the .lamda. light chain locus incapable of
rearranging to form a light chain gene. In another embodiment, all
or substantially all of the V.sub.L gene segments of the .lamda.
light chain locus are deleted.
[0024] In one embodiment, mouse makes a light chain that comprises
a somatically mutated V.sub.L domain derived from a human V.sub.L
gene segment. In one embodiment, the light chain comprises a
somatically mutated V.sub.L domain derived from a human V.sub.L
gene segment, and a mouse C.kappa. region. In one embodiment, the
mouse does not express a .lamda. light chain.
[0025] In one embodiment, the genetically modified mouse is capable
of somatically hypermutating the human V.sub.L region sequence. In
a specific embodiment, the mouse comprises a cell that comprises a
rearranged immunoglobulin light chain gene derived from a human
V.sub.L gene segment that is capable of rearranging and encoding a
V.sub.L domain, and the rearranged immunoglobulin light chain gene
comprises a somatically mutated V.sub.L domain.
[0026] In one embodiment, the mouse comprises a cell that expresses
a light chain comprising a somatically mutated human V.sub.L domain
linked to a mouse C.kappa., wherein the light chain associates with
a heavy chain comprising a somatically mutated V.sub.H domain
derived from a human V.sub.H gene segment and wherein the heavy
chain comprises a mouse heavy chain constant region (C.sub.H). In a
specific embodiment, the heavy chain comprises a mouse C.sub.H1, a
mouse hinge, a mouse C.sub.H2, and a mouse C.sub.H3. In a specific
embodiment, the heavy chain comprises a human C.sub.H1, a hinge, a
mouse C.sub.H2, and a mouse C.sub.H3.
[0027] In one embodiment, the mouse comprises a replacement of
endogenous mouse V.sub.H gene segments with one or more human
V.sub.H gene segments, wherein the human V.sub.H gene segments are
operably linked to a mouse C.sub.H region gene, such that the mouse
rearranges the human V.sub.H gene segments and expresses a reverse
chimeric immunoglobulin heavy chain that comprises a human V.sub.H
domain and a mouse C.sub.H. In one embodiment, 90-100% of
unrearranged mouse V.sub.H gene segments are replaced with at least
one unrearranged human V.sub.H gene segment. In a specific
embodiment, all or substantially all of the endogenous mouse
V.sub.H gene segments are replaced with at least one unrearranged
human V.sub.H gene segment. In one embodiment, the replacement is
with at least 19, at least 39, or at least 80 or 81 unrearranged
human V.sub.H gene segments. In one embodiment, the replacement is
with at least 12 functional unrearranged human V.sub.H gene
segments, at least 25 functional unrearranged human V.sub.H gene
segments, or at least 43 functional unrearranged human V.sub.H gene
segments. In one embodiment, the mouse comprises a replacement of
all mouse D.sub.H and J.sub.H segments with at least one
unrearranged human D.sub.H segment and at least one unrearranged
human J.sub.H segment. In one embodiment, the at least one
unrearranged human D.sub.H segment is selected from 1-1, D1-7,
1-26, 2-8, 2-15, 3-3, 3-10, 3-16, 3-22, 5-5, 5-12, 6-6, 6-13, 7-27,
and a combination thereof. In one embodiment, the at least one
unrearranged human J.sub.H segment is selected from 1, 2, 3, 4, 5,
6, and a combination thereof. In a specific embodiment, the one or
more human V.sub.H gene segment is selected from a 1-2, 1-8, 1-24,
1-69, 2-5, 3-7, 3-9, 3-11, 3-13, 3-15, 3-20, 3-23, 3-30, 3-33,
3-48, 3-53, 4-31, 4-39, 4-59, 5-51, a 6-1 human V.sub.H gene
segment, and a combination thereof.
[0028] In one embodiment, the mouse comprises a B cell that
expresses a binding protein that specifically binds an antigen of
interest, wherein the binding protein comprises a light chain
derived from a human V.kappa.1-39/J.kappa.5 rearrangement or a
human V.kappa.3-20/J.kappa.1 rearrangement, and wherein the cell
comprises a rearranged immunoglobulin heavy chain gene derived from
a rearrangement of human V.sub.H gene segments selected from a
1-69, 2-5, 3-13, 3-23, 3-30, 3-33, 3-53, 4-39, 4-59, and 5-51 gene
segment. In one embodiment, the one or more human V.sub.H gene
segments are rearranged with a human heavy chain J.sub.H gene
segment selected from 1, 2, 3, 4, 5, and 6. In one embodiment, the
one or more human V.sub.H and J.sub.H gene segments are rearranged
with a human D.sub.H gene segment selected from 1-1, 1-7, 1-26,
2-8, 2-15, 3-3, 3-10, 3-16, 3-22, 5-5, 5-12, 6-6, 6-13, and 7-27.
In a specific embodiment, the light chain gene has 1, 2, 3, 4, or 5
or more somatic hypermutations.
[0029] In one embodiment, the mouse comprises a B cell that
comprises a rearranged immunoglobulin heavy chain variable region
gene sequence comprising a V.sub.H/D.sub.H/J.sub.H region selected
from 2-5/6-6/1, 2-5/3-22/1, 3-13/6-6/5, 3-23/2-8/4, 3-23/3-3/4,
3-23/3-10/4, 3-23/6-6/4, 3-23/7-27/4, 3-30/1-1/4, 3-30/1-7/4,
3-30/3-3/3, 3-30/3-3/4, 3-30/3-22/5, 3-30/5-5/2, 3-30/5-12/4,
3-30/6-6/1, 3-30/6-6/3, 3-30/6-6/4, 3-30/6-6/5, 3-30/6-13/4,
3-30/7-27/4, 3-30/7-27/5, 3-30/7-27/6, 3-33/1-7/4, 3-33/2-15/4,
4-39/1-26/3, 4-59/3-16/3, 4-59/3-16/4, 4-59/3-22/3, 5-51/3-16/6,
5-51/5-5/3, 5-51/6-13/5, 3-53/1-1/4, 1-69/6-6/5, and 1-69/6-13/4.
In a specific embodiment, the B cell expresses a binding protein
comprising a human immunoglobulin heavy chain variable region fused
with a mouse heavy chain constant region, and a human
immunoglobulin light chain variable region fused with a mouse light
chain constant region.
[0030] In one embodiment, the rearranged human V.sub.L region is a
human V.kappa.1-39J.kappa.5 sequence, and the mouse expresses a
reverse chimeric light chain comprising (i) a V.sub.L domain
derived from the human V.sub.L/J.sub.L sequence and (ii) a mouse
C.sub.L; wherein the light chain is associated with a reverse
chimeric heavy chain comprising (i) a mouse C.sub.H and (ii) a
somatically mutated human V.sub.H domain derived from a human
V.sub.H gene segment selected from a 1-2, 1-8, 1-24, 1-69, 2-5,
3-7, 3-9, 3-11, 3-13, 3-15, 3-20, 3-23, 3-30, 3-33, 3-48, 3-53,
4-31, 4-39, 4-59, 5-51, a 6-1 human V.sub.H gene segment, and a
combination thereof. In one embodiment, the mouse expresses a light
chain that is somatically mutated. In one embodiment the C.sub.L is
a mouse C.kappa.. In a specific embodiment, the human V.sub.H gene
segment is selected from a 2-5, 3-13, 3-23, 3-30, 4-59, 5-51, and
1-69 gene segment. In a specific embodiment, the somatically
mutated human V.sub.H domain comprises a sequence derived from a
D.sub.H segment selected from 1-1, 1-7, 2-8, 3-3, 3-10, 3-16, 3-22,
5-5, 5-12, 6-6, 6-13, and 7-27. In a specific embodiment, the
somatically mutated human V.sub.H domain comprises a sequence
derived from a J.sub.H segment selected from 1, 2, 3, 4, 5, and 6.
In a specific embodiment, the somatically mutated human V.sub.H
domain is encoded by a rearranged human V.sub.H/D.sub.H/J.sub.H
sequence selected from 2-5/6-6/1, 2-5/3-22/1, 3-13/6-6/5,
3-23/2-8/4, 3-23/3-3/4, 3-23/3-10/4, 3-23/6-6/4, 3-23/7-27/4,
3-30/1-1/4, 3-30/1-7/4, 3-30/3-3/4, 3-30/3-22/5, 3-30/5-5/2,
3-30/5-12/4, 3-30/6-6/1, 3-30/6-6/3, 3-30/6-6/4, 3-30/6-6/5,
3-30/6-13/4, 3-30/7-27/4, 3-30/7-27/5, 3-30/7-27/6, 4-59/3-16/3,
4-59/3-16/4, 4-59/3-22/3, 5-51/5-5/3, 1-69/6-6/5, and
1-69/6-13/4.
[0031] In one embodiment, the rearranged human V.sub.L region is a
human V.kappa.3-20J.kappa.1 sequence, and the mouse expresses a
reverse chimeric light chain comprising (i) a V.sub.L domain
derived from the rearranged human V.sub.L/J.sub.L sequence, and
(ii) a mouse C.sub.L; wherein the light chain is associated with a
reverse chimeric heavy chain comprising (i) a mouse C.sub.H, and
(ii) a somatically mutated human V.sub.H derived from a human
V.sub.H gene segment selected from a 1-2, 1-8, 1-24, 1-69, 2-5,
3-7, 3-9, 3-11, 3-13, 3-15, 3-20, 3-23, 3-30, 3-33, 3-48, 3-53,
4-31, 4-39, 4-59, 5-51, a 6-1 human V.sub.H gene segment, and a
combination thereof. In one embodiment, the mouse expresses a light
chain that is somatically mutated. In one embodiment the C.sub.L is
a mouse C.kappa.. In a specific embodiment, the human V.sub.H gene
segment is selected from a 3-30, 3-33, 3-53, 4-39, and 5-51 gene
segment. In a specific embodiment, the somatically mutated human
V.sub.H domain comprises a sequence derived from a D.sub.H segment
selected from 1-1, 1-7, 1-26, 2-15, 3-3, 3-16, and 6-13. In a
specific embodiment, the somatically mutated human V.sub.H domain
comprises a sequence derived from a J.sub.H segment selected from
3, 4, 5, and 6. In a specific embodiment, the somatically mutated
human V.sub.H domain is encoded by a rearranged human
V.sub.H/D.sub.H/J.sub.H sequence selected from 3-30/1-1/4,
3-30/3-3/3, 3-33/1-7/4, 3-33/2-15/4, 4-39/1-26/3, 5-51/3-16/6,
5-51/6-13/5, and 3-53/1-1/4.
[0032] In one embodiment, the mouse comprises both a rearranged
human V.kappa.1-39J.kappa.5 sequence and a rearranged human
V.kappa.3-20J.kappa.1 sequence, and the mouse expresses a reverse
chimeric light chain comprising (i) a V.sub.L domain derived from
the human V.kappa.1-39J.kappa.5 sequence or the human
V.kappa.3-20J.kappa.1 sequence, and (ii) a mouse C.sub.L; wherein
the light chain is associated with a reverse chimeric heavy chain
comprising (i) a mouse C.sub.H, and (ii) a somatically mutated
human V.sub.H derived from a human V.sub.H gene segment selected
from a 1-2, 1-8, 1-24, 1-69, 2-5, 3-7, 3-9, 3-11, 3-13, 3-15, 3-20,
3-23, 3-30, 3-33, 3-48, 3-53, 4-31, 4-39, 4-59, 5-51, a 6-1 human
V.sub.H gene segment, and a combination thereof. In one embodiment,
the mouse expresses a light chain that is somatically mutated. In
one embodiment the C.sub.L is a mouse C.kappa..
[0033] In one embodiment, 90-100% of the endogenous unrearranged
mouse V.sub.H gene segments are replaced with at least one
unrearranged human V.sub.H gene segment. In a specific embodiment,
all or substantially all of the endogenous unrearranged mouse
V.sub.H gene segments are replaced with at least one unrearranged
human V.sub.H gene segment. In one embodiment, the replacement is
with at least 18, at least 39, at least 80, or 81 unrearranged
human V.sub.H gene segments. In one embodiment, the replacement is
with at least 12 functional unrearranged human V.sub.H gene
segments, at least 25 functional unrearranged human V.sub.H gene
segments, or at least 43 unrearranged human V.sub.H gene
segments.
[0034] In one embodiment, the genetically modified mouse is a C57BL
strain, in a specific embodiment selected from C57BL/A, C57BL/An,
C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6NJ,
C57BL/10, C57BL/10ScSn, C57BL/10Cr, and C57BL/Ola. In a specific
embodiment, the genetically modified mouse is a mix of an
aforementioned 129 strain and an aforementioned C57BL/6 strain. In
another specific embodiment, the mouse is a mix of aforementioned
129 strains, or a mix of aforementioned BL/6 strains. In a specific
embodiment, the 129 strain of the mix is a 129S6 (129/SvEvTac)
strain.
[0035] In one embodiment, the mouse expresses a reverse chimeric
antibody comprising a light chain that comprises a mouse C.kappa.
and a somatically mutated human V.sub.L domain derived from a
rearranged human V.kappa.1-39J.kappa.5 sequence or a rearranged
human V.kappa.3-20J.kappa.1 sequence, and a heavy chain that
comprises a mouse C.sub.H and a somatically mutated human V.sub.H
domain derived from a human V.sub.H gene segment selected from a
1-2, 1-8, 1-24, 1-69, 2-5, 3-7, 3-9, 3-11, 3-13, 3-15, 3-20, 3-23,
3-30, 3-33, 3-48, 3-53, 4-31, 4-39, 4-59, 5-51, and a 6-1 human
V.sub.H gene segment, wherein the mouse does not express a fully
mouse antibody and does not express a fully human antibody. In one
embodiment the mouse comprises a .kappa. light chain locus that
comprises a replacement of endogenous mouse .kappa. light chain
gene segments with the rearranged human V.kappa.1-39J.kappa.5
sequence or the rearranged human V.kappa.3-20J.kappa.1 sequence,
and comprises a replacement of all or substantially all endogenous
mouse V.sub.H gene segments with a complete or substantially
complete repertoire of human V.sub.H gene segments.
[0036] In one aspect, a population of antigen-specific antibodies
derived from a mouse as described herein is provided, wherein the
antibodies comprise a light chain gene derived from a human
V.kappa.1-39J.kappa.5 rearrangement or a human
V.kappa.3-20J.kappa.1 rearrangement, and wherein the antibodies
comprise a rearranged immunoglobulin heavy chain gene derived from
a rearrangement of a human V.sub.H gene segment selected from a
1-2, 1-3, 1-8, 1-18, 1-24, 1-46, 1-58, 1-69, 2-5, 2-26, 2-70, 3-7,
3-9, 3-11, 3-13, 3-15, 3-16, 3-20, 3-21, 3-23, 3-30, 3-33, 3-43,
3-48, 3-53, 3-64, 3-72, 3-73, 4-31, 4-34, 4-39, 4-59, 5-51, and a
6-1 human V.sub.H gene segment. In one embodiment, the one or more
human V.sub.H gene segments are rearranged with a human heavy chain
J.sub.H gene segment selected from 1, 2, 3, 4, 5, and 6. In a
specific embodiment, the light chain has 1, 2, 3, 4, or 5 or more
somatic hypermutations.
[0037] In one embodiment, the light chain has 1, 2, 3, or 4 somatic
hypermutations. In one embodiment, the light chain gene has 1 or 2
mutations. In various embodiments, the light chain gene is capable
of incurring multiple mutations along its sequence.
[0038] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and the light chain has at
least one or no more than four somatic hypermutations. In one
embodiment, the light chain comprises at least two somatic
hypermutations. In one embodiment, the light chain comprises at
least three somatic hypermutations. In one embodiment, the light
chain comprises at least four somatic hypermutations. In a specific
embodiment, the mutations are present in one or more framework
regions (FWs) of the light chain. In a specific embodiment, the
mutations are present in one or more complementarity determining
regions (CDRs) of the light chain. In a specific embodiment, the
mutations are present in one or more FWs and/or one or more CDRs of
the light chain. In various embodiments, the framework regions are
selected from framework 1 (FW1), framework 2 (FW2), framework 3
(FW3), and/or a combination thereof. In various embodiments, the
CDRs are selected from CDR1, CDR2, CDR3, and/or a combination
thereof.
[0039] In one embodiment, the heavy chain comprises at least one
mutation in one or more FWs or one or more CDRs. In one embodiment,
the heavy chain comprises at least one mutation in one or more FWs
and one or more CDRs. In one embodiment, the heavy chain comprises
at least two mutations in one or more FWs and one or more CDRs. In
one embodiment, the heavy chain comprises at least three mutations
in one or more FWs and one or more CDRs. In one embodiment, the
heavy chain comprises at least four mutations in one or more FWs
and one or more CDRs. In one embodiment, the heavy chain comprises
at least five or more than five mutations in one or more FWs and
one or more CDRs; in a specific embodiment, the heavy chain
comprises at least five or more than five mutations in two FWs; in
a specific embodiment, the heavy chain comprises at least five or
more than five mutations in one FW and one CDR.
[0040] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 9% of the
V.kappa.1-39/J.kappa.5-derived light chains have at least one
mutation present in FW1; in one embodiment, at least 9% of the
light chains comprise one mutation present in FW1. In one
embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 25% of the
V.kappa.1-39/J.kappa.5-derived light chains have at least one or no
more than two mutations present in CDR1; in one embodiment, at
least 19% of the light chains have one mutation present in CDR1; in
one embodiment, at least 5% of the light chains have two mutations
present in CDR1.
[0041] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 20% of the
V.kappa.1-39/J.kappa.5-derived light chains have at least one or no
more than three mutations present in FW2; in one embodiment, at
least 17% of the light chains have one mutation present in FW2; in
one embodiment, at least 1% of the light chains have two mutations
present in FW2; in one embodiment, at least 1% of the light chains
have three mutations present in FW2.
[0042] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 10% of the
V.kappa.1-39/J.kappa.5-derived light chains have at least one or no
more than two mutations present in CDR2; in one embodiment, at
least 10% of the light chains have one mutation present in CDR2; in
one embodiment, at least 1% of the light chains have two mutations
present in CDR2.
[0043] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 29% of the
V.kappa.1-39/J.kappa.5-derived light chains have at least one or no
more than four mutations present in FW3; in one embodiment, at
least 21% of the light chains have one mutation present in FW3; in
one embodiment, at least 5% of the light chains have two mutations
present in FW3; in one embodiment, at least 2% of the light chains
have three mutations present in FW3; in one embodiment, at least 2%
of the light chains have four mutations present in FW3.
[0044] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 37% of the
V.kappa.1-39/J.kappa.5-derived light chains have at least one or no
more than four mutations present in CDR3; in one embodiment, at
least 27% of the light chains have one mutation present in CDR3; in
one embodiment, at least 8% of the light chains have two mutations
present in CDR3; in one embodiment, at least 1% of the light chains
have three mutations present in CDR3; in one embodiment, at least
1% of the light chains have four mutations present in CDR3.
[0045] In one embodiment, a population of antigen-specific
antibodies derived from a mouse as described herein is provided,
wherein the antibodies comprise a light chain derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 9% of the
V.kappa.1-39/J.kappa.5-derived light chains have one or more
mutations present in FW1, about 25% of the
V.kappa.1-39/J.kappa.5-derived light chains have one or more
mutations present in CDR1, about 20% of the
V.kappa.1-39/J.kappa.5-derived light chains have one or more
mutations present in FW2, about 10% of the
V.kappa.1-39/J.kappa.5-derived light chains have one or more
mutations present in CDR2, about 29% of the
V.kappa.1-39/J.kappa.5-derived light chains have one or more
mutations present in FW3, and about 37% of the
V.kappa.1-39/J.kappa.5-derived light chains have one or more
mutations present in CDR3.
[0046] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 35% of the heavy
chains have at least one mutation present in FW1; in one
embodiment, at least 25% of the heavy chains have one mutation
present in FW1; in one embodiment, at least 9% of the heavy chains
have two mutations present in FW1; in one embodiment, at least 1%
of the heavy chains have three mutations present in FW1; in one
embodiment, at least 1% of the heavy chains have more than five
mutations present in FW1.
[0047] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 92% of the heavy
chains have at least one or no more than four mutations present in
CDR1; in one embodiment, at least 92% of the heavy chains have at
least one, at least two, at least three, or at least four mutations
present in CDR1; in one embodiment, at least 26% of the heavy
chains have one mutation present in CDR1; in one embodiment, at
least 44% of the heavy chains have two mutations present in CDR1;
in one embodiment, at least 19% of the heavy chains have three
mutations present in CDR1; in one embodiment, at least 3% of the
heavy chains have four mutations present in CDR1.
[0048] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 66% of the heavy
chains have at least one or no more than three mutations present in
FW2; in one embodiment, at least 66% of the heavy chains have at
least one, at least two, or at least three mutations present in
FW2; in one embodiment, at least 35% of the heavy chains have one
mutation present in FW2; in one embodiment, at least 23% of the
heavy chains have two mutations present in FW2; in one embodiment,
at least 8% of the heavy chains have three mutations present in
FW2.
[0049] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 70% of the heavy
chains have at least one or no more than four mutations present in
CDR2; in one embodiment, at least 70% of the heavy chains have at
least two, at least three, or at least four mutations present in
CDR2; in one embodiment, at least 34% have one mutation present in
CDR2; in one embodiment, at least 20% of the heavy chains have two
mutations present in CDR2; in one embodiment, at least 12% of the
heavy chains have three mutations present in CDR2; in one
embodiment, at least 5% of the heavy chains have four mutations
present in CDR2.
[0050] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 91% of the heavy
chains have at least one or up to five or more mutations present in
FW3; in one embodiment, at least 91% of the heavy chains have at
least two, at least three, at least four, or at least five or more
mutations present in FW3; in one embodiment, at least 19% of the
heavy chains have one mutation present in FW3; in one embodiment,
at least 33% of the heavy chains have two mutations present in FW3;
in one embodiment, at least 22% of the heavy chains have three
mutations present in FW3; in one embodiment, at least 11% of the
heavy chains have four mutations present in FW3; in one embodiment,
at least 7% of the heavy chains have five or more mutations present
in FW3.
[0051] In one embodiment, the light chain is derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and about 63% of the heavy
chains have at least one or no more than two mutations present in
CDR3; in one embodiment, at least 63% of the heavy chains have at
one mutation present in CDR3; in one embodiment, at least 54% of
the heavy chains have one mutation present in CDR3; in one
embodiment, at least 9% of the heavy chains have two mutations
present in CDR3.
[0052] In one embodiment, a population of antigen-specific
antibodies derived from a mouse as described herein is provided,
wherein the antibodies comprise a light chain derived from a human
V.kappa.1-39/J.kappa.5 rearrangement and at least 35% of the heavy
chains have one or more mutations present in FW1, about 92% of the
heavy chains have one or more mutations present in CDR1, about 66%
of the heavy chains have one or more mutations present in FW2,
about 70% of the heavy chains have one or more mutations present in
CDR2, about 91% of the heavy chains have one or more mutations
present in FW3, and about 63% of the heavy chains have one or more
mutations present in CDR3.
[0053] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and the light chain gene has
at least one or no more than two somatic hypermutations; in one
embodiment, the light chain gene has at least two, at least three,
at least four or more somatic hypermutations. In a specific
embodiment, the mutations are present in one or more framework
regions of the light chain. In a specific embodiment, the mutations
are present in one or more CDR regions of the light chain. In a
specific embodiment, the mutations are present in one or more
framework regions and/or one or more CDR regions of the light
chain. In various embodiments, the framework regions are selected
from framework 1 (FW1), framework 2 (FW2), framework 3 (FW3),
and/or a combination thereof.
[0054] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 10% of the
V.kappa.3-20/J.kappa.1-derived light chains have at least one
mutation present in FW1; in one embodiment, at least 10% of the
light chains have one mutation in FW1.
[0055] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 53% of the
V.kappa.3-20/J.kappa.1-derived light chains have at least one or no
more than two mutations present in CDR1; in one embodiment, at
least 27% of the light chains have one or more mutations in CDR1;
in one embodiment, about 54% of the light chains have one or two
mutations present in CDR1.
[0056] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 6% of the
V.kappa.3-20/J.kappa.1-derived light chains have at least one or no
more than two mutations present in FW2; in one embodiment, at least
6% of light chains have at least one mutation present in FW2; in
one embodiment, at least 3% of the light chains have one mutation
present in FW2; in one embodiment, at least 3% of the light chains
have two mutations present in FW2.
[0057] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and at least about 3% of the
V.kappa.3-20/J.kappa.1-derived light chains have at least one
mutation present in CDR2; in one embodiment, at least 3% of the
light chains have one mutation in CDR2.
[0058] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 17% or more of the
V.kappa.3-20/J.kappa.1-derived light chains have at least one or no
more than two mutations present in FW3; in one embodiment, at least
20% of the light chain have one mutation present in FW3; in one
embodiment, at least 17% of the light chains have two mutations
present in FW3.
[0059] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and at least 43% of the
V.kappa.3-20/J.kappa.1-derived light chains have at least one
mutation present in CDR3; in one embodiment, at least 43% of the
light chains have one mutation in CDR3.
[0060] In one embodiment, a population of antigen-specific
antibodies derived from a mouse as described herein is provided,
wherein the antibodies comprise a light chain derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 10% of the
V.kappa.3-20/J.kappa.1-derived light chains have one or more
mutations present in at least, about 53% of the
V.kappa.3-20/J.kappa.1-derived light chains have one or more
mutations present in CDR1, about 6% of the
V.kappa.3-20/J.kappa.1-derived light chains have one or more
mutations present in FW2, about 3% of the
V.kappa.3-20/J.kappa.1-derived light chains have one or more
mutations present in CDR2, about 37% of the
V.kappa.3-20/J.kappa.1-derived light chains have one or more
mutations present in FW3, and about 43% of the
V.kappa.3-20/J.kappa.1-derived light chains have one or more
mutations present in CDR3.
[0061] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 43% of the heavy
chains have at least one or no more than two mutations present in
FW1; in one embodiment, at least 41% of the heavy chains have at
least one mutation present in FW1; in one embodiment, about 41% of
the heavy chains have one mutation present in FW1; in one
embodiment, about 2% of the heavy chains have two mutations present
in FW1.
[0062] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 92% of the heavy
chains have at least one or no more than four mutations present in
CDR1; in one embodiment, at least 43% of heavy chains have at least
one mutation present in CDR1; in one embodiment, at least 25% of
heavy chains have at least two mutations present in CDR1; in one
embodiment, at least 15% of heavy chains have at least 3 mutations
present in CDR1; in one embodiment, at least 10% of heavy chains
have 4 or more mutations present in CDR1.
[0063] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 46% of the heavy
chains have at least one or no more than three mutations present in
FW2; in one embodiment, at least 34% of heavy chains have at least
one mutation present in FW2; in one embodiment, at least 10% of
heavy chains have two or more mutations present in FW2; in one
embodiment, at least 2% of heavy chains have three or more
mutations present in FW2.
[0064] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 84% of the heavy
chains have at least one or up to five or more than five mutations
present in CDR2; in one embodiment, at least 39% of the heavy
chains have one or more mutations present in CDR2; in one
embodiment, at least 18% of the heavy chains have two or more
mutations present in CDR2; in one embodiment, at least 21% of the
heavy chains have three or more mutations present in CDR2; in one
embodiment, at least 3% of the heavy chains have four or more
mutations present in CDR2; in one embodiment, at least 2% of the
heavy chains have five or more mutations present in CDR2.
[0065] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 92% of the heavy
chains have at least one or up to five or more than five mutations
present in FW3; in one embodiment, at least 21% of the light chains
have at least one mutation present in FW3; in one embodiment, at
least 20% of heavy chains have at least two mutations present in
FW3; in one embodiment, at least 13% of the heavy chains have at
least three mutations present in FW3; in one embodiment, at least
20% of the heavy chains have at least four mutations in FW3; in one
embodiment, at least 18% of the heavy chains have at least 5
mutations in FW3.
[0066] In one embodiment, the light chain is derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 7% of the heavy
chains have at least one mutation present in CDR3; in one
embodiment, about 7% of the heavy chains have one mutation in
CDR3.
[0067] In one embodiment, a population of antigen-specific
antibodies derived from a mouse as described herein is provided,
wherein the antibodies comprise a light chain derived from a human
V.kappa.3-20/J.kappa.1 rearrangement and about 43% of the heavy
chains have one or more mutations present in FW1, about 92% of the
heavy chains have one or more mutations present in CDR1, about 46%
of the heavy chains have one or more mutations present in FW2,
about 84% of the heavy chains have one or more mutations present in
CDR2, about 92% of the heavy chains have one or more mutations
present in FW3, and about 7% of the heavy chains have one or more
mutations present in CDR3.
[0068] In one aspect, a mouse that expresses an immunoglobulin
light chain from a rearranged immunoglobulin light chain sequence
is provided, wherein the rearranged immunoglobulin light chain
sequence is present in the germline of the mouse, wherein the
immunoglobulin light chain comprises a human variable sequence. In
one embodiment, the germline of the mouse comprises a rearranged
immunoglobulin light chain sequence that is derived from the same V
segment and the same J segment as all non-surrogate light chain
sequences present in every B cell of the mouse that comprises a
rearranged light chain sequence.
[0069] In one embodiment, the germline of the mouse lacks a
functional unrearranged immunoglobulin light chain V gene segment.
In one embodiment, the germline of the mouse lacks a functional
unrearranged immunoglobulin light chain J gene segment.
[0070] In one embodiment, the germline of the mouse comprises no
more than one, no more than two, or no more than three rearranged
(V/J) light chain sequences.
[0071] In one embodiment, the rearranged V/J sequence comprises a
.kappa. light chain sequence. In a specific embodiment, the .kappa.
light chain sequence is a human .kappa. light chain sequence. In a
specific embodiment, the .kappa. light chain sequence is selected
from a human V.kappa.1-39/J sequence, a human V.kappa.3-20/J
sequence, and a combination thereof. In a specific embodiment, the
.kappa. light chain sequence is a human V.kappa.1-39/J.kappa.5
sequence. In a specific embodiment, the .kappa. light chain
sequence is a human V.kappa.3-20/J.kappa.1 sequence.
[0072] In one embodiment, the mouse further comprises in its
germline a sequence selected from a mouse .kappa. intronic enhancer
5' with respect to the rearranged immunoglobulin light chain
sequence, a mouse .kappa.3' enhancer, and a combination
thereof.
[0073] In one embodiment, the mouse comprises an unrearranged human
V.sub.H gene segment, an unrearranged human D.sub.H gene segment,
and an unrearranged human J.sub.H gene segment, wherein said
V.sub.H, D.sub.H, and J.sub.H gene segments are capable of
rearranging to form an immunoglobulin heavy chain variable gene
sequence operably linked to a heavy chain constant gene sequence.
In one embodiment, the mouse comprises a plurality of human
V.sub.H, D.sub.H, and J.sub.H gene segments. In a specific
embodiment, the human V.sub.H, D.sub.H, and J.sub.H gene segments
replace endogenous mouse V.sub.H, D.sub.H, and J.sub.H gene
segments at the endogenous mouse immunoglobulin heavy chain locus.
In a specific embodiment, the mouse comprises a replacement of all
or substantially all functional mouse V.sub.H, D.sub.H, and J.sub.H
gene segments with all or substantially all functional human
V.sub.H, D.sub.H, and J.sub.H gene segments.
[0074] In one embodiment, the mouse expresses an immunoglobulin
light chain that comprises a mouse constant sequence. In one
embodiment, the mouse expresses an immunoglobulin light chain that
comprises a human constant sequence.
[0075] In one embodiment, the mouse expresses an immunoglobulin
heavy chain that comprises a mouse sequence selected from a
C.sub.H1 sequence, a hinge sequence, a C.sub.H2 sequence, a
C.sub.H3 sequence, and a combination thereof.
[0076] In one embodiment, the mouse expresses an immunoglobulin
heavy chain that comprises a human sequence selected from a
C.sub.H1 sequence, a hinge sequence, a C.sub.H2 sequence, a
C.sub.H3 sequence, and a combination thereof.
[0077] In one embodiment, the rearranged immunoglobulin light chain
sequence in the germline of the mouse is at an endogenous mouse
immunoglobulin light chain locus. In a specific embodiment, the
rearranged immunoglobulin light chain sequence in the germline of
the mouse replaces all or substantially all mouse light chain V and
J sequences at the endogenous mouse immunoglobulin light chain
locus.
[0078] In one aspect, a mouse is provided that comprises a B cell
population characterized by each B cell that comprises a
non-surrogate light chain sequence comprises a rearranged light
chain gene that is derived from a single human V segment and a
single human J segment, wherein the only light chain variable
sequence in the germline of the mouse is a rearranged sequence
derived from the single human V segment and the single human J
segment, and wherein each B ell that comprises the rearranged light
chain gene further comprises a gene encoding a cognate human heavy
chain variable domain, and wherein the rearranged light chain gene
comprises at least one, at least two, at least three, or at least
four somatic hypermutations.
[0079] In one aspect, a pluripotent, induced pluripotent, or
totipotent cell derived from a mouse as described herein is
provided. In a specific embodiment, the cell is a mouse embryonic
stem (ES) cell.
[0080] In one aspect, a tissue derived from a mouse as described
herein is provided. In one embodiment, the tissue is derived from
spleen, lymph node or bone marrow of a mouse as described
herein.
[0081] In one aspect, a nucleus derived from a mouse as described
herein is provided. In one embodiment, the nucleus is from a
diploid cell that is not a B cell.
[0082] In one aspect, a mouse cell is provided that is isolated
from a mouse as described herein. In one embodiment, the cell is an
ES cell. In one embodiment, the cell is a lymphocyte. In one
embodiment, the lymphocyte is a B cell. In one embodiment, the B
cell expresses a chimeric heavy chain comprising a variable domain
derived from a human gene segment; and a light chain derived from a
rearranged human V.kappa.1-39/J sequence, rearranged human
V.kappa.3-20/J sequence, or a combination thereof; wherein the
heavy chain variable domain is fused to a mouse constant region and
the light chain variable domain is fused to a mouse or a human
constant region.
[0083] In one aspect, a hybridoma is provided, wherein the
hybridoma is made with a B cell of a mouse as described herein. In
a specific embodiment, the B cell is from a mouse as described
herein that has been immunized with an immunogen comprising an
epitope of interest, and the B cell expresses a binding protein
that binds the epitope of interest, the binding protein has a
somatically mutated human V.sub.H domain and a mouse C.sub.H, and
has a human V.sub.L domain derived from a rearranged human
V.kappa.1-39J.kappa.5 or a rearranged human V.kappa.3-20J.kappa.1
and a mouse C.sub.L.
[0084] In one aspect, a mouse embryo is provided, wherein the
embryo comprises a donor ES cell that is derived from a mouse as
described herein.
[0085] In one aspect, a targeting vector is provided, comprising,
from 5' to 3' in transcriptional direction with reference to the
sequences of the 5' and 3' mouse homology arms of the vector, a 5'
mouse homology arm, a human or mouse immunoglobulin promoter, a
human or mouse leader sequence, and a human V.sub.L region selected
from a rearranged human V.kappa.1-39J.kappa.5 or a rearranged human
V.kappa.3-20J.kappa.1, and a 3' mouse homology arm. In one
embodiment, the 5' and 3' homology arms target the vector to a
sequence 5' with respect to an enhancer sequence that is present 5'
and proximal to the mouse C.kappa. gene. In one embodiment, the
promoter is a human immunoglobulin variable region gene segment
promoter. In a specific embodiment, the promoter is a human
V.kappa.3-15 promoter. In one embodiment, the leader sequence is a
mouse leader sequence. In a specific embodiment, the mouse leader
sequence is a mouse V.kappa.3-7 leader sequence.
[0086] In one aspect, a targeting vector is provided as described
above, but in place of the 5' mouse homology arm the human or mouse
promoter is flanked 5' with a site-specific recombinase recognition
site (SRRS), and in place of the 3' mouse homology arm the human
V.sub.L region is flanked 3' with an SRRS.
[0087] In one aspect, a reverse chimeric antibody made by a mouse
as described herein, wherein the reverse chimeric antibody
comprises a light chain comprising a human V.sub.L and a mouse
C.sub.L, and a heavy chain comprising a human V.sub.H and a mouse
C.sub.H.
[0088] In one aspect, a method for making an antibody is provided,
comprising expressing in a single cell (a) a first V.sub.H gene
sequence of an immunized mouse as described herein fused with a
human C.sub.H gene sequence; (b) a V.sub.L gene sequence of an
immunized mouse as described herein fused with a human C.sub.L gene
sequence; and, (c) maintaining the cell under conditions sufficient
to express a fully human antibody, and isolating the antibody. In
one embodiment, the cell comprises a second V.sub.H gene sequence
of a second immunized mouse as described herein fused with a human
C.sub.H gene sequence, the first V.sub.H gene sequence encodes a
V.sub.H domain that recognizes a first epitope, and the second
V.sub.H gene sequence encodes a V.sub.H domain that recognizes a
second epitope, wherein the first epitope and the second epitope
are not identical.
[0089] In one aspect, a method for making an epitope-binding
protein is provided, comprising exposing a mouse as described
herein with an immunogen that comprises an epitope of interest,
maintaining the mouse under conditions sufficient for the mouse to
generate an immunoglobulin molecule that specifically binds the
epitope of interest, and isolating the immunoglobulin molecule that
specifically binds the epitope of interest; wherein the
epitope-binding protein comprises a heavy chain that comprises a
somatically mutated human V.sub.H and a mouse C.sub.H, associated
with a light chain comprising a mouse C.sub.L and a human V.sub.L
derived from a rearranged human V.kappa.1-39J.kappa.5 or a
rearranged human V.kappa.3-20J.kappa.1.
[0090] In one aspect, a cell that expresses an epitope-binding
protein is provided, wherein the cell comprises: (a) a human
nucleotide sequence encoding a human V.sub.L domain that is derived
from a rearranged human V.kappa.1-39J.kappa.5 or a rearranged human
V.kappa.3-20J.kappa.1, wherein the human nucleotide sequence is
fused (directly or through a linker) to a human immunoglobulin
light chain constant domain cDNA sequence (e.g., a human .kappa.
constant domain DNA sequence); and, (b) a first human V.sub.H
nucleotide sequence encoding a human V.sub.H domain derived from a
first human V.sub.H nucleotide sequence, wherein the first human
V.sub.H nucleotide sequence is fused (directly or through a linker)
to a human immunoglobulin heavy chain constant domain cDNA
sequence; wherein the epitope-binding protein recognizes a first
epitope. In one embodiment, the epitope-binding protein binds the
first epitope with a dissociation constant of lower than 10.sup.-6
M, lower than 10.sup.-8M, lower than 10.sup.-9 M, lower than
10.sup.-10 M, lower than 10.sup.-11 M, or lower than 10.sup.-12
M.
[0091] In one embodiment, the cell comprises a second human
nucleotide sequence encoding a second human V.sub.H domain, wherein
the second human sequence is fused (directly or through a linker)
to a human immunoglobulin heavy chain constant domain cDNA
sequence, and wherein the second human V.sub.H domain does not
specifically recognize the first epitope (e.g., displays a
dissociation constant of, e.g., 10.sup.-6 M, 10.sup.-5 M, 10.sup.-4
M, or higher), and wherein the epitope-binding protein recognizes
the first epitope and the second epitope, and wherein the first and
the second immunoglobulin heavy chains each associate with an
identical light chain of (a).
[0092] In one embodiment, the second V.sub.H domain binds the
second epitope with a dissociation constant that is lower than
10.sup.-6 M, lower than 10.sup.-7 M, lower than 10.sup.-8 M, lower
than 10.sup.-9 M, lower than 10.sup.-10 M, lower than 10.sup.-11 M,
or lower than 10.sup.-12 M.
[0093] In one embodiment, the epitope-binding protein comprises a
first immunoglobulin heavy chain and a second immunoglobulin heavy
chain, each associated with an identical light chain derived from a
rearranged human V.sub.L region selected from a human
V.kappa.1-39J.kappa.5 or a human V.kappa.3-20J.kappa.1, wherein the
first immunoglobulin heavy chain binds a first epitope with a
dissociation constant in the nanomolar to picomolar range, the
second immunoglobulin heavy chain binds a second epitope with a
dissociation constant in the nanomolar to picomolar range, the
first epitope and the second epitope are not identical, the first
immunoglobulin heavy chain does not bind the second epitope or
binds the second epitope with a dissociation constant weaker than
the micromolar range (e.g., the millimolar range), the second
immunoglobulin heavy chain does not bind the first epitope or binds
the first epitope with a dissociation constant weaker than the
micromolar range (e.g., the millimolar range), and one or more of
the V.sub.L, the V.sub.H of the first immunoglobulin heavy chain,
and the V.sub.H of the second immunoglobulin heavy chain, are
somatically mutated.
[0094] In one embodiment, the first immunoglobulin heavy chain
comprises a protein A-binding residue, and the second
immunoglobulin heavy chain lacks the protein A-binding residue.
[0095] In one embodiment, the cell is selected from CHO, COS, 293,
HeLa, and a retinal cell expressing a viral nucleic acid sequence
(e.g., a PERC.6.TM. cell).
[0096] In one aspect, a reverse chimeric antibody is provided,
comprising a human V.sub.H and a mouse heavy chain constant domain,
a human V.sub.L and a mouse light chain constant domain, wherein
the antibody is made by a process that comprises immunizing a mouse
as described herein with an immunogen comprising an epitope, and
the antibody specifically binds the epitope of the immunogen with
which the mouse was immunized. In one embodiment, the V.sub.L
domain is somatically mutated. In one embodiment the V.sub.H domain
is somatically mutated. In one embodiment, both the V.sub.L domain
and the V.sub.H domain are somatically mutated. In one embodiment,
the V.sub.L is linked to a mouse C.kappa. domain.
[0097] In one aspect, a mouse is provided, comprising human V.sub.H
gene segments replacing all or substantially all mouse V.sub.H gene
segments at the endogenous mouse heavy chain locus; no more than
one or two rearranged human light chain V.sub.L/J.sub.L sequences
selected from a rearranged V.kappa.1-39/J and a rearranged
V.kappa.3-20/J or a combination thereof, replacing all mouse light
chain gene segments; wherein the human heavy chain variable gene
segments are linked to a mouse constant gene, and the rearranged
human light chain sequences are linked to a human or mouse constant
gene.
[0098] In one aspect, a mouse ES cell comprising a replacement of
all or substantially all mouse heavy chain variable gene segments
with human heavy chain variable gene segments, and no more than one
or two rearranged human light chain V.sub.L/J.sub.L sequences,
wherein the human heavy chain variable gene segments are linked to
a mouse immunoglobulin heavy chain constant gene, and the
rearranged human light chain V.sub.L/J.sub.L sequences are linked
to a mouse or human immunoglobulin light chain constant gene. In a
specific embodiment, the light chain constant gene is a mouse
constant gene.
[0099] In one aspect, an antigen-binding protein made by a mouse as
described herein is provided. In a specific embodiment, the
antigen-binding protein comprises a human immunoglobulin heavy
chain variable region fused with a mouse constant region, and a
human immunoglobulin light chain variable region derived from a
V.kappa.1-39 gene segment or a V.kappa.3-20 gene segment, wherein
the light chain constant region is a mouse constant region.
[0100] In one aspect, a fully human antigen-binding protein made
from an immunoglobulin variable region gene sequence from a mouse
as described herein is provided, wherein the antigen-binding
protein comprises a fully human heavy chain comprising a human
variable region derived from a sequence of a mouse as described
herein, and a fully human light chain comprising a V.kappa.1-39 or
a V.kappa.3-20. In one embodiment, the light chain variable region
comprises one to five somatic mutations. In one embodiment, the
light chain variable region is a cognate light chain variable
region that is paired in a B cell of the mouse with the heavy chain
variable region.
[0101] In one embodiment, the fully human antigen-binding protein
comprises a first heavy chain and a second heavy chain, wherein the
first heavy chain and the second heavy chain comprise non-identical
variable regions independently derived from a mouse as described
herein, and wherein each of the first and second heavy chains
express from a host cell associated with a human light chain
derived from a V.kappa.1-39 gene segment or a V.kappa.3-20 gene
segment. In one embodiment, the first heavy chain comprises a first
heavy chain variable region that specifically binds a first epitope
of a first antigen, and the second heavy chain comprises a second
heavy chain variable region that specifically binds a second
epitope of a second antigen. In a specific embodiment, the first
antigen and the second antigen are different. In a specific
embodiment, the first antigen and the second antigen are the same,
and the first epitope and the second epitope are not identical; in
a specific embodiment, binding of the first epitope by a first
molecule of the binding protein does not block binding of the
second epitope by a second molecule of the binding protein.
[0102] In one aspect, a fully human binding protein derived from a
human immunoglobulin sequence of a mouse as described herein
comprises a first immunoglobulin heavy chain and a second
immunoglobulin heavy chain, wherein the first immunoglobulin heavy
chain comprises a first variable region that is not identical to a
variable region of the second immunoglobulin heavy chain, and
wherein the first immunoglobulin heavy chain comprises a wild type
protein A binding determinant, and the second heavy chain lacks a
wild type protein A binding determinant. In one embodiment, the
first immunoglobulin heavy chain binds protein A under isolation
conditions, and the second immunoglobulin heavy chain does not bind
protein A or binds protein A at least 10-fold, a hundred-fold, or a
thousand-fold weaker than the first immunoglobulin heavy chain
binds protein A under isolation conditions. In a specific
embodiment, the first and the second heavy chains are IgG1
isotypes, wherein the second heavy chain comprises a modification
selected from 95R (EU 435R), 96F (EU 436F), and a combination
thereof, and wherein the first heavy chain lacks such
modification.
[0103] In one aspect, a method for making a bispecific
antigen-binding protein is provided, comprising exposing a first
mouse as described herein to a first antigen of interest that
comprises a first epitope, exposing a second mouse as described
herein to a second antigen of interest that comprises a second
epitope, allowing the first and the second mouse to each mount
immune responses to the antigens of interest, identifying in the
first mouse a first human heavy chain variable region that binds
the first epitope of the first antigen of interest, identifying in
the second mouse a second human heavy chain variable region that
binds the second epitope of the second antigen of interest, making
a first fully human heavy chain gene that encodes a first heavy
chain that binds the first epitope of the first antigen of
interest, making a second fully human heavy chain gene that encodes
a second heavy chain that binds the second epitope of the second
antigen of interest, expressing the first heavy chain and the
second heavy chain in a cell that expresses a single fully human
light chain derived from a human V.kappa.1-39 or a human
V.kappa.3-20 gene segment to form a bispecific antigen-binding
protein, and isolating the bispecific antigen-binding protein.
[0104] In one embodiment, the first antigen and the second antigen
are not identical.
[0105] In one embodiment, the first antigen and the second antigen
are identical, and the first epitope and the second epitope are not
identical. In one embodiment, binding of the first heavy chain
variable region to the first epitope does not block binding of the
second heavy chain variable region to the second epitope.
[0106] In one embodiment, the human light chain when paired with
the first heavy chain specifically binds the first epitope of the
first antigen and when paired the second heavy chain specifically
binds the second epitope of the second antigen.
[0107] In one embodiment, the first antigen is selected from a
soluble antigen and a cell surface antigen (e.g., a tumor antigen),
and the second antigen comprises a cell surface receptor. In a
specific embodiment, the cell surface receptor is an immunoglobulin
receptor. In a specific embodiment, the immunoglobulin receptor is
an Fc receptor. In one embodiment, the first antigen and the second
antigen are the same cell surface receptor, and binding of the
first heavy chain to the first epitope does not block binding of
the second heavy chain to the second epitope.
[0108] In one embodiment, the light chain variable domain of the
light chain comprises 2 to 5 somatic mutations. In one embodiment,
the light chain variable domain is a somatically mutated cognate
light chain expressed in a B cell of the first or the second
immunized mouse with either the first or the second heavy chain
variable domain. In one embodiment, the light chain of the cell
comprises a germline sequence.
[0109] In one embodiment, the first fully human heavy chain bears
an amino acid modification that reduces its affinity to protein A,
and the second fully human heavy chain does not comprise a
modification that reduces its affinity to protein A.
[0110] In one aspect, a method of preparing a bispecific antibody
that specifically binds to a first and a second antigen is
provided, wherein the method comprises (a) identifying a first
nucleic acid sequence that encodes a first human heavy chain
variable (V.sub.H) domain that is specific for the first antigen;
(b) identifying a second nucleic acid sequence that encodes a
second human heavy chain variable (V.sub.H) domain that is specific
for the second antigen; (c) providing a third nucleic acid sequence
that encodes a human light chain variable (V.sub.L) region which,
when paired with the V.sub.H region of (a) specifically binds the
first antigen, and when paired with the V.sub.H region of (b)
specifically binds to the second antigen; (d) culturing a host cell
comprising the first, second, and third nucleic acid sequences to
allow expression of the first and second human V.sub.H regions and
the human V.sub.L region to form the bispecific antibody; and (d)
recovering said bispecific antibody. In various aspects, the first
and second antigens are different from one another. In various
aspects the first and second nucleic acid sequences are isolated
from an immunized mouse that expresses a human immunoglobulin
V.sub.L region from a rearranged immunoglobulin light chain
sequence, wherein the rearranged immunoglobulin sequence is in the
germline of the mouse.
[0111] In one embodiment, the human V.sub.L region is derived from
a rearranged human light chain sequence comprising a human
V.kappa.1-39 gene segment or a human V.kappa.3-20 gene segment. In
a specific embodiment, the rearranged human light chain sequence is
a germline sequence (i.e., does not comprise a somatic
hypermutation within the V gene segment sequence).
[0112] In one embodiment, the third nucleic acid sequence is
isolated from a mouse that expresses a human immunoglobulin V.sub.L
region from a rearranged immunoglobulin light chain sequence in the
germline of the mouse. In one embodiment, the rearranged
immunoglobulin light chain sequence comprises a human V.kappa.1-39
or human V.kappa.3-20 gene segment. In a specific embodiment, the
rearranged immunoglobulin light chain sequence comprises a human
V.kappa.1-39 gene segment. In one embodiment, the human
immunoglobulin V.sub.L region is expressed from a modified
endogenous immunoglobulin light chain locus.
[0113] In one embodiment, the first and second antigens are present
on one molecule. In one embodiment, the first and second antigens
are present on different molecules. In various embodiments, the
first or second nucleic acid sequence comprises a modification that
reduces the affinity of the encoded heavy chain to protein A.
[0114] In one embodiment, the first or second nucleic acid
sequences comprise a rearranged human heavy chain variable region
sequence comprising a human heavy chain gene segment selected from
V.sub.H1-2, V.sub.H1-3, V.sub.H1-8, V.sub.H1-18, V.sub.H1-24,
V.sub.H1-46, V.sub.H1-58, V.sub.H1-69, V.sub.H2-5, V.sub.H2-26,
V.sub.H2-70, V.sub.H3-7, V.sub.H3-9, V.sub.H3-11, V.sub.H3-13,
V.sub.H3-15, V.sub.H3-20, V.sub.H3-21, V.sub.H3-23, V.sub.H3-30,
V.sub.H3-33, V.sub.H3-43, V.sub.H3-48, V.sub.H3-53, V.sub.H3-64,
V.sub.H3-72, V.sub.H3-73, V.sub.H4-31, V.sub.H4-34, V.sub.H4-39,
V.sub.H4-59, V.sub.H5-51, and V.sub.H6-1. In a specific embodiment,
the heavy chain gene segment is V.sub.H2-5, V.sub.H3-23 or
V.sub.H3-30.
[0115] In one aspect, a method of preparing a bispecific antibody
that specifically binds to a first and a second antigen is
provided, wherein the method comprises (a) identifying a first
nucleic acid sequence that encodes a first human heavy chain
variable (V.sub.H) domain that is specific for the first antigen;
(b) identifying a second nucleic acid sequence that encodes a
second human heavy chain variable (V.sub.H) domain that is specific
for the second antigen; (c) providing a third nucleic acid sequence
that encodes a human light chain variable (V.sub.L) region derived
from a human V.kappa.1-39 or human V.kappa.3-20 gene segment which,
when paired with the V.sub.H region of (a) specifically binds the
first antigen, and when paired with the V.sub.H region of (b)
specifically binds to the second antigen; (d) culturing a host cell
comprising the first, second, and third nucleic acid sequences to
allow expression of the first and second human V.sub.H regions and
the human V.sub.L region to form the bispecific antibody; and (d)
recovering said bispecific antibody. In various aspects, the first
and second antigens are different from one another. In various
aspects, the first and second nucleic acid sequences are isolated
from an immunized mouse that expresses a human immunoglobulin
V.sub.L region from a rearranged immunoglobulin sequence that is
derived from a human V.kappa.1-39 or human V.kappa.3-20 gene
segment, wherein the rearranged human V.kappa.1-39 or V.kappa.3-30
gene segment is in the germline of the mouse.
[0116] In one embodiment, the third nucleic acid sequence is a
germline sequence (i.e., does not comprise a somatic hypermutation
within the V gene segment sequence). In one embodiment, the third
nucleic acid sequence is isolated from the mouse that expresses a
human immunoglobulin V.sub.L region derived from a human
V.kappa.1-39 or human V.kappa.3-20 gene segment from a rearranged
immunoglobulin light chain sequence in the germline of the mouse.
In a specific embodiment, the third nucleic acid sequence comprises
two to five somatic hypermutations in a complementary determining
region (CDR) and/or a framework region (FWR). In one embodiment,
the human immunoglobulin V.sub.L region is expressed from a
modified endogenous immunoglobulin light chain locus.
[0117] In one embodiment, the first and second antigens are present
on one molecule. In one embodiment, the first and second antigens
are present on different molecules. In one embodiment, the first or
second nucleic acid sequence comprises a modification that reduces
the affinity of the encoded heavy chain to protein A.
[0118] In one embodiment, the first or second nucleic acid
sequences comprise a rearranged human heavy chain variable region
sequence comprising a human heavy chain gene segment selected from
V.sub.H1-2, V.sub.H1-3, V.sub.H1-8, V.sub.H1-18, V.sub.H1-24,
V.sub.H1-46, V.sub.H1-58, V.sub.H1-69, V.sub.H2-5, V.sub.H2-26,
V.sub.H2-70, V.sub.H3-7, V.sub.H3-9, V.sub.H3-11, V.sub.H3-13,
V.sub.H3-15, V.sub.H3-20, V.sub.H3-21, V.sub.H3-23, V.sub.H3-30,
V.sub.H3-33, V.sub.H3-43, V.sub.H3-48, V.sub.H3-53, V.sub.H3-64,
V.sub.H3-72, V.sub.H3-73, V.sub.H4-31, V.sub.H4-34, V.sub.H4-39,
V.sub.H4-59, V.sub.H5-51, and V.sub.H6-1. In a specific embodiment,
the heavy chain gene segment is V.sub.H2-5, V.sub.H3-23 or
V.sub.H3-30.
[0119] In one aspect, a method for making a bispecific antibody is
provided, comprising exposing a mouse as described herein to an
antigen of interest, allowing the mouse to mount an immune response
to the antigen of interest, identifying a first human heavy chain
variable region that binds a first epitope of the antigen of
interest, identifying a second human heavy chain variable region
that binds a second epitope of the antigen of interest, making a
first fully human heavy chain gene that encodes the first heavy
chain that binds the first epitope of the antigen of interest,
making a second fully human heavy chain gene that encodes a second
heavy chain that binds the second epitope of the antigen of
interest, expressing the first heavy chain and the second heavy
chain in a cell that expresses a single fully human light chain
derived from a human V.kappa.-39 or a human V.kappa.3-20 gene
segment to form a bispecific antibody, and isolating the bispecific
antigen-binding protein.
[0120] In one embodiment, the first epitope and the second epitope
are not identical. In one embodiment, binding of the first heavy
chain variable region to the first epitope does not block binding
of the second heavy chain variable region to the second epitope. In
one embodiment, the first and second heavy chains are capable of
binding the first and second epitopes simultaneously.
[0121] In one embodiment, the bispecific antibody binds the first
and second epitopes simultaneously. In one embodiment, the
bispecific antibody binds the first epitope and second epitope
independently.
[0122] In one embodiment, the binding response of the bispecific
antibody to the antigen is about 2-fold higher than the binding
response of the first heavy chain variable region to the antigen.
In one embodiment, the binding response of the bispecific antibody
to the antigen is about 2-fold higher than the binding response of
the second heavy chain variable region to the antigen. In one
embodiment, the binding response of the bispecific antibody to the
antigen is about the same as, or about equal to, the binding
response of the first heavy chain variable region and or the second
heavy chain variable region to the antigen.
[0123] In one embodiment, the antigen is selected from a soluble
antigen, a cell surface antigen (e.g., a tumor antigen) and a cell
surface receptor. In a specific embodiment, the cell surface
receptor is an immunoglobulin receptor. In a specific embodiment,
the immunoglobulin receptor is an Fc receptor.
[0124] In one embodiment, the light chain variable domain of the
light chain comprises 2 to 5 somatic mutations. In one embodiment,
the light chain variable domain is a somatically mutated cognate
light chain expressed in a B cell of the immunized mouse with
either the first or the second heavy chain variable domain.
[0125] In one embodiment, the first fully human heavy chain bears
an amino acid modification that reduces its affinity to protein A,
and the second fully human heavy chain does not comprise a
modification that reduces its affinity to protein A.
[0126] In various embodiments, methods for making bispecific
antibodies are enhanced by employing a common light chain to pair
with each heavy chain variable regions of the bispecific
antibodies. In various embodiments, employing a common light chain
as described herein reduces the number of inappropriate species of
immunoglobulins lacking bispecificity as compared to employing
original cognate light chains. In various embodiments, the heavy
chain variable regions of the bispecific antibodies are identified
from monospecific antibodies comprising a common light chain. In
various embodiments, the heavy chain variable regions of the
bispecific antibodies comprise human heavy chain variable gene
segments that are rearranged in vivo within mouse B cells that have
been previously engineered to express a limited human light chain
repertoire, or a single human light chain, cognate with human heavy
chains and, in response to exposure with an antigen of interest,
generate a chimeric antibody repertoire containing a plurality of
human heavy chain variable regions that are cognate with one or one
of two possible human light chain variable regions, wherein the
chimeric antibodies are specific for the antigen of interest.
[0127] In various aspects, a method of preparing a bispecific
antibody is provided, the bispecific antibody comprising 1) a first
polypeptide and a second polypeptide, wherein the first and second
polypeptides each include a multimerization domain (e.g., an
immunoglobulin Fc domain) allowing the first and second
polypeptides to form a dimer, and the multimerization domains
promote stable interaction between first and second polypeptides,
and wherein one of the multimerization domains bears an amino acid
modification that reduces its affinity to protein A and the other
multimerization domain lacks the modification, 2) a binding domain
in each of the first and second polypeptide, each binding domain
comprising a variable heavy chain and a variable light chain,
wherein the variable light chain of the first polypeptide and the
variable light chain of the second polypeptide have a common amino
acid sequence, which common sequence has an amino acid sequence
identity to an original light chain of each of the polypeptides of
at least 80%, of at least 85%, preferably at least 90%, more
preferably at least 95% and most preferably 100% sequence identity.
In various embodiments, the variable light chain is derived from a
human V.kappa.1-39 or a human V.kappa.3-20 gene segment. In various
embodiments, the variable light chain is a rearranged human light
chain sequence. In various embodiments, the variable light chain is
isolated from a mouse as described herein.
[0128] In various embodiments, the method comprises the steps of
(i) culturing a host cell comprising a nucleic acid encoding the
first polypeptide, the second polypeptide, and the common light
chain, wherein the nucleic acid is expressed; and (ii) recovering
the bispecific antibody from the host cell culture; in one
embodiment, the nucleic acid encoding the first polypeptide or the
nucleic acid encoding the second polypeptide, bears an amino acid
modification that reduces its affinity to protein A. In one
embodiment, the nucleic acid encoding the first polypeptide, the
second polypeptide, and the common light chain is present in a
single vector or in separate vectors. In one embodiment, the host
cell is used to make a bispecific antibody according to the
preceding paragraph.
[0129] In one aspect, a method of preparing a bispecific antibody
is provided, comprising (a) selecting a first nucleic acid encoding
a first human heavy chain variable region isolated from a mouse as
described herein; (b) selecting a second nucleic acid encoding a
second human heavy chain variable region isolated from the same or
separate mouse as described herein; (c) providing a third nucleic
acid encoding a human light chain variable region isolated from a
mouse as described herein or derived from a rearranged human light
chain variable region as described herein; (c) introducing into a
host cell the first, second and third nucleic acids and culturing
the host cell so that expression of the first, second and third
nucleic acid occurs; and (d) recovering the bispecific antibody
formed from the cell culture.
[0130] In one embodiment, the first and second human heavy chain
variable regions are somatically mutated. In a specific embodiment,
the first and second human heavy chain variable regions are
independently derived from a rearranged human V.sub.H gene segment
selected from 1-2, 1-3, 1-8, 1-18, 1-24, 1-46, 1-58, 1-69, 2-5,
2-26, 2-70, 3-7, 3-9, 3-11, 3-13, 3-15, 3-16, 3-20, 3-21, 3-23,
3-30, 3-33, 3-43, 3-48, 3-53, 3-64, 3-72, 3-73, 4-31, 4-34, 4-39,
4-59, 5-51, and a 6-1 human V.sub.H gene segment. In one
embodiment, the first and second human heavy chain variable regions
are independently derived from a rearranged human V.sub.H gene
segment selected from 2-5, 3-30 and 3-23. In one embodiment, the
first human heavy chain variable region is derived from a human
V.sub.H2-5 gene segment and the second human heavy chain variable
region is derived from a human V.sub.H3-30 gene segment. In one
embodiment, the first human heavy chain variable region is derived
from a human V.sub.H3-30 gene segment and the second human heavy
chain variable region is derived from a human V.sub.H3-23 gene
segment. In one embodiment, the first human heavy chain variable
region is derived from a human V.sub.H3-23 gene segment and the
second human heavy chain variable region is derived from a human
V.sub.H3-30 gene segment.
[0131] In one embodiment, the first or second nucleic acid is
modified prior to step (c), wherein the first or second nucleic
acid is modified such that it has a reduced affinity to protein
A.
[0132] In one embodiment, the third nucleic acid is isolated from a
mouse as described herein. In one embodiment, the third nucleic
acid comprises 2 to 5 somatic mutations. In one embodiment, the
third nucleic acid encodes a human light chain variable region
derived from a human V.kappa.1-39 gene segment. In one embodiment,
the third nucleic acid encodes a human light chain variable region
derived from a human V.kappa.3-20 gene segment.
[0133] In one embodiment, the third nucleic acid is derived from a
rearranged human light chain variable region. In one embodiment,
the rearranged human light chain variable region comprises a
sequence derived from a human V.kappa.1-39 gene segment or a human
V.kappa.3-20 gene segment. In one embodiment, the rearranged human
light chain variable region comprises a germline human V.kappa.1-39
sequence (i.e., does not comprise a somatic hypermutation within
the V gene segment sequence). In one embodiment, the rearranged
human light chain variable region comprises a germline human
V.kappa.3-20 sequence.
[0134] In various embodiments, a method of preparing a bispecific
antibody that incorporates a first human heavy chain comprising a
variable domain derived from a modified mouse that lacks a
rearranged human light chain sequence in its germline is provided,
wherein the first human heavy chain is paired with a cognate human
light chain that comprises a rearranged human light chain variable
region derived from a human V.kappa.1-39 or a human V.kappa.3-20
gene segment. In various embodiments, a second human heavy chain
with a different specificity from the first human heavy chain is
identified from an immunized mouse as described herein. Nucleic
acids encoding the two heavy chains and the common light chain are
introduced into a host cell as described in the preceding
paragraphs so that expression of all three chains occurs and the
bispecific antibody is recovered from the cell culture.
[0135] In one embodiment, the mouse is immunized with the same
antigen used to generate the first human heavy chain variable
domain. In one embodiment, the mouse is immunized with a different
antigen used to generate the first human heavy chain variable
domain.
[0136] In one aspect, a method of selecting human heavy chains that
can pair with a single human light chain to make a bispecific
antibody is provided, including nucleic acids that encode the
bispecific antibody and a host cell comprising the nucleic
acids.
[0137] In one aspect, a method of increasing the amount of a
desired bispecific antibody in a cell culture over undesired
products such as monospecific antibodies is provided, wherein one
of the heavy chains of the bispecific antibody is modified to
reduce its affinity to protein A.
[0138] In one aspect, an isolated host cell is provided, wherein
the host cell comprises (a) a first nucleic acid sequence encoding
a first human heavy chain variable region that binds a first
antigen, wherein the first nucleic acid sequence is isolated from a
mouse immunized with the first antigen that expresses a human
immunoglobulin V.sub.L region from a rearranged immunoglobulin
light chain sequence in the germline of the mouse; (b) a second
nucleic acid sequence encoding a second human heavy chain variable
region that binds a second antigen, wherein the second nucleic acid
sequence is isolated from a mouse immunized with the second antigen
that expresses a human immunoglobulin V.sub.L region from a
rearranged immunoglobulin light chain sequence in the germline of
the mouse; (c) a third nucleic acid sequence encoding a human light
chain variable region which, when paired with the heavy chain
variable region of (a) specifically binds the first antigen, and
when paired with the heavy chain variable region of (b)
specifically binds to the second antigen.
[0139] In various aspects, the first and second antigens are
different from one another. In various aspects, the expression of
the first, second and third nucleic acid sequences leads to the
formation of a bispecific antibody that specifically binds to the
first and second antigens.
[0140] In one embodiment, the human V.sub.L region is derived from
a rearranged human light chain sequence comprising a human
V.kappa.1-39 gene segment or a human V.kappa.3-20 gene segment. In
a specific embodiment, the rearranged human light chain sequence is
a germline sequence (i.e., does not comprise a somatic
hypermutation within the variable domain). In one embodiment, the
third nucleic acid sequence is isolated from a mouse that expresses
a human immunoglobulin V.sub.L region from a rearranged
immunoglobulin light chain sequence, wherein the rearranged human
light chain sequence is present in the germline of the mouse. In
one embodiment, the rearranged immunoglobulin light chain sequence
comprises a human V.kappa.1-39 gene segment or a human V.kappa.3-20
gene segment. In a specific embodiment, the human V.kappa.1-39 gene
segment or human V.kappa.3-20 gene segment comprises at least one
somatic hypermutation in a complementary determining region (CDR)
or framework region (FWR). In a specific embodiment, the first,
second and third nucleic acid sequences are isolated from a mouse
that expresses a human immunoglobulin V.sub.L region derived from a
human V.kappa.1-39 or human V.kappa.3-20 gene segment from a
rearranged immunoglobulin light chain sequence, wherein the
rearranged immunoglobulin light chain sequence is present in the
germline of the mouse.
[0141] In various embodiments, the mouse does not contain an
endogenous light chain variable region gene segment that is capable
of rearranging to form an immunoglobulin light chain.
[0142] In one embodiment, the human immunoglobulin V.sub.L region
is expressed from a modified endogenous immunoglobulin light chain
locus. In one embodiment, the first and second antigens are present
on one molecule. In one embodiment, the first and second antigens
are present on different molecules. In one embodiment, the first or
second nucleic acid sequence comprises a modification that reduces
the affinity of the encoded heavy chain to protein A.
[0143] In one embodiment, the first or second nucleic acid
sequences comprise a rearranged human heavy chain variable region
sequence comprising a human heavy chain gene segment selected from
V.sub.H1-2, V.sub.H1-3, V.sub.H1-8, V.sub.H1-18, V.sub.H1-24,
V.sub.H1-46, V.sub.H1-58, V.sub.H1-69, V.sub.H2-5, V.sub.H2-26,
V.sub.H2-70, V.sub.H3-7, V.sub.H3-9, V.sub.H3-11, V.sub.H3-13,
V.sub.H3-15, V.sub.H3-20, V.sub.H3-21, V.sub.H3-23, V.sub.H3-30,
V.sub.H3-33, V.sub.H3-43, V.sub.H3-48, V.sub.H3-53, V.sub.H3-64,
V.sub.H3-72, V.sub.H3-73, V.sub.H4-31, V.sub.H4-34, V.sub.H4-39,
V.sub.H4-59, V.sub.HS-51, and V.sub.H6-1. In a specific embodiment,
the heavy chain gene segment is V.sub.H2-5, V.sub.H3-23 or
V.sub.H3-30.
[0144] In one aspect, an antibody or a bispecific antibody
comprising a human heavy chain variable domain made in accordance
with the invention is provided. In another aspect, use of a mouse
as described herein to make a fully human antibody or a fully human
bispecific antibody is provided.
[0145] In one aspect, a genetically modified mouse, embryo, or cell
described herein comprises a .kappa. light chain locus that retains
endogenous regulatory or control elements, e.g., a mouse .kappa.
intronic enhancer, a mouse .kappa.3' enhancer, or both an intronic
enhancer and a 3' enhancer, wherein the regulatory or control
elements facilitate somatic mutation and affinity maturation of an
expressed sequence of the .kappa. light chain locus.
[0146] In one aspect, a mouse is provided that comprises a B cell
population characterized by having immunoglobulin light chains
derived from no more than one, or no more than two, rearranged or
unrearranged immunoglobulin light chain V and J gene segments,
wherein the mouse exhibits a .kappa.:.lamda. light chain ratio that
is about the same as a mouse that comprises a wild type complement
of immunoglobulin light chain V and J gene segments.
[0147] In one embodiment, the immunoglobulin light chains are
derived from no more than one, or no more than two, rearranged
immunoglobulin light chain V and J gene segments. In a specific
embodiment, the light chains are derived from no more than one
rearranged immunoglobulin light chain V and J gene segments.
[0148] In one aspect, a mouse as described herein is provided that
expresses an immunoglobulin light chain derived from no more than
one, or no more than two, human V.kappa./J.kappa. sequences,
wherein the mouse comprises a replacement of all or substantially
all endogenous mouse heavy chain variable region gene segments with
one or more human heavy chain variable region gene segments, and
the mouse exhibits a ratio of (a) CD19.sup.+ B cells that express
an immunoglobulin having a .lamda. light chain, to (b) CD19.sup.+ B
cells that express an immunoglobulin having a .kappa. light chain,
of about 1 to about 20.
[0149] In one embodiment, the mouse expresses a single .kappa.
light chain derived from a human V.kappa.1-39J.kappa.5 sequence,
and the ratio of CD19.sup.+ B cells that express an immunoglobulin
having a .lamda., light chain to CD19.sup.+ B cells that express an
immunoglobulin having a .kappa. light chain is about 1 to about 20;
in one embodiment, the ratio is about 1 to at least about 66; in a
specific embodiment, the ratio is about 1 to 66.
[0150] In one embodiment, the mouse expresses a single .kappa.
light chain derived from a human V.kappa.3-20J.kappa.5 sequence,
and the ratio of CD19.sup.+ B cells that express an immunoglobulin
having a .lamda. light chain to CD19.sup.+ B cells that express an
immunoglobulin having a .kappa. light chain is about 1 to about 20;
in one embodiment, the ratio is about 1 to about 21. In specific
embodiments, the ratio is 1 to 20, or 1 to 21.
[0151] In one aspect, a genetically modified mouse is provided that
expresses a single rearranged .kappa. light chain, wherein the
mouse comprises a functional .lamda. light chain locus, and wherein
the mouse expresses a B cell population that comprises
Ig.kappa..sup.+ cells that express a .kappa. light chain derived
from the same single rearranged .kappa. light chain. In one
embodiment, the percent of Ig.kappa..sup.+ B cells in the mouse is
about the same as in a wild type mouse. In a specific embodiment,
the percent of Ig.kappa..sup.+Ig.lamda..sup.+ B cells in the mouse
is about 2 to about 6 percent. In a specific embodiment, the
percent of Ig.kappa..sup.+Ig.lamda..sup.+ B cells in a mouse
wherein the single rearranged .kappa. light chain is derived from a
V.kappa.1-39J.kappa.5 sequence is about 2 to about 3; in a specific
embodiment, the percent is about 2.6. In a specific embodiment, the
percent of Ig.kappa..sup.+Ig.lamda..sup.+ B cells in a mouse
wherein the single rearranged .kappa. light chain is derived from a
V.kappa.3-20J.kappa.1 sequence is about 4 to about 8; in a specific
embodiment, the percent is about 6.
[0152] In one aspect, a genetically modified mouse is provided,
wherein the mouse expresses a single rearranged .kappa. light chain
derived from a human V.kappa. and J.kappa. gene segment, wherein
the mouse expresses a B cell population that comprises a single
.kappa. light chain derived from the single rearranged .kappa.
light chain sequence, wherein the genetically modified mouse has
not been rendered resistant to somatic hypermutations. In one
embodiment, at least 90% of the .kappa. light chains expressed on a
B cell of the mouse exhibit from at least one to about five somatic
hypermutations.
[0153] In one aspect, a genetically modified mouse is provided that
is modified to express a single .kappa. light chain derived from no
more than one, or no more than two, rearranged .kappa. light chain
sequences, wherein the mouse exhibits a .kappa. light chain usage
that is about two-fold or more, at least about three-fold or more,
or at least about four-fold or more greater than the .kappa. light
chain usage exhibited by a wild type mouse, or greater than the
.kappa. light chain usage exhibited by a mouse of the same strain
that comprises a wild type repertoire of .kappa. light chain gene
segments. In a specific embodiment, the mouse expresses the single
.kappa. light chain from no more than one rearranged .kappa. light
chain sequence. In a more specific embodiment, the rearranged
.kappa. light chain sequence is selected from a
V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1 sequence. In one
embodiment, the rearranged .kappa. light chain sequence is a
V.kappa.1-39J.kappa.5 sequence. In one embodiment, the rearranged
.kappa. light chain sequence is a V.kappa.3-20J.kappa.1
sequence.
[0154] In one aspect, a genetically modified mouse is provided that
expresses a single .kappa. light chain derived from no more than
one, or no more than two, rearranged .kappa. light chain sequences,
wherein the mouse exhibits a .lamda. light chain usage that is
about 100-fold or more, at least about 200-fold or more, at least
about 300-fold or more, at least about 400-fold or more, at least
about 500-fold or more, at least about 600-fold or more, at least
about 700-fold or more, at least about 800-fold or more, at least
about 900-fold or more, at least about 1000-fold or more greater
than the same .kappa. light chain usage exhibited by a mouse
bearing a complete or substantially complete human .kappa. light
chain locus. In a specific embodiment, the mouse bearing a complete
or substantially complete human .kappa. light chain locus lacks a
functional unrearranged mouse .kappa. light chain sequence. In a
specific embodiment, the mouse expresses the single .kappa. light
chain from no more than one rearranged .kappa. light chain
sequence. In one embodiment, the mouse comprises one copy of a
rearranged .kappa. light chain sequence (e.g., a heterozygote). In
one embodiment, the mouse comprises two copies of a rearranged
.kappa. light chain sequence (e.g., a homozygote). In a more
specific embodiment, the rearranged .kappa. light chain sequence is
selected from a V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1
sequence. In one embodiment, the rearranged .kappa. light chain
sequence is a V.kappa.1-39J.kappa.5 sequence. In one embodiment,
the rearranged .kappa. light chain sequence is a
V.kappa.3-20J.kappa.1 sequence.
[0155] In one aspect, a genetically modified mouse is provided that
expresses a single light chain derived from no more than one, or no
more than two, rearranged light chain sequences, wherein the light
chain in the genetically modified mouse exhibits a level of
expression that is at least 10-fold to about 1,000-fold, 100-fold
to about 1,000-fold, 200-fold to about 1,000-fold, 300-fold to
about 1,000-fold, 400-fold to about 1,000-fold, 500-fold to about
1,000-fold, 600-fold to about 1,000-fold, 700-fold to about
1,000-fold, 800-fold to about 1,000-fold, or 900-fold to about
1,000-fold higher than expression of the same rearranged light
chain exhibited by a mouse bearing a complete or substantially
complete light chain locus. In one embodiment, the light chain
comprises a human sequence. In a specific embodiment, the human
sequence is a .kappa. sequence. In one embodiment, the human
sequence is a .lamda. sequence. In one embodiment, the light chain
is a fully human light chain.
[0156] In one embodiment, the level of expression is characterized
by quantitating mRNA of transcribed light chain sequence, and
comparing it to transcribed light chain sequence of a mouse bearing
a complete or substantially complete light chain locus.
[0157] In one aspect, a genetically modified mouse is provided that
expresses a single .kappa. light chain derived from no more than
one, or no more than two, rearranged .kappa. light chain sequences,
wherein the mouse, upon immunization with antigen, exhibits a serum
titer that is comparable to a wild type mouse immunized with the
same antigen. In a specific embodiment, the mouse expresses a
single .kappa. light chain from no more than one rearranged .kappa.
light chain sequence. In one embodiment, the serum titer is
characterized as total immunoglobulin. In a specific embodiment,
the serum titer is characterized as IgM specific titer. In a
specific embodiment, the serum titer is characterized as IgG
specific titer. In a more specific embodiment, the rearranged
.kappa. light chain sequence is selected from a
V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1 sequence. In one
embodiment, the rearranged .kappa. light chain sequence is a
V.kappa.1-39J.kappa.5 sequence. In one embodiment, the rearranged
.kappa. light chain sequence is a V.kappa.3-20J.kappa.1
sequence.
[0158] In one aspect, a genetically modified mouse is provided that
expresses a population of antigen-specific antibodies, wherein all
of the immunoglobulin light chains of the population of
antigen-specific antibodies comprise a human light chain variable
(V.sub.L) region derived from the same single human V.sub.L gene
segment and the immunoglobulin heavy chains comprise a human heavy
chain variable (V.sub.H) region derived from one of a plurality of
human V.sub.H gene segments.
[0159] In various embodiments, the human V.sub.H gene segments are
selected from V.sub.H1-2, V.sub.H1-3, V.sub.H1-8, V.sub.H1-18,
V.sub.H1-24, V.sub.H1-46, V.sub.H1-58, V.sub.H1-69, V.sub.H2-5,
V.sub.H2-26, V.sub.H2-70, V.sub.H3-7, V.sub.H3-9, V.sub.H3-11,
V.sub.H3-13, V.sub.H3-15, V.sub.H3-20, V.sub.H3-21, V.sub.H3-23,
V.sub.H3-30, V.sub.H3-33, V.sub.H3-43, V.sub.H3-48, V.sub.H3-53,
V.sub.H3-64, V.sub.H3-72, V.sub.H3-73, V.sub.H4-31, V.sub.H4-34,
V.sub.H4-39, V.sub.H4-59, V.sub.H5-51, and V.sub.H6-1.
[0160] In various embodiments, same single human V.sub.L gene
segment is selected from a human V.kappa.1-39 gene segment and a
human V.kappa.3-20 gene segment. In various embodiments, all of the
immunoglobulin light chains comprise a human light chain J
(J.sub.L) gene segment selected from a J.kappa. and a J.lamda. gene
segment. In a specific embodiment, the human J.sub.L gene segment
is selected from a human J.kappa.1 and a J.kappa.5 gene segment. In
various embodiments, the mouse lacks a sequence selected from a
mouse immunoglobulin V.sub.L gene segment, a mouse immunoglobulin
J.sub.L gene segment, and a combination thereof. In various
embodiments, the human V.sub.L region is operably linked to a
human, mouse, or rat immunoglobulin light chain constant (C.sub.L)
region. In a specific embodiment, the human V.sub.L region is
operably linked to a mouse C.kappa. region. In a specific
embodiment, the human V.sub.L region is operably linked to a rat
C.kappa. region.
[0161] In various embodiments, the human V.sub.L region is
expressed from an endogenous immunoglobulin light chain locus. In
various embodiments, the human V.sub.H region is operably linked to
a human, mouse, or rat immunoglobulin heavy chain constant
(C.sub.H) region. In various embodiments the (C.sub.H) region
comprises a human sequence selected from a C.sub.H1, a hinge, a
C.sub.H2, a C.sub.H3, a C.sub.H4, and/or a combination thereof. In
various embodiments, the human V.sub.H region is expressed from an
endogenous immunoglobulin heavy chain locus.
[0162] In one aspect, a genetically modified mouse is provided that
expresses a plurality of immunoglobulin heavy chains associated
with a single light chain. In one embodiment, the heavy chain
comprises a human sequence. In various embodiments, the human
sequence is selected from a variable sequence, a C.sub.H1, a hinge,
a C.sub.H2, a C.sub.H3, and a combination thereof. In one
embodiment, the single light chain comprises a human sequence. In
various embodiments, the human sequence is selected from a variable
sequence, a constant sequence, and a combination thereof. In one
embodiment, the mouse comprises a disabled endogenous
immunoglobulin locus and expresses the heavy chain and/or the light
chain from a transgene or extrachromosomal episome. In one
embodiment, the mouse comprises a replacement at an endogenous
mouse locus of some or all endogenous mouse heavy chain gene
segments (i.e., V, D, J), and/or some or all endogenous mouse heavy
chain constant sequences (e.g., C.sub.H1, hinge, C.sub.H2,
C.sub.H3, or a combination thereof), and/or some or all endogenous
mouse light chain sequences (e.g., V, J, constant, or a combination
thereof), with one or more human immunoglobulin sequences.
[0163] In one aspect, a mouse suitable for making antibodies that
have the same light chain is provided, wherein all or substantially
all antibodies made in the mouse are expressed with the same light
chain. In one embodiment, the light chain is expressed from an
endogenous light chain locus.
[0164] In one aspect, a method for making a light chain for a human
antibody is provided, comprising obtaining from a mouse as
described herein a light chain sequence and a heavy chain sequence,
and employing the light chain sequence and the heavy chain sequence
in making a human antibody. In one embodiment, the human antibody
is a bispecific antibody.
[0165] In one aspect, a method for identifying a human heavy chain
variable domain that is capable of binding an antigen of interest
with an engineered light chain as described herein is provided,
wherein the method comprises providing a heavy chain variable
domain derived from a first antibody that is capable of binding the
antigen, repairing the heavy chain variable domain with a germline
light chain sequence and transfecting a cell so that each are
expressed to form a second antibody, exposing the second antibody
to the antigen, and measuring binding of the second antibody to the
antigen.
[0166] In one embodiment, the light chain of the first antibody
comprises a human V.kappa.1-39 sequence. In one embodiment, the
light chain of the first antibody comprises a human V.kappa.3-20
sequence. In one embodiment, the germline light chain sequence
comprises a human V.kappa.1-39 or V.kappa.3-20 sequence. In various
embodiments, binding of the second antibody to the antigen is
determined by comparison of binding of the first antibody to the
antigen.
[0167] Any of the embodiments and aspects described herein can be
used in conjunction with one another, unless otherwise indicated or
apparent from the context. Other embodiments will become apparent
to those skilled in the art from a review of the ensuing
description.
BRIEF DESCRIPTION OF FIGURES
[0168] FIG. 1 illustrates a targeting strategy for replacing
endogenous mouse immunoglobulin light chain variable region gene
segments with a human V.kappa.1-39J.kappa.5 gene region.
[0169] FIG. 2 illustrates a targeting strategy for replacing
endogenous mouse immunoglobulin light chain variable region gene
segments with a human V.kappa.3-20J.kappa.1 gene region.
[0170] FIG. 3 illustrates a targeting strategy for replacing
endogenous mouse immunoglobulin light chain variable region gene
segments with a human VpreB/J.lamda.5 gene region.
[0171] FIG. 4 shows the percent of CD19.sup.+ B cells (y-axis) from
peripheral blood for wild type mice (WT), mice homozygous for an
engineered human rearranged V.kappa.1-39J.kappa.5 light chain
region (V.kappa.1-39J.kappa.5 HO) and mice homozygous for an
engineered human rearranged V.kappa.3-20J.kappa.1 light chain
region (V.kappa.3-20J.kappa.1 HO).
[0172] FIG. 5A shows the relative mRNA expression (y-axis) of a
V.kappa.1-39-derived light chain in a quantitative PCR assay using
probes specific for the junction of an engineered human rearranged
V.kappa.1-39J.kappa.5 light chain region (V.kappa.1-39J.kappa.5
Junction Probe) and the human V.kappa.1-39 gene segment
(V.kappa.1-39 Probe) in a mouse homozygous for a replacement of the
endogenous V.kappa. and J.kappa. gene segments with human V.kappa.
and J.kappa. gene segments (H.kappa.), a wild type mouse (WT), and
a mouse heterozygous for an engineered human rearranged
V.kappa.1-39J.kappa.5 light chain region (V.kappa.1-39J.kappa.5
HET). Signals are normalized to expression of mouse C.kappa.. N.D.:
not detected.
[0173] FIG. 5B shows the relative mRNA expression (y-axis) of a
V.kappa.1-39-derived light chain in a quantitative PCR assay using
probes specific for the junction of an engineered human rearranged
V.kappa.1-39J.kappa.5 light chain region (V.kappa.1-39J.kappa.5
Junction Probe) and the human V.kappa.1-39 gene segment
(V.kappa.1-39 Probe) in a mouse homozygous for a replacement of the
endogenous V.kappa. and J.kappa. gene segments with human V.kappa.
and J.kappa. gene segments (H.kappa.), a wild type mouse (WT), and
a mouse homozygous for an engineered human rearranged
V.kappa.1-39J.kappa.5 light chain region (V.kappa.1-39J.kappa.5
HO). Signals are normalized to expression of mouse C.kappa..
[0174] FIG. 5C shows the relative mRNA expression (y-axis) of a
V.kappa.3-20-derived light chain in a quantitative PCR assay using
probes specific for the junction of an engineered human rearranged
V.kappa.3-20J.kappa.1 light chain region (V.kappa.3-20J.kappa.1
Junction Probe) and the human V.kappa.3-20 gene segment
(V.kappa.3-20 Probe) in a mouse homozygous for a replacement of the
endogenous V.kappa. and J.kappa. gene segments with human V.kappa.
and J.kappa. gene segments (H.kappa.), a wild type mouse (WT), and
a mouse heterozygous (HET) and homozygous (HO) for an engineered
human rearranged V.kappa.3-20J.kappa.1 light chain region. Signals
are normalized to expression of mouse C.kappa..
[0175] FIG. 6A shows IgM (left) and IgG (right) titer in wild type
(WT; N=2) and mice homozygous for an engineered human rearranged
V.kappa.1-39J.kappa.5 light chain region (V.kappa.1-39J.kappa.5 HO;
N=2) immunized with .beta.-galactosidase.
[0176] FIG. 6B shows total immunoglobulin (IgM, IgG, IgA) titer in
wild type (WT; N=5) and mice homozygous for an engineered human
rearranged V.kappa.3-20J.kappa.1 light chain region
(V.kappa.3-20J.kappa.1 HO; N=5) immunized with
.beta.-galactosidase.
[0177] FIG. 7A shows a schematic of monospecific antibodies
(Parent-1 and Parent-2) and a bispecific antibody (Bispecific)
constructed from heavy chain variable regions from each parent
monospecific antibody. A common light chain variable region
(darkened) is indicated in the bispecific antibody.
[0178] FIG. 7B shows a schematic for the binding characteristics of
two parent monoclonal antibodies (Parent-1 and Parent-2) for an
antigen of interest, as well as the binding characteristic of a
bispecific antibody constructed from pairing the heavy chain
variable regions from each monospecific parent antibody with a
common light chain. The capability of the bispecific antibody to
bind to two distinct epitopes of the antigen of interest either
separately (bottom left) or simultaneously (bottom right) is
indicated.
[0179] FIG. 8 shows a bar graph of the binding of 300 nM bispecific
(darkened bars) and monospecific (striped and gray bars) antibodies
to a captured monomeric Antigen E surface in BIACORE.TM. units
(RU). Monoclonal parent-1 antibody (P1 Ab), monoclonal parent-2 (P2
Ab) and bispecific antibodies (BsAb) are indicated.
DETAILED DESCRIPTION
[0180] This invention is not limited to particular methods, and
experimental conditions described, as such methods and conditions
may vary. It is also to be understood that the terminology used
herein is for the purpose of describing particular embodiments
only, and is not intended to be limiting, since the scope of the
present invention is defined by the claims.
[0181] Unless defined otherwise, all terms and phrases used herein
include the meanings that the terms and phrases have attained in
the art, unless the contrary is clearly indicated or clearly
apparent from the context in which the term or phrase is used.
Although any methods and materials similar or equivalent to those
described herein can be used in the practice or testing of the
present invention, particular methods and materials are now
described. All publications mentioned are hereby incorporated by
reference in their entirety.
[0182] The term "antibody", as used herein, includes immunoglobulin
molecules comprising four polypeptide chains, two heavy (H) chains
and two light (L) chains inter-connected by disulfide bonds. Each
heavy chain comprises a heavy chain variable (V.sub.H) region and a
heavy chain constant region (C.sub.H). The heavy chain constant
region comprises three domains, C.sub.H1, C.sub.H2 and C.sub.H3.
Each light chain comprises a light chain variable (V.sub.L) region
and a light chain constant region (C.sub.L). The V.sub.H and
V.sub.L regions can be further subdivided into regions of
hypervariability, termed complementarity determining regions (CDR),
interspersed with regions that are more conserved, termed framework
regions (FR). Each V.sub.H and V.sub.L comprises three CDRs and
four FRs, arranged from amino-terminus to carboxy-terminus in the
following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (heavy chain
CDRs may be abbreviated as HCDR1, HCDR2 and HCDR3; light chain CDRs
may be abbreviated as LCDR1, LCDR2 and LCDR3. The term "high
affinity" antibody refers to an antibody that has a K.sub.D with
respect to its target epitope about of 10.sup.-9 M or lower (e.g.,
about 1.times.10.sup.-9 M, 1.times.10.sup.-10 M, 1.times.10.sup.-11
M, or about 1.times.10.sup.-12 M). In one embodiment, K.sub.D is
measured by surface plasmon resonance, e.g., BIACORE.TM.; in
another embodiment, K.sub.D is measured by ELISA.
[0183] The phrase "bispecific antibody" includes an antibody
capable of selectively binding two or more epitopes. Bispecific
antibodies include fragments of two different monoclonal antibodies
(FIG. 7A) and generally comprise two nonidentical heavy chains
derived from the two different monoclonal antibodies, with each
heavy chain specifically binding a different epitope--either on two
different molecules (e.g., different epitopes on two different
immunogens; see FIG. 7B, bottom left) or on the same molecule
(e.g., different epitopes on the same immunogen; see FIG. 7B,
bottom right). If a bispecific antibody is capable of selectively
binding two different epitopes (a first epitope and a second
epitope), the affinity of the first heavy chain for the first
epitope will generally be at least one to two or three or four or
more orders of magnitude lower than the affinity of the first heavy
chain for the second epitope, and vice versa. Epitopes specifically
bound by the bispecific antibody can be on the same or a different
target (e.g., on the same or a different protein; see FIG. 7B).
Exemplary bispecific antibodies include those with a first heavy
chain specific for a tumor antigen and a second heavy chain
specific for a cytotoxic marker, e.g., an Fc receptor (e.g.,
Fc.gamma.RI, Fc.gamma.RII, Fc.gamma.RIII, etc.) or a T cell marker
(e.g., CD3, CD28, etc.). Further, the second heavy chain variable
region can be substituted with a heavy chain variable region having
a different desired specificity. For example, a bispecific antibody
with a first heavy chain specific for a tumor antigen and a second
heavy chain specific for a toxin can be paired so as to deliver a
toxin (e.g., saporin, vinca alkaloid, etc.) to a tumor cell. Other
exemplary bispecific antibodies include those with a first heavy
chain specific for an activating receptor (e.g., B cell receptor,
Fc.gamma.RI, Fc.gamma.RIIA, Fc.gamma.RIIIA, Fc.alpha.RI, T cell
receptor, etc.) and a second heavy chain specific for an inhibitory
receptor (e.g., Fc.gamma.RIIB, CD5, CD22, CD72, CD300a, etc.). Such
bispecific antibodies can be constructed for therapeutic conditions
associated with cell activation (e.g. allergy and asthma).
Bispecific antibodies can be made, for example, by combining heavy
chains that recognize different epitopes of the same or different
immunogen (FIG. 7B). For example, nucleic acid sequences encoding
heavy chain variable sequences that recognize different epitopes of
the same or different immunogen can be fused to nucleic acid
sequences encoding the same or different heavy chain constant
regions, and such sequences can be expressed in a cell that
expresses an immunoglobulin light chain. A typical bispecific
antibody has two heavy chains each having three heavy chain CDRs,
followed by (N-terminal to C-terminal) a C.sub.H1 domain, a hinge,
a C.sub.H2 domain, and a C.sub.H3 domain, and an immunoglobulin
light chain that either does not confer epitope-binding specificity
but that can associate with each heavy chain, or that can associate
with each heavy chain and that can bind one or more of the epitopes
bound by the heavy chain epitope-binding regions, or that can
associate with each heavy chain and enable binding or one or both
of the heavy chains to one or both epitopes.
[0184] The term "cell" includes any cell that is suitable for
expressing a recombinant nucleic acid sequence. Cells include those
of prokaryotes and eukaryotes (single-cell or multiple-cell),
bacterial cells (e.g., strains of E. coli, Bacillus spp.,
Streptomyces spp., etc.), mycobacteria cells, fungal cells, yeast
cells (e.g., S. cerevisiae, S. pombe, P. pastoris, P. methanolica,
etc.), plant cells, insect cells (e.g., SF-9, SF-21,
baculovirus-infected insect cells, Trichoplusia ni, etc.),
non-human animal cells, human cells, or cell fusions such as, for
example, hybridomas or quadromas. In some embodiments, the cell is
a human, monkey, ape, hamster, rat, or mouse cell. In some
embodiments, the cell is eukaryotic and is selected from the
following cells: CHO (e.g., CHO K1, DXB-11 CHO, Veggie-CHO), COS
(e.g., COS-7), retinal cell, Vero, CV1, kidney (e.g., HEK293, 293
EBNA, MSR 293, MDCK, HaK, BHK), HeLa, HepG2, WI38, MRC 5, Colo205,
HB 8065, HL-60, (e.g., BHK21), Jurkat, Daudi, A431 (epidermal),
CV-1, U937, 3T3, L cell, C127 cell, SP2/0, NS-0, MMT 060562,
Sertoli cell, BRL 3A cell, HT1080 cell, myeloma cell, tumor cell,
and a cell line derived from an aforementioned cell. In some
embodiments, the cell comprises one or more viral genes, e.g., a
retinal cell that expresses a viral gene (e.g., a PER.C6.TM.
cell).
[0185] The phrase "complementarity determining region," or the term
"CDR," includes an amino acid sequence encoded by a nucleic acid
sequence of an organism's immunoglobulin genes that normally (i.e.,
in a wild type animal) appears between two framework regions in a
variable region of a light or a heavy chain of an immunoglobulin
molecule (e.g., an antibody or a T cell receptor). A CDR can be
encoded by, for example, a germline sequence or a rearranged or
unrearranged sequence, and, for example, by a naive or a mature B
cell or a T cell. A CDR can be somatically mutated (e.g., vary from
a sequence encoded in an animal's germline), humanized, and/or
modified with amino acid substitutions, additions, or deletions. In
some circumstances (e.g., for a CDR3), CDRs can be encoded by two
or more sequences (e.g., germline sequences) that are not
contiguous (e.g., in an unrearranged nucleic acid sequence) but are
contiguous in a B cell nucleic acid sequence, e.g., as the result
of splicing or connecting the sequences (e.g., V-D-J recombination
to form a heavy chain CDR3).
[0186] The term "conservative," when used to describe a
conservative amino acid substitution, includes substitution of an
amino acid residue by another amino acid residue having a side
chain R group with similar chemical properties (e.g., charge or
hydrophobicity). In general, a conservative amino acid substitution
will not substantially change the functional properties of interest
of a protein, for example, the ability of a variable region to
specifically bind a target epitope with a desired affinity.
Examples of groups of amino acids that have side chains with
similar chemical properties include aliphatic side chains such as
glycine, alanine, valine, leucine, and isoleucine;
aliphatic-hydroxyl side chains such as serine and threonine;
amide-containing side chains such as asparagine and glutamine;
aromatic side chains such as phenylalanine, tyrosine, and
tryptophan; basic side chains such as lysine, arginine, and
histidine; acidic side chains such as aspartic acid and glutamic
acid; and, sulfur-containing side chains such as cysteine and
methionine. Conservative amino acids substitution groups include,
for example, valine/leucine/isoleucine, phenylalanine/tyrosine,
lysine/arginine, alanine/valine, glutamate/aspartate, and
asparagine/glutamine. In some embodiments, a conservative amino
acid substitution can be substitution of any native residue in a
protein with alanine, as used in, for example, alanine scanning
mutagenesis. In some embodiments, a conservative substitution is
made that has a positive value in the PAM250 log-likelihood matrix
disclosed in Gonnet et al. (1992) Exhaustive Matching of the Entire
Protein Sequence Database, Science 256:1443-45, hereby incorporated
by reference. In some embodiments, the substitution is a moderately
conservative substitution wherein the substitution has a
nonnegative value in the PAM250 log-likelihood matrix.
[0187] In some embodiments, residue positions in an immunoglobulin
light chain or heavy chain differ by one or more conservative amino
acid substitutions. In some embodiments, residue positions in an
immunoglobulin light chain or functional fragment thereof (e.g., a
fragment that allows expression and secretion from, e.g., a B cell)
are not identical to a light chain whose amino acid sequence is
listed herein, but differs by one or more conservative amino acid
substitutions.
[0188] The phrase "epitope-binding protein" includes a protein
having at least one CDR and that is capable of selectively
recognizing an epitope, e.g., is capable of binding an epitope with
a K.sub.D that is at about one micromolar or lower (e.g., a K.sub.D
that is about 1.times.10.sup.-6 M, 1.times.10.sup.-7 M,
1.times.10.sup.-9 M, 1.times.10.sup.-9 M, 1.times.10.sup.-10 M,
1.times.10.sup.-11 M, or about 1.times.10.sup.-12 M). Therapeutic
epitope-binding proteins (e.g., therapeutic antibodies) frequently
require a K.sub.D that is in the nanomolar or the picomolar
range.
[0189] The phrase "functional fragment" includes fragments of
epitope-binding proteins that can be expressed, secreted, and
specifically bind to an epitope with a K.sub.D in the micromolar,
nanomolar, or picomolar range. Specific recognition includes having
a K.sub.D that is at least in the micromolar range, the nanomolar
range, or the picomolar range.
[0190] The term "germline" includes reference to an immunoglobulin
nucleic acid sequence in a non-somatically mutated cell, e.g., a
non-somatically mutated B cell or pre-B cell or hematopoietic
cell.
[0191] The phrase "heavy chain," or "immunoglobulin heavy chain"
includes an immunoglobulin heavy chain constant region sequence
from any organism. Heavy chain variable domains include three heavy
chain CDRs and four FR regions, unless otherwise specified.
Fragments of heavy chains include CDRs, CDRs and FRs, and
combinations thereof. A typical heavy chain has, following the
variable domain (from N-terminal to C-terminal), a C.sub.H1 domain,
a hinge, a C.sub.H2 domain, and a C.sub.H3 domain. A functional
fragment of a heavy chain includes a fragment that is capable of
specifically recognizing an epitope (e.g., recognizing the epitope
with a K.sub.D in the micromolar, nanomolar, or picomolar range),
that is capable of expressing and secreting from a cell, and that
comprises at least one CDR.
[0192] The term "identity" when used in connection with sequence
includes identity as determined by a number of different algorithms
known in the art that can be used to measure nucleotide and/or
amino acid sequence identity. In some embodiments described herein,
identities are determined using a ClustalW v. 1.83 (slow) alignment
employing an open gap penalty of 10.0, an extend gap penalty of
0.1, and using a Gonnet similarity matrix (MACVECTOR.TM. 10.0.2,
MacVector Inc., 2008). The length of the sequences compared with
respect to identity of sequences will depend upon the particular
sequences, but in the case of a light chain constant domain, the
length should contain sequence of sufficient length to fold into a
light chain constant domain that is capable of self-association to
form a canonical light chain constant domain, e.g., capable of
forming two beta sheets comprising beta strands and capable of
interacting with at least one C.sub.H1 domain of a human or a
mouse. In the case of a C.sub.H1 domain, the length of sequence
should contain sequence of sufficient length to fold into a
C.sub.H1 domain that is capable of forming two beta sheets
comprising beta strands and capable of interacting with at least
one light chain constant domain of a mouse or a human.
[0193] The phrase "immunoglobulin molecule" includes two
immunoglobulin heavy chains and two immunoglobulin light chains.
The heavy chains may be identical or different, and the light
chains may be identical or different.
[0194] The phrase "light chain" includes an immunoglobulin light
chain sequence from any organism, and unless otherwise specified
includes human .kappa. and .lamda. light chains and a VpreB, as
well as surrogate light chains. Light chain variable (V.sub.L)
domains typically include three light chain CDRs and four framework
(FR) regions, unless otherwise specified. Generally, a full-length
light chain includes, from amino terminus to carboxyl terminus, a
V.sub.L domain that includes FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, and a
light chain constant domain. Light chains include those, e.g., that
do not selectively bind either a first or a second epitope
selectively bound by the epitope-binding protein in which they
appear. Light chains also include those that bind and recognize, or
assist the heavy chain with binding and recognizing, one or more
epitopes selectively bound by the epitope-binding protein in which
they appear. Common light chains are those derived from a
rearranged human V.kappa.1-39J.kappa.5 sequence or a rearranged
human V.kappa.3-20J.kappa.1 sequence, and include somatically
mutated (e.g., affinity matured) versions.
[0195] The phrase "micromolar range" is intended to mean 1-999
micromolar; the phrase "nanomolar range" is intended to mean 1-999
nanomolar; the phrase "picomolar range" is intended to mean 1-999
picomolar.
[0196] The phrase "somatically mutated" includes reference to a
nucleic acid sequence from a B cell that has undergone
class-switching, wherein the nucleic acid sequence of an
immunoglobulin variable region (e.g., a heavy chain variable domain
or including a heavy chain CDR or FR sequence) in the
class-switched B cell is not identical to the nucleic acid sequence
in the B cell prior to class-switching, such as, for example, a
difference in a CDR or framework nucleic acid sequence between a B
cell that has not undergone class-switching and a B cell that has
undergone class-switching. "Somatically mutated" includes reference
to nucleic acid sequences from affinity-matured B cells that are
not identical to corresponding immunoglobulin variable region
sequences in B cells that are not affinity-matured (i.e., sequences
in the genome of germline cells). The phrase "somatically mutated"
also includes reference to an immunoglobulin variable region
nucleic acid sequence from a B cell after exposure of the B cell to
an epitope of interest, wherein the nucleic acid sequence differs
from the corresponding nucleic acid sequence prior to exposure of
the B cell to the epitope of interest. The phrase "somatically
mutated" refers to sequences from antibodies that have been
generated in an animal, e.g., a mouse having human immunoglobulin
variable region nucleic acid sequences, in response to an immunogen
challenge, and that result from the selection processes inherently
operative in such an animal.
[0197] The term "unrearranged," with reference to a nucleic acid
sequence, includes nucleic acid sequences that exist in the
germline of an animal cell.
[0198] The phrase "variable domain" includes an amino acid sequence
of an immunoglobulin light or heavy chain (modified as desired)
that comprises the following amino acid regions, in sequence from
N-terminal to C-terminal (unless otherwise indicated): FR1, CDR1,
FR2, CDR2, FR3, CDR3, FR4.
Universal Light Chain
[0199] Prior efforts to make useful multispecific epitope-binding
proteins, e.g., bispecific antibodies, have been hindered by
variety of problems that frequently share a common paradigm: in
vitro selection or manipulation of sequences to rationally
engineer, or to engineer through trial-and-error, a suitable format
for pairing a heterodimeric bispecific human immunoglobulin.
Unfortunately, most if not all of the in vitro engineering
approaches provide largely ad hoc fixes that are suitable, if at
all, for individual molecules. On the other hand, in vivo methods
for employing complex organisms to select appropriate pairings that
are capable of leading to human therapeutics have not been
realized.
[0200] Generally, native mouse sequences are frequently not a good
source for human therapeutic sequences. For at least that reason,
generating mouse heavy chain immunoglobulin variable regions that
pair with a common human light chain is of limited practical
utility. More in vitro engineering efforts would be expended in a
trial-and-error process to try to humanize the mouse heavy chain
variable sequences while hoping to retain epitope specificity and
affinity while maintaining the ability to couple with the common
human light chain, with uncertain outcome. At the end of such a
process, the final product may maintain some of the specificity and
affinity, and associate with the common light chain, but ultimately
immunogenicity in a human would likely remain a profound risk.
[0201] Therefore, a suitable mouse for making human therapeutics
would include a suitably large repertoire of human heavy chain
variable region gene segments in place of endogenous mouse heavy
chain variable region gene segments. The human heavy chain variable
region gene segments should be able to rearrange and recombine with
an endogenous mouse heavy chain constant domain to form a reverse
chimeric heavy chain (i.e., a heavy chain comprising a human
variable domain and a mouse constant region). The heavy chain
should be capable of class switching and somatic hypermutation so
that a suitably large repertoire of heavy chain variable domains
are available for the mouse to select one that can associate with
the limited repertoire of human light chain variable regions.
[0202] A mouse that selects a common light chain for a plurality of
heavy chains has a practical utility. In various embodiments,
antibodies that express in a mouse that can only express a common
light chain will have heavy chains that can associate and express
with an identical or substantially identical light chain. This is
particularly useful in making bispecific antibodies. For example,
such a mouse can be immunized with a first immunogen to generate a
B cell that expresses an antibody that specifically binds a first
epitope. The mouse (or a mouse genetically the same) can be
immunized with a second immunogen to generate a B cell that
expresses an antibody that specifically binds the second epitope.
Variable heavy regions can be cloned from the B cells and expresses
with the same heavy chain constant region, and the same light
chain, and expressed in a cell to make a bispecific antibody,
wherein the light chain component of the bispecific antibody has
been selected by a mouse to associate and express with the light
chain component.
[0203] The inventors have engineered a mouse for generating
immunoglobulin light chains that will suitably pair with a rather
diverse family of heavy chains, including heavy chains whose
variable regions depart from germline sequences, e.g., affinity
matured or somatically mutated variable regions. In various
embodiments, the mouse is devised to pair human light chain
variable domains with human heavy chain variable domains that
comprise somatic mutations, thus enabling a route to high affinity
binding proteins suitable for use as human therapeutics.
[0204] The genetically engineered mouse, through the long and
complex process of antibody selection within an organism, makes
biologically appropriate choices in pairing a diverse collection of
human heavy chain variable domains with a limited number of human
light chain options. In order to achieve this, the mouse is
engineered to present a limited number of human light chain
variable domain options in conjunction with a wide diversity of
human heavy chain variable domain options. Upon challenge with an
immunogen, the mouse maximizes the number of solutions in its
repertoire to develop an antibody to the immunogen, limited largely
or solely by the number or light chain options in its repertoire.
In various embodiments, this includes allowing the mouse to achieve
suitable and compatible somatic mutations of the light chain
variable domain that will nonetheless be compatible with a
relatively large variety of human heavy chain variable domains,
including in particular somatically mutated human heavy chain
variable domains.
[0205] To achieve a limited repertoire of light chain options, the
mouse is engineered to render nonfunctional or substantially
nonfunctional its ability to make, or rearrange, a native mouse
light chain variable domain. This can be achieved, e.g., by
deleting the mouse's light chain variable region gene segments. The
endogenous mouse locus can then be modified by an exogenous
suitable human light chain variable region gene segment of choice,
operably linked to the endogenous mouse light chain constant
domain, in a manner such that the exogenous human variable region
gene segments can combine with the endogenous mouse light chain
constant region gene and form a rearranged reverse chimeric light
chain gene (human variable, mouse constant). In various
embodiments, the light chain variable region is capable of being
somatically mutated. In various embodiments, to maximize ability of
the light chain variable region to acquire somatic mutations, the
appropriate enhancer(s) is retained in the mouse. For example, in
modifying a mouse .kappa. light chain locus to replace endogenous
mouse .kappa. light chain gene segments with human .kappa. light
chain gene segments, the mouse .kappa. intronic enhancer and mouse
.kappa.3' enhancer are functionally maintained, or undisrupted.
[0206] A genetically engineered mouse is provided that expresses a
limited repertoire of reverse chimeric (human variable, mouse
constant) light chains associated with a diversity of reverse
chimeric (human variable, mouse constant) heavy chains. In various
embodiments, the endogenous mouse .kappa. light chain gene segments
are deleted and replaced with a single (or two) rearranged human
light chain region, operably linked to the endogenous mouse
C.kappa. gene. In embodiments for maximizing somatic hypermutation
of the rearranged human light chain region, the mouse .kappa.
intronic enhancer and the mouse .kappa.3' enhancer are maintained.
In various embodiments, the mouse also comprises a nonfunctional
.lamda. light chain locus, or a deletion thereof or a deletion that
renders the locus unable to make a .lamda. light chain.
[0207] A genetically engineered mouse is provided that, in various
embodiments, comprises a light chain variable region locus lacking
endogenous mouse light chain V.sub.L and J.sub.L gene segments and
comprising a rearranged human light chain variable region, in one
embodiment a rearranged human V.sub.L/J.sub.L sequence, operably
linked to a mouse constant region, wherein the locus is capable of
undergoing somatic hypermutation, and wherein the locus expresses a
light chain comprising the human V.sub.L/J.sub.L sequence linked to
a mouse constant region. Thus, in various embodiments, the locus
comprises a mouse .kappa.3' enhancer, which is correlated with a
normal, or wild type, level of somatic hypermutation.
[0208] The genetically engineered mouse in various embodiments when
immunized with an antigen of interest generates B cells that
exhibit a diversity of rearrangements of human immunoglobulin heavy
chain variable regions that express and function with one or with
two rearranged light chains, including embodiments where the one or
two light chains comprise human light chain variable regions that
comprise, e.g., 1 to 5 somatic mutations. In various embodiments,
the human light chains so expressed are capable of associating and
expressing with any human immunoglobulin heavy chain variable
region expressed in the mouse.
Epitope-Binding Proteins Binding More than One Epitope
[0209] The compositions and methods of described herein can be used
to make binding proteins that bind more than one epitope with high
affinity, e.g., bispecific antibodies. Advantages of the invention
include the ability to select suitably high binding (e.g., affinity
matured) heavy chain immunoglobulin chains each of which will
associate with a single light chain.
[0210] Several techniques for making bispecific antibody fragments
from recombinant cell culture have been reported. However,
synthesis and expression of bispecific binding proteins has been
problematic, in part due to issues associated with identifying a
suitable light chain that can associate and express with two
different heavy chains, and in part due to isolation issues. In
various embodiments, compositions and methods described herein
provide the advantage of full length bispecific antibodies that do
not require special modification(s) to maintain traditional
immunoglobulin structure by increasing stability/interaction of the
components (FIG. 7A). In various embodiments, such modification(s)
has proven cumbersome and served as an obstacle to development of
bispecific antibody technology and their potential use in treating
for human disease. Thus, in various embodiments, through providing
a natural immunoglobulin structure (i.e., full length) having the
added property of multiple specificities, full length bispecific
antibodies maintain their critical effector functions that previous
bispecific fragments lack, and further provide therapeutics that
demonstrate the important pharmacokinetic parameter of a longer
half-life.
[0211] The methods and compositions described herein allow for a
genetically modified mouse to select, through otherwise natural
processes, a suitable light chain that can associate and express
with more than one heavy chain, including heavy chains that are
somatically mutated (e.g., affinity matured). Human V.sub.L and
V.sub.H sequences from suitable B cells of immunized mice as
described herein that express affinity matured antibodies having
reverse chimeric heavy chains (i.e., human variable and mouse
constant) can be identified and cloned in frame in an expression
vector with a suitable human constant region gene sequence (e.g., a
human IgG1). Two such constructs can be prepared, wherein each
construct encodes a human heavy chain variable domain that binds a
different epitope. One of the human V.sub.Ls (e.g., human
V.kappa.1-39J.kappa.5 or human V.kappa.3-20J.kappa.1), in germline
sequence or from a B cell wherein the sequence has been somatically
mutated, can be fused in frame to a suitable human constant region
gene (e.g., a human .kappa. constant gene). These three fully human
heavy and light constructs can be placed in a suitable cell for
expression. The cell will express two major species: a homodimeric
heavy chain with the identical light chain, and a heterodimeric
heavy chain with the identical light chain. To allow for a facile
separation of these major species, one of the heavy chains is
modified to omit a Protein A-binding determinant, resulting in a
differential affinity of a homodimeric binding protein from a
heterodimeric binding protein. Compositions and methods that
address this issue are described in U.S. Ser. No. 12/832,838, filed
25 Jun. 2010, entitled "Readily Isolated Bispecific Antibodies with
Native Immunoglobulin Format," published as US 2010/0331527A1,
hereby incorporated by reference.
[0212] In one aspect, an epitope-binding protein as described
herein is provided, wherein human V.sub.L and V.sub.H sequences are
derived from mice described herein that have been immunized with an
antigen comprising an epitope of interest.
[0213] In one embodiment, an epitope-binding protein is provided
that comprises a first and a second polypeptide, the first
polypeptide comprising, from N-terminal to C-terminal, a first
epitope-binding region that selectively binds a first epitope,
followed by a constant region that comprises a first C.sub.H3
region of a human IgG selected from IgG1, IgG2, IgG4, and a
combination thereof; and, a second polypeptide comprising, from
N-terminal to C-terminal, a second epitope-binding region that
selectively binds a second epitope, followed by a constant region
that comprises a second C.sub.H3 region of a human IgG selected
from IgG1, IgG2, IgG4, and a combination thereof, wherein the
second C.sub.H3 region comprises a modification that reduces or
eliminates binding of the second C.sub.H3 domain to protein A.
[0214] In one embodiment, the second C.sub.H3 region comprises an
H95R modification (by IMGT exon numbering; H435R by EU numbering).
In another embodiment, the second C.sub.H3 region further comprises
a Y96F modification (IMGT; Y436F by EU).
[0215] In one embodiment, the second C.sub.H3 region is from a
modified human IgG1, and further comprises a modification selected
from the group consisting of D16E, L18M, N44S, K52N, V57M, and V82I
(IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU).
[0216] In one embodiment, the second C.sub.H3 region is from a
modified human IgG2, and further comprises a modification selected
from the group consisting of N44S, K52N, and V82I (IMGT; N384S,
K392N, and V422I by EU).
[0217] In one embodiment, the second C.sub.H3 region is from a
modified human IgG4, and further comprises a modification selected
from the group consisting of Q15R, N44S, K52N, V57M, R69K, E79Q,
and V82I (IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I
by EU).
[0218] One method for making an epitope-binding protein that binds
more than one epitope is to immunize a first mouse in accordance
with the invention with an antigen that comprises a first epitope
of interest, wherein the mouse comprises an endogenous
immunoglobulin light chain variable region locus that does not
contain an endogenous mouse V.sub.L that is capable of rearranging
and forming a light chain, wherein at the endogenous mouse
immunoglobulin light chain variable region locus is a single
rearranged human V.sub.L region operably linked to the mouse
endogenous light chain constant region gene, and the rearranged
human V.sub.L region is selected from a human V.kappa.1-39J.kappa.5
and a human V.kappa.3-20J.kappa.1, and the endogenous mouse V.sub.H
gene segments have been replaced in whole or in part with human
V.sub.H gene segments, such that immunoglobulin heavy chains made
by the mouse are solely or substantially heavy chains that comprise
human variable domains and mouse constant domains. When immunized,
such a mouse will make a reverse chimeric antibody, comprising only
one of two human light chain variable domains (e.g., one of human
V.kappa.1-39J.kappa.5 or human V.kappa.3-20J.kappa.1). Once a B
cell is identified that encodes a V.sub.H that binds the epitope of
interest, the nucleotide sequence of the V.sub.H (and, optionally,
the V.sub.L) can be retrieved (e.g., by PCR) and cloned into an
expression construct in frame with a suitable human immunoglobulin
constant domain. This process can be repeated to identify a second
V.sub.H domain that binds a second epitope, and a second V.sub.H
gene sequence can be retrieved and cloned into an expression vector
in frame to a second suitable immunoglobulin constant domain. The
first and the second immunoglobulin constant domains can the same
or different isotype, and one of the immunoglobulin constant
domains (but not the other) can be modified as described herein or
in US 2010/0331527A1, and epitope-binding protein can be expressed
in a suitable cell and isolated based on its differential affinity
for Protein A as compared to a homodimeric epitope-binding protein,
e.g., as described in US 2010/0331527A1.
[0219] In one embodiment, a method for making a bispecific
epitope-binding protein is provided, comprising identifying a first
affinity-matured (e.g., comprising one or more somatic
hypermutations) human V.sub.H nucleotide sequence (V.sub.H1) from a
mouse as described herein, identifying a second affinity-matured
(e.g., comprising one or more somatic hypermutations) human V.sub.H
nucleotide sequence (V.sub.H2) from a mouse as described herein,
cloning V.sub.H1 in frame with a human heavy chain lacking a
Protein A-determinant modification as described in US
2010/0331527A1 for form heavy chain 1 (HC1), cloning V.sub.H2 in
frame with a human heavy chain comprising a Protein A-determinant
as described in US 2010/0331527A1 to form heavy chain 2 (HC2),
introducing an expression vector comprising HC1 and the same or a
different expression vector comprising HC2 into a cell, wherein the
cell also expresses a human immunoglobulin light chain that
comprises a human V.kappa.1-39/human J.kappa.5 or a human
V.kappa.3-20/human J.kappa.1 fused to a human light chain constant
domain, allowing the cell to express a bispecific epitope-binding
protein comprising a V.sub.H domain encoded by V.sub.H1 and a
V.sub.H domain encoded by V.sub.H2, and isolating the bispecific
epitope-binding protein based on its differential ability to bind
Protein A as compared with a monospecific homodimeric
epitope-binding protein. In a specific embodiment, HC1 is an IgG1,
and HC2 is an IgG1 that comprises the modification H95R (IMGT;
H435R by EU) and further comprises the modification Y96F (IMGT;
Y436F by EU). In one embodiment, the VH domain encoded by V.sub.H1,
the V.sub.H domain encoded by V.sub.H2, or both, are somatically
mutated.
Human V.sub.H Genes that Express with a Common Human V.sub.L
[0220] A variety of human variable regions from affinity-matured
antibodies raised against four different antigens were expressed
with either their cognate light chain, or at least one of a human
light chain selected from human V.kappa.1-39/J.kappa.5, human
V.kappa.3-20/J.kappa.1, or human VpreB/J.lamda.5 (see Example 1).
For antibodies to each of the antigens, somatically mutated high
affinity heavy chains from different gene families paired
successfully with rearranged human germline V.kappa.1-39J.kappa.5
and V.kappa.3-20J.kappa.1 regions and were secreted from cells
expressing the heavy and light chains. For V.kappa.1-39J.kappa.5
and V.kappa.3-20J.kappa.1, V.sub.H domains derived from the
following human V.sub.H gene families expressed favorably: 1-2,
1-8, 1-24, 2-5, 3-7, 3-9, 3-11, 3-13, 3-15, 3-20, 3-23, 3-30, 3-33,
3-48, 4-31, 4-39, 4-59, 5-51, and 6-1. Thus, a mouse that is
engineered to express a limited repertoire of human V.sub.L domains
from one or both of V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1
will generate a diverse population of somatically mutated human
V.sub.H domains from a V.sub.H locus modified to replace mouse
V.sub.H gene segments with human V.sub.H gene segments.
[0221] Mice genetically engineered to express reverse chimeric
(human variable, mouse constant) immunoglobulin heavy chains
associated with a single rearranged light chain (e.g., a
V.kappa.1-39/J or a V.kappa.3-20/J), when immunized with an antigen
of interest, generated B cells that comprised a diversity of human
V.sub.H rearrangements and expressed a diversity of high-affinity
antigen-specific antibodies with diverse properties with respect to
their ability to block binding of the antigen to its ligand, and
with respect to their ability to bind variants of the antigen (see
Examples 5 through 10).
[0222] Thus, the mice and methods described herein are useful in
making and selecting human immunoglobulin heavy chain variable
domains, including somatically mutated human heavy chain variable
domains, that result from a diversity of rearrangements, that
exhibit a wide variety of affinities (including exhibiting a
K.sub.D of about a nanomolar or less), a wide variety of
specificities (including binding to different epitopes of the same
antigen), and that associate and express with the same or
substantially the same human immunoglobulin light chain variable
region.
Fully Human Bispecific Antibodies Having a Common Light Chain
[0223] As a first step in various embodiments, the first and second
nucleic acid sequences that each encode human heavy chain variable
domains (and any additional nucleic acid sequences forming the
bispecific antibody) are selected from parent monoclonal antibodies
having desired characteristics such as, for example, capable of
binding different epitopes (see FIGS. 7A and 7B), having different
affinities, etc. Normally, the nucleic acid sequences encoding the
human heavy chain variable domains are isolated from immunized
mice, as described herein, to allow for fusing with human heavy
chain constant regions to be suitable for human administration.
Further modifications to the sequence(s) can be made by introducing
mutations that add additional functionality to the bispecific
antibody can be achieved, which include, for example, increasing
serum half-life (e.g., see U.S. Pat. No. 7,217,797) and/or
increasing antibody-dependent cell-mediated cytotoxicity (e.g., see
U.S. Pat. No. 6,737,056). Introducing mutations into the constant
regions of antibodies is known in the art. Additionally, part of
the bispecific antibody can be made recombinantly in cell culture
and other part(s) of the molecule can be made by those techniques
mentioned above.
[0224] Several techniques for the producing antibodies have been
described. For example, in various embodiments chimeric antibodies
are produced in mice as described herein. Antibodies can be
isolated directly from B cells of an immunized mouse (e.g., see
U.S. 2007/0280945A1) and/or the B cells of the immunized mouse can
be used to make hybridomas (Kohler and Milstein, 1975, Nature
256:495-497). DNA encoding the antibodies (human heavy and/or light
chains) from mice as described herein is readily isolated and
sequenced using conventional techniques. Hybridoma and/or B cells
of derived from mice as described herein serve as a preferred
source of such DNA. Once isolated, the DNA may be placed into
expression vectors, which are then transfected into host cells that
do not otherwise produce immunoglobulin protein, to obtain the
synthesis of monoclonal antibodies in the recombinant host cells.
The DNA also may be modified, for example, by substituting the
coding sequence for human heavy and light chain constant domains in
place of the murine sequences.
[0225] In various embodiments, following isolation of the DNA and
selection of the first and second nucleic acid sequences that
encode the first and second human heavy chain variable domains
having the desired specificities/affinities, and a third nucleic
acid sequence that encodes a human light chain domain (a germline
rearranged sequence or a light chain sequence isolated from a mouse
as described herein), the three nucleic acids sequences encoding
the molecules are expressed to form the bispecific antibody using
recombinant techniques which are widely available in the art.
Often, the expression system of choice will involve a mammalian
cell expression vector and host so that the bispecific antibody is
appropriately glycosylated (e.g., in the case of bispecific
antibodies comprising antibody domains which are glycosylated).
However, the molecules can also be produced in the prokaryotic
expression systems. Normally, the host cell will be transformed
with DNA encoding both the first human heavy chain variable domain,
the second human heavy chain variable domain, the human light chain
domain on a single vector or independent vectors. However, it is
possible to express the first human heavy chain variable domain,
second human heavy chain variable domain, and human light chain
domain (the bispecific antibody components) in independent
expression systems and couple the expressed polypeptides in vitro.
In various embodiments, the human light chain domain comprises a
germline sequence. In various embodiments, the human light chain
domain comprises no more than one, no more than two, no more than
three, no more than four, or no more than five somatic
hypermutations with the light chain variable sequence of the light
chain domain.
[0226] In various embodiments, the nucleic acid(s) (e.g., cDNA or
genomic DNA) encoding the two heavy chains and single human light
chain is inserted into a replicable vector for further cloning
(amplification of the DNA) and/or for expression. Many vectors are
available, and generally include, but are not limited to, one or
more of the following: a signal sequence, an origin of replication,
one or more marker genes, an enhancer element, a promoter, and a
transcription termination sequence. Each component may be selected
individually or based on a host cell choice or other criteria
determined experimentally. Several examples of each component are
known in the art.
[0227] Expression and cloning vectors usually contain a promoter
that is recognized by the host organism and is operably linked to
the nucleic acid sequences that encode each or all the components
of the bispecific antibody. A large number of promoters recognized
by a variety of potential host cells are well known. These
promoters are operably linked to bispecific antibody-encoding DNA
by removing the promoter from the source DNA by restriction enzyme
digestion and inserting the isolated promoter sequence into the
vector.
[0228] Expression vectors used in eukaryotic host cells (yeast,
fungi, insect, plant, animal, human, or nucleated cells from other
multicellular organisms) may also contain sequences necessary for
the termination of transcription and for stabilizing the mRNA. Such
sequences are commonly available from the 5' and, occasionally 3',
untranslated regions of eukaryotic or viral DNAs or cDNAs. These
regions contain nucleotide segments transcribed as polyadenylated
fragments in the untranslated portion of the mRNA encoding the
bispecific antibody components. Suitable expression vectors for
various embodiments include those that provide for the transient
expression in mammalian cells of DNA encoding the bispecific
antibody. In general, transient expression involves the use of an
expression vector that is able to replicate efficiently in a host
cell, such that the host cell accumulates many copies of the
expression vector and, in turn, synthesizes high levels of a
desired polypeptide encoded by the expression vector. Transient
expression systems, comprising a suitable expression vector and a
host cell, allow for the convenient positive identification of
polypeptides encoded by cloned DNAs, as well as for the rapid
screening of bispecific antibodies having desired binding
specificities/affinities or the desired gel migration
characteristics relative to the parental antibodies having
homodimers of the first or second human heavy chain variable
domains.
[0229] In various embodiments, once the DNA encoding the components
of the bispecific antibody are assembled into the desired vector(s)
as described above, they are introduced into a suitable host cell
for expression and recovery. Transfecting host cells can be
accomplished using standard techniques known in the art appropriate
to the host cell selected (e.g., electroporation, nuclear
microinjection, bacterial protoplast fusion with intact cells, or
polycations, e.g., polybrene, polyornithine, etc.).
[0230] A host cell is chosen, in various embodiments, that best
suits the expression vector containing the components and allows
for the most efficient and favorable production of the bispecific
antibody species. Exemplary host cells for expression include those
of prokaryotes and eukaryotes (single-cell or multiple-cell),
bacterial cells (e.g., strains of E. coli, Bacillus spp.,
Streptomyces spp., etc.), mycobacteria cells, fungal cells, yeast
cells (e.g., S. cerevisiae, S. pombe, P. pastoris, P. methanolica,
etc.), plant cells, insect cells (e.g., SF-9, SF-21,
baculovirus-infected insect cells, Trichoplusia ni, etc.),
non-human animal cells, human cells, or cell fusions such as, for
example, hybridomas or quadromas. In various embodiments, the cell
is a human, monkey, ape, hamster, rat, or mouse cell. In various
embodiments, the cell is eukaryotic cell selected from CHO (e.g.,
CHO K1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cell,
Vero, CV1, kidney (e.g., HEK293, 293 EBNA, MSR 293, MDCK, HaK,
BHK), HeLa, HepG2, WI38, MRC 5, Colo205, HB 8065, HL-60, (e.g.,
BHK21), Jurkat, Daudi, A431 (epidermal), CV-1, U937, 3T3, L cell,
C127 cell, SP2/0, NS-0, MMT 060562, Sertoli cell, BRL 3A cell,
HT1080 cell, myeloma cell, tumor cell, and a cell line derived from
an aforementioned cell. In various embodiments, the cell comprises
one or more viral genes, e.g. a retinal cell that expresses a viral
gene (e.g., a PER.C6.TM. cell).
[0231] Mammalian host cells used to produce the bispecific antibody
may be cultured in a variety of media. Commercially available media
such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma),
RPMI-1640 (Sigma), and Dulbeccols Modified Eagle's Medium ((DMEM),
Sigma) are suitable for culturing the host cells. Media may be
supplemented as necessary with hormones and/or other growth factors
(such as insulin, transferrin, or epidermal growth factor), salts
(such as sodium chloride, calcium, magnesium, and phosphate),
buffers (such as HEPES), nucleosides (such as adenosine and
thymidine), antibiotics (such as GENTAMYCIN.TM.), trace elements
(defined as inorganic compounds usually present at final
concentrations in the micromolar range), and glucose or an
equivalent energy source. Any other supplements may also be
included at appropriate concentrations as known to those skilled in
the art. The culture conditions, such as temperature, pH, and the
like, are, in various embodiments, those previously used with the
host cell selected for expression, and will be apparent to those
skilled in the art.
[0232] The bispecific antibody is in various embodiments recovered
from the culture medium as a secreted polypeptide, although it also
may be recovered from host cell lysate when directly produced
without a secretory signal. If the bispecific antibody is
membrane-bound, it can be released from the membrane using a
suitable detergent solution (e.g., Triton-X 100). Preferably, the
bispecific antibodies described herein involves the use of a first
immunoglobulin C.sub.H3 domain and a second immunoglobulin C.sub.H3
domain, wherein the first and second immunoglobulin C.sub.H3
domains differ from one another by at least one amino acid, and
wherein at least one amino acid difference reduces binding of the
bispecific antibody to Protein A as compared to a bi-specific
antibody lacking the amino acid difference (see U.S.
2010/0331527A1; herein incorporated by reference). In one
embodiment, the first immunoglobulin C.sub.H3 domain binds Protein
A and the second immunoglobulin C.sub.H3 domain contains a mutation
that reduces or abolishes Protein A binding such as an H95R
modification (by IMGT exon numbering; H435R by EU numbering). The
second C.sub.H3 may further comprise a Y96F modification (by IMGT;
Y436F by EU). Further modifications that may be found within the
second C.sub.H3 include: D16E, L18M, N44S, K52N, V57M, and V82I (by
IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU) in the
case of IgG1 antibodies; N44S, K52N, and V82I (IMGT; N384S, K392N,
and V422I by EU) in the case of IgG2 antibodies; and Q15R, N44S,
K52N, V57M, R69K, E79Q, and V82I (by IMGT; Q355R, N384S, K392N,
V397M, R409K, E419Q, and V422I by EU) in the case of IgG4
antibodies. Variations on the bi-specific antibody format described
above are contemplated within the scope of the present
invention.
[0233] Because of the dual nature of bispecific antibodies (i.e.,
may be specific for different epitopes of one polypeptide or may
contain antigen-binding domains specific for more than one target
polypeptide, see FIG. 7B; see also, e.g., Tutt et al., 1991, J.
Immunol. 147:60-69; Kufer et al., 2004, Trends Biotechnol.
22:238-244), they offer many useful advantages for therapeutic
application. For example, the bispecific antibodies can be used for
redirected cytotoxicity (e.g., to kill tumor cells), as a vaccine
adjuvant, for delivering thrombolytic agents to clots, for
converting enzyme activated prodrugs at a target site (e.g., a
tumor), for treating infectious diseases, targeting immune
complexes to cell surface receptors, or for delivering immunotoxins
to tumor cells.
[0234] The bispecific antibodies described herein can also be used
in several therapeutic and non-therapeutic and/or diagnostic assay
methods, such as, enzyme immunoassays, two-site immunoassays, in
vitro or in vivo immunodiagnosis of various diseases (e.g.,
cancer), competitive binding assays, direct and indirect sandwich
assays, and immunoprecipitation assays. Other uses for the
bispecific antibodies will be apparent to those skilled in the
art.
[0235] The following examples are provided so as to describe to
those of ordinary skill in the art how to make and use methods and
compositions of the invention, and are not intended to limit the
scope of what the inventors regard as their invention. Efforts have
been made to ensure accuracy with respect to numbers used (e.g.,
amounts, temperature, etc.) but some experimental errors and
deviations should be accounted for. Unless indicated otherwise,
parts are parts by weight, molecular weight is average molecular
weight, temperature is indicated in Celsius, and pressure is at or
near atmospheric.
EXAMPLES
[0236] The following examples are provided so as to describe to
those of ordinary skill in the art how to make and use methods and
compositions of the invention, and are not intended to limit the
scope of what the inventors regard as their invention. Efforts have
been made to ensure accuracy with respect to numbers used (e.g.,
amounts, temperature, etc.) but some experimental errors and
deviations should be accounted for. Unless indicated otherwise,
temperature is indicated in Celsius, pressure is at or near
atmospheric, parts are by parts by weight, and molecular weight is
average molecular weight.
Example 1
Identification of Human V.sub.H Regions that Associate with
Selected Human V.sub.L Regions
[0237] An in vitro expression system was constructed to determine
if a single rearranged human germline light chain could be
co-expressed with human heavy chains from antigen specific human
antibodies.
[0238] Methods for generating human antibodies in genetically
modified mice are known (see e.g., U.S. Pat. No. 6,596,541,
Regeneron Pharmaceuticals, VELOCIMMUNE.RTM.). The VELOCIMMUNE.RTM.
technology involves generation of a genetically modified mouse
having a genome comprising human heavy and light chain variable
regions operably linked to endogenous mouse constant region loci
such that the mouse produces an antibody comprising a human
variable region and a mouse constant region in response to
antigenic stimulation. The DNA encoding the variable regions of the
heavy and light chains of the antibodies produced from a
VELOCIMMUNE.RTM. mouse are fully human. Initially, high affinity
chimeric antibodies are isolated having a human variable region and
a mouse constant region. As described below, the antibodies are
characterized and selected for desirable characteristics, including
affinity, selectivity, epitope, etc. The mouse constant regions are
replaced with a desired human constant region to generate a fully
human antibody containing a non-IgM isotype, for example, wild type
or modified IgG1, IgG2, IgG3 or IgG4. While the constant region
selected may vary according to specific use, high affinity
antigen-binding and target specificity characteristics reside in
the variable region.
[0239] A VELOCIMMUNE.RTM. mouse was immunized with a growth factor
that promotes angiogenesis (Antigen C) and antigen-specific human
antibodies were isolated and sequenced for V gene usage using
standard techniques recognized in the art. Selected antibodies were
cloned onto human heavy and light chain constant regions and 69
heavy chains were selected for pairing with one of three human
light chains: (1) the cognate .kappa. light chain linked to a human
.kappa. constant region, (2) a rearranged human germline
V.kappa.1-39J.kappa.5 linked to a human .kappa. constant region, or
(3) a rearranged human germline V.kappa.3-20J.kappa.1 linked to a
human .kappa. constant region. Each heavy chain and light chain
pair were co-transfected in CHO-K1 cells using standard techniques.
Presence of antibody in the supernatant was detected by anti-human
IgG in an ELISA assay. Antibody titer (ng/ml) was determined for
each heavy chain/light chain pair and titers with the different
rearranged germline light chains were compared to the titers
obtained with the parental antibody molecule (i.e., heavy chain
paired with cognate light chain) and percent of native titer was
calculated (Table 1). V.sub.H: Heavy chain variable gene. ND: no
expression detected under current experimental conditions.
TABLE-US-00001 TABLE 1 Antibody Titer Percent of (ng/mL) Native
Titer Cognate V.kappa.1- V.kappa.3- V.kappa.1- V.kappa.3- V.sub.H
LC 39J.kappa.5 20J.kappa.1 39J.kappa.5 20J.kappa.1 3-15 63 23 11
36.2 17.5 1-2 103 53 ND 51.1 -- 3-23 83 60 23 72.0 27.5 3-33 15 77
ND 499.4 -- 4-31 22 69 17 309.4 76.7 3-7 53 35 28 65.2 53.1 -- 22
32 19 148.8 89.3 1-24 3 13 ND 455.2 -- 3-33 1 47 ND 5266.7 -- 3-33
58 37 ND 63.1 -- -- 110 67 18 60.6 16.5 3-23 127 123 21 96.5 16.3
3-33 28 16 2 57.7 7.1 3-23 32 50 38 157.1 119.4 -- 18 45 18 254.3
101.7 3-9 1 30 23 2508.3 1900.0 3-11 12 26 6 225.9 48.3 1-8 16 ND
13 -- 81.8 3-33 54 81 10 150.7 19.1 -- 34 9 ND 25.9 -- 3-20 7 14 54
203.0 809.0 3-33 19 38 ND 200.5 -- 3-11 48 ND 203 -- 423.6 -- 11 23
8 212.7 74.5 3-33 168 138 182 82.0 108.2 3-20 117 67 100 57.5 86.1
3-23 86 61 132 70.7 154.1 3-33 20 12 33 60.9 165.3 4-31 69 92 52
133.8 75.0 3-23 87 78 62 89.5 71.2 1-2 31 82 51 263.0 164.6 3-23 53
93 151 175.4 285.4 -- 11 8 17 75.7 151.4 3-33 114 36 27 31.6 23.4
3-15 73 39 44 53.7 59.6 3-33 1 34 16 5600.0 2683.3 3-9 58 112 57
192.9 97.6 3-33 67 20 105 30.1 157.0 3-33 34 21 24 62.7 70.4 3-20
10 49 91 478.4 888.2 3-33 66 32 25 48.6 38.2 3-23 17 59 56 342.7
329.8 -- 58 108 19 184.4 32.9 -- 68 54 20 79.4 29.9 3-33 42 35 32
83.3 75.4 -- 29 19 13 67.1 43.9 3-9 24 34 29 137.3 118.4 3-30/33 17
33 7 195.2 43.1 3-7 25 70 74 284.6 301.6 3-33 87 127 ND 145.1 --
6-1 28 56 ND 201.8 -- 3-33 56 39 20 69.9 36.1 3-33 10 53 1 520.6
6.9 3-33 20 67 10 337.2 52.3 3-33 11 36 18 316.8 158.4 3-23 12 42
32 356.8 272.9 3-33 66 95 15 143.6 22.5 3-15 55 68 ND 123.1 -- --
32 68 3 210.9 10.6 1-8 28 48 ND 170.9 -- 3-33 124 192 21 154.3 17.0
3-33 0 113 ND 56550.0 -- 3-33 10 157 1 1505.8 12.5 3-33 6 86 15
1385.5 243.5 3-23 70 115 22 163.5 31.0 3-7 71 117 21 164.6 29.6
3-33 82 100 47 122.7 57.1 3-7 124 161 41 130.0 33.5
[0240] In a similar experiment, VELOCIMMUNE.RTM. mice were
immunized with several different antigens and selected heavy chains
of antigen specific human antibodies were tested for their ability
to pair with different rearranged human germline light chains (as
described above). The antigens used in this experiment included an
enzyme involved in cholesterol homeostasis (Antigen A), a serum
hormone involved in regulating glucose homeostasis (Antigen B), a
growth factor that promotes angiogenesis (Antigen C) and a
cell-surface receptor (Antigen D). Antigen specific antibodies were
isolated from mice of each immunization group and the heavy chain
and light chain variable regions were cloned and sequenced. From
the sequence of the heavy and light chains, V gene usage was
determined and selected heavy chains were paired with either their
cognate light chain or a rearranged human germline
V.kappa.1-39J.kappa.5 region. Each heavy/light chain pair was
co-transfected in CHO-K1 cells and the presence of antibody in the
supernatant was detected by anti-human IgG in an ELISA assay.
Antibody titer (.mu.g/ml) was determined for each heavy chain/light
chain pairing and titers with the different rearranged human
germline light chains were compared to the titers obtained with the
parental antibody molecule (i.e., heavy chain paired with cognate
light chain) and percent of native titer was calculated (Table 2).
V.sub.H: Heavy chain variable gene. V.kappa.: .kappa. light chain
variable gene. ND: no expression detected under current
experimental conditions.
TABLE-US-00002 TABLE 2 Titer (.mu.g/ml) Percent of Anti- V.sub.H
V.sub.H + V.sub.H + Native Antigen body V.sub.H V.kappa. Alone
V.kappa. V.kappa.1-39J.kappa.5 Titer A 320 1-18 2-30 0.3 3.1 2.0 66
321 2-5 2-28 0.4 0.4 1.9 448 334 2-5 2-28 0.4 2.7 2.0 73 313 3-13
3-15 0.5 0.7 4.5 670 316 3-23 4-1 0.3 0.2 4.1 2174 315 3-30 4-1 0.3
0.2 3.2 1327 318 4-59 1-17 0.3 4.6 4.0 86 B 257 3-13 1-5 0.4 3.1
3.2 104 283 3-13 1-5 0.4 5.4 3.7 69 637 3-13 1-5 0.4 4.3 3.0 70 638
3-13 1-5 0.4 4.1 3.3 82 624 3-23 1-17 0.3 5.0 3.9 79 284 3-30 1-17
0.3 4.6 3.4 75 653 3-33 1-17 0.3 4.3 0.3 7 268 4-34 1-27 0.3 5.5
3.8 69 633 4-34 1-27 0.6 6.9 3.0 44 C 730 3-7 1-5 0.3 1.1 2.8 249
728 3-7 1-5 0.3 2.0 3.2 157 691 3-9 3-20 0.3 2.8 3.1 109 749 3-33
3-15 0.3 3.8 2.3 62 750 3-33 1-16 0.3 3.0 2.8 92 724 3-33 1-17 0.3
2.3 3.4 151 706 3-33 1-16 0.3 3.6 3.0 84 744 1-18 1-12 0.4 5.1 3.0
59 696 3-11 1-16 0.4 3.0 2.9 97 685 3-13 3-20 0.3 0.5 3.4 734 732
3-15 1-17 0.3 4.5 3.2 72 694 3-15 1-5 0.4 5.2 2.9 55 743 3-23 1-12
0.3 3.2 0.3 10 742 3-23 2-28 0.4 4.2 3.1 74 693 3-23 1-12 0.5 4.2
4.0 94 D 136 3-23 2-28 0.4 5.0 2.7 55 155 3-30 1-16 0.4 1.0 2.2 221
163 3-30 1-16 0.3 0.6 3.0 506 171 3-30 1-16 0.3 1.0 2.8 295 145
3-43 1-5 0.4 4.4 2.9 65 49 3-48 3-11 0.3 1.7 2.6 155 51 3-48 1-39
0.1 1.9 0.1 4 159 3-7 6-21 0.4 3.9 3.6 92 169 3-7 6-21 0.3 1.3 3.1
235 134 3-9 1-5 0.4 5.0 2.9 58 141 4-31 1-33 2.4 4.2 2.6 63 142
4-31 1-33 0.4 4.2 2.8 67
[0241] The results obtained from these experiments demonstrate that
somatically mutated, high affinity heavy chains from different gene
families are able to pair with rearranged human germline
V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1 regions and be
secreted from the cell as a normal antibody molecule. As shown in
Table 1, antibody titer was increased for about 61% (42 of 69)
heavy chains when paired with the rearranged human
V.kappa.1-39J.kappa.5 light chain and about 29% (20 of 69) heavy
chains when paired with the rearranged human V.kappa.3-20J.kappa.1
light chain as compared to the cognate light chain of the parental
antibody. For about 20% (14 of 69) of the heavy chains, both
rearranged human germline light chains conferred an increase in
expression as compared to the cognate light chain of the parental
antibody. As shown in Table 2, the rearranged human germline
V.kappa.1-39J.kappa.5 region conferred an increase in expression of
several heavy chains specific for a range of different classes of
antigens as compared to the cognate light chain for the parental
antibodies. Antibody titer was increased by more than two-fold for
about 35% (15/43) of the heavy chains as compared to the cognate
light chain of the parental antibodies. For two heavy chains (315
and 316), the increase was greater than ten-fold as compared to the
parental antibody. Within all the heavy chains that showed increase
expression relative to the cognate light chain of the parental
antibody, family three (V.sub.H3) heavy chains are over represented
in comparison to other heavy chain variable region gene families.
This demonstrates a favorable relationship of human V.sub.H3 heavy
chains to pair with rearranged human germline V.kappa.1-39J.kappa.5
and V.kappa.3-20J.kappa.1 light chains.
Example 2
Generation of a Rearranged Human Germline Light Chain Locus
[0242] Various rearranged human germline light chain targeting
vectors were made using VELOCIGENE.RTM. technology (see, e.g., U.S.
Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput
engineering of the mouse genome coupled with high-resolution
expression analysis, Nature Biotech. 21(6): 652-659) to modify
mouse genomic Bacterial Artificial Chromosome (BAC) clones 302g12
and 254m04 (Invitrogen). Using these two BAC clones, genomic
constructs were engineered to contain a single rearranged human
germline light chain region and inserted into an endogenous .kappa.
light chain locus that was previously modified to delete the
endogenous .kappa. variable and joining gene segments.
[0243] Construction of Rearranged Human Germline Light Chain
Targeting Vectors.
[0244] Three different rearranged human germline light chain
regions were made using standard molecular biology techniques
recognized in the art. The human variable gene segments used for
constructing these three regions included rearranged human
V.kappa.1-39J.kappa.5 sequence, a rearranged human
V.kappa.3-20J.kappa.1 sequence and a rearranged human
VpreBJ.lamda.5 sequence.
[0245] A DNA segment containing exon 1 (encoding the leader
peptide) and intron 1 of the mouse V.kappa.3-7 gene was made by de
novo DNA synthesis (Integrated DNA Technologies). Part of the 5'
untranslated region up to a naturally occurring BlpI restriction
enzyme site was included. Exons of human V.kappa.1-39 and
V.kappa.3-20 genes were PCR amplified from human genomic BAC
libraries. The forward primers had a 5' extension containing the
splice acceptor site of intron 1 of the mouse V.kappa.3-7 gene. The
reverse primer used for PCR of the human V.kappa.1-39 sequence
included an extension encoding human J.kappa.5, whereas the reverse
primer used for PCR of the human V.kappa.3-20 sequence included an
extension encoding human J.kappa.1. The human VpreBJ.lamda.5
sequence was made by de novo DNA synthesis (Integrated DNA
Technologies). A portion of the human J.kappa.-C.kappa. intron
including the splice donor site was PCR amplified from plasmid
pBS-296-HA18-PISceI. The forward PCR primer included an extension
encoding part of either a human J.kappa.5, J.kappa.1, or J.lamda.5
sequence. The reverse primer included a PI-SceI site, which was
previously engineered into the intron.
[0246] The mouse V.kappa.3-7 exon1/intron 1, human variable light
chain exons, and human J.kappa.-C.kappa. intron fragments were sewn
together by overlap extension PCR, digested with BlpI and PI-SceI,
and ligated into plasmid pBS-296-HA18-PISceI, which contained the
promoter from the human V.kappa.3-15 variable gene segment. A loxed
hygromycin cassette within plasmid pBS-296-HA18-PISceI was replaced
with a FRTed hygromycin cassette flanked by NotI and AscI sites.
The NotI/PI-SceI fragment of this plasmid was ligated into modified
mouse BAC 254m04, which contained part of the mouse
J.kappa.-C.kappa. intron, the mouse C.kappa. exon, and about 75 kb
of genomic sequence downstream of the mouse .kappa. locus, which
provided a 3' homology arm for homologous recombination in mouse ES
cells. The NotI/AscI fragment of this BAC was then ligated into
modified mouse BAC 302g12, which contained a FRTed neomycin
cassette and about 23 kb of genomic sequence upstream of the
endogenous .kappa. locus for homologous recombination in mouse ES
cells.
[0247] Rearranged Human Germline V.kappa.1-39J.kappa.5 Targeting
Vector (FIG. 1).
[0248] Restriction enzyme sites were introduced at the 5' and 3'
ends of an engineered light chain insert for cloning into a
targeting vector: an AscI site at the 5' end and a PI-SceI site at
the 3' end. Within the 5' AscI site and the 3' PI-SceI site the
targeting construct from 5' to 3' included a 5' homology arm
containing sequence 5' to the endogenous mouse .kappa. light chain
locus obtained from mouse BAC clone 302g12, a FRTed neomycin
resistance gene, an genomic sequence including the human
V.kappa.3-15 promoter, a leader sequence of the mouse V.kappa.3-7
variable gene segment, a intron sequence of the mouse V.kappa.3-7
variable gene segment, an open reading frame of a rearranged human
germline V.kappa.1-39J.kappa.5 region, a genomic sequence
containing a portion of the human J.kappa.-C.kappa. intron, and a
3' homology arm containing sequence 3' of the endogenous mouse
J.kappa.5 gene segment obtained from mouse BAC clone 254m04 (FIG.
1, middle). Genes and/or sequences upstream of the endogenous mouse
.kappa. light chain locus and downstream of the most 3' J.kappa.
gene segment (e.g., the endogenous 3' enhancer) were unmodified by
the targeting construct (see FIG. 1). The sequence of the
engineered human V.kappa.1-39J.kappa.5 locus is shown in SEQ ID NO:
1.
[0249] Targeted insertion of the rearranged human germline
V.kappa.1-39J.kappa.5 region into BAC DNA was confirmed by
polymerase chain reaction (PCR) using primers located at sequences
within the rearranged human germline light chain region. Briefly,
the intron sequence 3' to the mouse V.kappa.3-7 leader sequence was
confirmed with primers ULC-m1F (AGGTGAGGGT ACAGATAAGT GTTATGAG; SEQ
ID NO: 2) and ULC-m1R (TGACAAATGC CCTAATTATA GTGATCA; SEQ ID NO:
3). The open reading frame of the rearranged human germline
V.kappa.1-39J.kappa.5 region was confirmed with primers 1633-h2F
(GGGCAAGTCA GAGCATTAGC A; SEQ ID NO: 4) and 1633-h2R (TGCAAACTGG
ATGCAGCATA G; SEQ ID NO: 5). The neomycin cassette was confirmed
with primers neoF (GGTGGAGAGG CTATTCGGC; SEQ ID NO: 6) and neoR
(GAACACGGCG GCATCAG; SEQ ID NO: 7). Targeted BAC DNA was then used
to electroporate mouse ES cells to created modified ES cells for
generating chimeric mice that express a rearranged human germline
V.kappa.1-39J.kappa.5 region.
[0250] Positive ES cell clones were confirmed by TAQMAN.TM.
screening and karyotyping using probes specific for the engineered
V.kappa.1-39J.kappa.5 light chain region inserted into the
endogenous locus. Briefly, probe neoP (TGGGCACAAC AGACAATCGG CTG;
SEQ ID NO:8) which binds within the neomycin marker gene, probe
ULC-m1P (CCATTATGAT GCTCCATGCC TCTCTGTTC; SEQ ID NO: 9) which binds
within the intron sequence 3' to the mouse V.kappa.3-7 leader
sequence, and probe 1633h2P (ATCAGCAGAA ACCAGGGAAA GCCCCT; SEQ ID
NO: 10) which binds within the rearranged human germline
V.kappa.1-39J.kappa.5 open reading frame. Positive ES cell clones
were then used to implant female mice to give rise to a litter of
pups expressing the germline V.kappa.1-39J.kappa.5 light chain
region.
[0251] Alternatively, ES cells bearing the rearranged human
germline V.kappa.1-39J.kappa.5 light chain region are transfected
with a construct that expresses FLP in order to remove the FRTed
neomycin cassette introduced by the targeting construct.
Optionally, the neomycin cassette is removed by breeding to mice
that express FLP recombinase (e.g., U.S. Pat. No. 6,774,279).
Optionally, the neomycin cassette is retained in the mice.
[0252] Rearranged Human Germline V.kappa.3-20J.kappa.1 Targeting
Vector (FIG. 2).
[0253] In a similar fashion, an engineered light chain locus
expressing a rearranged human germline V.kappa.3-20J.kappa.1 region
was made using a targeting construct including, from 5' to 3', a 5'
homology arm containing sequence 5' to the endogenous mouse .kappa.
light chain locus obtained from mouse BAC clone 302g12, a FRTed
neomycin resistance gene, a genomic sequence including the human
V.kappa.3-15 promoter, a leader sequence of the mouse V.kappa.3-7
variable gene segment, an intron sequence of the mouse V.kappa.3-7
variable gene segment, an open reading frame of a rearranged human
germline V.kappa.3-20J.kappa.1 region, a genomic sequence
containing a portion of the human J.kappa.-C.kappa. intron, and a
3' homology arm containing sequence 3' of the endogenous mouse
J.kappa.5 gene segment obtained from mouse BAC clone 254m04 (FIG.
2, middle). The sequence of the engineered human
V.kappa.3-20J.kappa.1 locus is shown in SEQ ID NO: 11.
[0254] Targeted insertion of the rearranged human germline
V.kappa.3-20J.kappa.1 region into BAC DNA was confirmed by
polymerase chain reaction (PCR) using primers located at sequences
within the rearranged human germline V.kappa.3-20J.kappa.1 light
chain region. Briefly, the intron sequence 3' to the mouse
V.kappa.3-7 leader sequence was confirmed with primers ULC-m1F (SEQ
ID NO: 2) and ULC-m1R (SEQ ID NO: 3). The open reading frame of the
rearranged human germline V.kappa.3-20J.kappa.1 region was
confirmed with primers 1635-h2F (TCCAGGCACC CTGTCTTTG; SEQ ID NO:
12) and 1635-h2R (AAGTAGCTGC TGCTAACACT CTGACT; SEQ ID NO: 13). The
neomycin cassette was confirmed with primers neoF (SEQ ID NO: 6)
and neoR (SEQ ID NO: 7). Targeted BAC DNA was then used to
electroporate mouse ES cells to created modified ES cells for
generating chimeric mice that express the rearranged human germline
V.kappa.3-20J.kappa.1 light chain.
[0255] Positive ES cell clones were confirmed by TAQMAN.TM.
screening and karyotyping using probes specific for the engineered
V.kappa.3-20J.kappa.1 light chain region inserted into the
endogenous .kappa. light chain locus. Briefly, probe neoP (SEQ ID
NO:8) which binds within the neomycin marker gene, probe ULC-m1P
(SEQ ID NO: 9) which binds within the mouse V.kappa.3-7 leader
sequence, and probe 1635h2P (AAAGAGCCAC CCTCTCCTGC AGGG; SEQ ID NO:
14) which binds within the human V.kappa.3-20J.kappa.1 open reading
frame. Positive ES cell clones were then used to implant female
mice. A litter of pups expressing the human germline
V.kappa.3-20J.kappa.1 light chain region.
[0256] Alternatively, ES cells bearing human germline
V.kappa.3-20J.kappa.1 light chain region can be transfected with a
construct that expresses FLP in order to remove the FRTed neomycin
cassette introduced by the targeting construct. Optionally, the
neomycin cassette may be removed by breeding to mice that express
FLP recombinase (e.g., U.S. Pat. No. 6,774,279). Optionally, the
neomycin cassette is retained in the mice.
[0257] Rearranged Human Germline VpreBJ.lamda.5 Targeting Vector
(FIG. 3).
[0258] In a similar fashion, an engineered light chain locus
expressing a rearranged human germline VpreBJ.lamda.5 region was
made using a targeting construct including, from 5' to 3', a 5'
homology arm containing sequence 5' to the endogenous mouse .kappa.
light chain locus obtained from mouse BAC clone 302g12, a FRTed
neomycin resistance gene, an genomic sequence including the human
V.kappa.3-15 promoter, a leader sequence of the mouse V.kappa.3-7
variable gene segment, an intron sequence of the mouse V.kappa.3-7
variable gene segment, an open reading frame of a rearranged human
germline VpreBJ.lamda.25 region, a genomic sequence containing a
portion of the human J.kappa.-C.kappa. intron, and a 3' homology
arm containing sequence 3' of the endogenous mouse J.kappa.5 gene
segment obtained from mouse BAC clone 254m04 (FIG. 3, middle). The
sequence of the engineered human VpreBJ.lamda.5 locus is shown in
SEQ ID NO: 15.
[0259] Targeted insertion of the rearranged human germline
VpreBJ.lamda.5 region into BAC DNA was confirmed by polymerase
chain reaction (PCR) using primers located at sequences within the
rearranged human germline VpreBJ.lamda.5 region light chain region.
Briefly, the intron sequence 3' to the mouse V.kappa.3-7 leader
sequence was confirmed with primers ULC-m1F (SEQ ID NO: 2) and
ULC-m1R (SEQ ID NO: 3). The open reading frame of the rearranged
human germline VpreBJ.lamda.5 region was confirmed with primers
1616-h1F (TGTCCTCGGC CCTTGGA; SEQ ID NO: 16) and 1616-h1R
(CCGATGTCAT GGTCGTTCCT; SEQ ID NO: 17). The neomycin cassette was
confirmed with primers neoF (SEQ ID NO: 6) and neoR (SEQ ID NO: 7).
Targeted BAC DNA was then used to electroporate mouse ES cells to
created modified ES cells for generating chimeric mice that express
the rearranged human germline VpreBJ.lamda.5 light chain.
[0260] Positive ES cell clones are confirmed by TAQMAN.TM.
screening and karyotyping using probes specific for the engineered
VpreBJ.lamda.5 light chain region inserted into the endogenous
.kappa. light chain locus. Briefly, probe neoP (SEQ ID NO:8), which
binds within the neomycin marker gene, probe ULC-m1P (SEQ ID NO:
9), which binds within the mouse IgV.kappa.3-7 leader sequence, and
probe 1616h1P (ACAATCCGCC TCACCTGCAC CCT; SEQ ID NO: 18) which
binds within the human VpreBJ.lamda.5 open reading frame. Positive
ES cell clones are then used to implant female mice to give rise to
a litter of pups expressing a germline light chain region.
[0261] Alternatively, ES cells bearing the rearranged human
germline VpreBJ.lamda.5 light chain region are transfected with a
construct that expresses FLP in order to remove the FRTed neomycin
cassette introduced by the targeting construct. Optionally, the
neomycin cassette is removed by breeding to mice that express FLP
recombinase (e.g., U.S. Pat. No. 6,774,279). Optionally, the
neomycin cassette is retained in the mice.
Example 3
Generation of Mice Expressing a Single Rearranged Human Light
Chain
[0262] Targeted ES cells described above were used as donor ES
cells and introduced into an 8-cell stage mouse embryo by the
VELOCIMOUSE.RTM. method (see, e.g., U.S. Pat. No. 7,294,754 and
Poueymirou et al. (2007) F0 generation mice that are essentially
fully derived from the donor gene-targeted ES cells allowing
immediate phenotypic analyses Nature Biotech. 25(1): 91-99.
VELOCIMICE.RTM. independently bearing an engineered human germline
V.kappa.1-39J.kappa.5 light chain region, a V.kappa.3-20J.kappa.1
light chain region or a VpreBJ.lamda.5 light chain region are
identified by genotyping using a modification of allele assay
(Valenzuela et al., supra) that detects the presence of the unique
rearranged human germline light chain region.
[0263] Pups are genotyped and a pup heterozygous or homozygous for
the unique rearranged human germline light chain region are
selected for characterizing expression of the rearranged human
germline light chain region.
[0264] Flow Cytometry.
[0265] Expression of the rearranged human light chain region in the
normal antibody repertoire of common light chain mice was validated
by analysis of immunoglobulin .kappa. and .lamda. expression in
splenocytes and peripheral blood of common light chain mice. Cell
suspensions from harvested spleens and peripheral blood of wild
type (n=5), V.kappa.1-39J.kappa.5 common light chain heterozygote
(n=3), V.kappa.1-39J.kappa.5 common light chain homozygote (n=3),
V.kappa.3-20J.kappa.1 common light chain heterozygote (n=2), and
V.kappa.3-20J.kappa.1 common light chain homozygote (n=2) mice were
made using standard methods and stained with CD19.sup.+,
Ig.lamda..sup.+ and Ig.kappa..sup.+ using fluorescently labeled
antibodies (BD Pharmigen).
[0266] Briefly, 1.times.10.sup.6 cells were incubated with
anti-mouse CD16/CD32 (clone 2.4G2, BD Pharmigen) on ice for 10
minutes, followed by labeling with the following antibody cocktail
for 30 minutes on ice: APC conjugated anti-mouse CD19 (clone 1D3,
BD Pharmigen), PerCP-Cy5.5 conjugated anti-mouse CD3 (clone 17A2,
BioLegend), FITC conjugated anti-mouse Ig.kappa. (clone 187.1, BD
Pharmigen), PE conjugated anti-mouse Ig.lamda. (clone RML-42,
BioLegend). Following staining, cells were washed and fixed in 2%
formaldehyde. Data acquisition was performed on an LSRII flow
cytometer and analyzed with FlowJo. Gating: total B cells
(CD19.sup.+ CD3), Ig.kappa..sup.+ B cells
(Ig.kappa..sup.+Ig.lamda..sup.-CD19.sup.+CD3.sup.-),
Ig.lamda..sup.+ B cells
(Ig.kappa..sup.-Ig.lamda..sup.+CD19.sup.+CD3.sup.-). Data gathered
from blood and splenocyte samples demonstrated similar results.
Table 3 sets forth the percent positive CD19.sup.+ B cells from
peripheral blood of one representative mouse from each group that
are Ig.lamda..sup.+, Ig.kappa..sup.+, or
Ig.lamda..sup.+Ig.kappa..sup.+. Percent of CD19.sup.+ B cells in
peripheral blood from wild type (WT) and mice homozygous for either
the V.kappa.1-39J.kappa.5 or V.kappa.3-20J.kappa.1 common light
chain are shown in FIG. 4.
TABLE-US-00003 TABLE 3 CD19.sup.+ B cells Mouse Ig.lamda..sup.+
Ig.kappa..sup.+ Ig.lamda..sup.+Ig.kappa..sup.+ Wild type 4.8 93
0.53 V.kappa.1-39J.kappa.5 1.4 93 2.6 V.kappa.3-20J.kappa.1 4.2 88
6
[0267] Common Light Chain Expression. Expression of each common
light chain (V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1) was
analyzed in heterozygous and homozygous mice using a quantitative
PCR assay (e.g. TAQMAN.TM.).
[0268] Briefly, CD19.sup.+ B cells were purified from the spleens
of wild type, mice homozygous for a replacement of the mouse heavy
chain and .kappa. light chain variable region loci with
corresponding human heavy chain and .kappa. light chain variable
region loci (H.kappa.), as well as mice homozygous and heterozygous
for each rearranged human light chain region (V.kappa.1-39J.kappa.5
or V.kappa.3-20J.kappa.1) using mouse CD19 Microbeads (Miltenyi
Biotec) according to manufacturer's specifications. Total RNA was
purified from CD19.sup.+ B cells using RNeasy Mini kit (Qiagen)
according to manufacturer's specifications and genomic RNA was
removed using an RNase-free DNase on-column treatment (Qiagen). 200
ng mRNA was reverse-transcribed into cDNA using the First Stand
cDNA Synthesis kit (Invitrogen) and the resulting cDNA was
amplified with the Taqman Universal PCR Master Mix (Applied
Biosystems). All reactions were performed using the ABI 7900
Sequence Detection System (Applied Biosystems) using primers and
Taqman MGB probes spanning (1) the V.kappa.-J.kappa. junction for
both common light chains, (2) the V.kappa. gene alone (i.e.
V.kappa.1-39 and V.kappa.-20), and (3) the mouse C.kappa. region.
Table 4 sets forth the sequences of the primers and probes employed
for this assay. Relative expression was normalized to expression of
the mouse C.kappa. region. Results are shown in FIGS. 5A, 5B and
5C.
TABLE-US-00004 TABLE 4 SEQ Primer/Probe Description ID Region
(5'-3') NOs: V.kappa.1-39J.kappa.5 (Sense) 19 Junction AGCAGTCTGC
AACCTGAAGA TTT (Anti-sense) 20 GTTTAATCTC CAGTCGTGTC CCTT (Probe)
21 CCTCCGATCA CCTTC V.kappa.1-39 (Sense) 22 AAACCAGGGA AAGCCCCTAA
(Anti-sense) 23 ATGGGACCCC ACTTTGCA (Probe) 24 CTCCTGATCT ATGCTGCAT
v.kappa.3-20J.kappa.1 (Sense) 25 Junction CAGCAGACTG GAGCCTGAAG A
(Anti-sense) 26 TGATTTCCAC CTTGGTCCCT T (Probe) 27 TAGCTCACCT
TGGACGTT V.kappa.3-20 (Sense) 28 CTCCTCATCT ATGGTGCATC CA
(Anti-sense) 29 GACCCACTGC CACTGAACCT (Probe) 30 CCACTGGCAT CCC
Mouse C.kappa. (Sense) 31 TGAGCAGCAC CCTCACGTT (Anti-sense) 32
GTGGCCTCAC AGGTATAGCT GTT (Probe) 33 ACCAAGGACG AGTATGAA
[0269] Antigen Specific Common Light Chain Antibodies.
[0270] Common light chain mice bearing either a
V.kappa.1-39J.kappa.5 or V.kappa.3-20J.kappa.1 common light chain
at the endogenous mouse .kappa. light chain locus were immunized
with .beta.-galactosidase and antibody titer was measured.
[0271] Briefly, .beta.-galactosidase (Sigma) was emulsified in
titermax adjuvant (Sigma), as per manufacturers directions. Wild
type (n=7), V.kappa.1-39J.kappa.5 common light chain homozygotes
(n=2) and V.kappa.3-20J.kappa.1 common light chain homozygotes
(n=5) were immunized by subcutaneous injection with 100 .mu.g
.beta.-galactosidase/Titermax. Mice were boosted by subcutaneous
injection two times, 3 weeks apart, with 50 .mu.g
.beta.-galactosidase/Titermax. After the second boost, blood was
collected from anaesthetized mice using a retro-orbital bleed into
serum separator tubes (BD Biosciences) as per manufacturer's
directions. To measure anti-.beta.-galactosidase IgM or IgG
antibodies, ELISA plates (Nunc) were coated with 1 .mu.g/mL
.beta.-galactosidase overnight at 4.degree. C. Excess antigen was
washed off before blocking with PBS with 1% BSA for one hour at
room temperature. Serial dilutions of serum were added to the
plates and incubated for one hour at room temperature before
washing. Plates were then incubated with HRP conjugated anti-IgM
(Southern Biotech) or anti-IgG (Southern Biotech) for one hour at
room temperature. Following another wash, plates were developed
with TMB substrate (BD Biosciences). Reactions were stopped with 1N
sulfuric acid and OD.sub.450 was read using a Victor X5 Plate
Reader (Perkin Elmer). Data was analyzed with GraphPad Prism and
signal was calculated as the dilution of serum that is two times
above background. Results are shown in FIGS. 6A and 6B.
[0272] As shown in this Example, the ratio of .kappa./.lamda.. B
cells in both the splenic and peripheral compartments of
V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1 common light chain
mice demonstrated a near wild type pattern (Table 3 and FIG. 4).
VpreBJ.lamda.5 common light chain mice, however, demonstrated fewer
peripheral B cells, of which about 1-2% express the engineered
human light chain region (data not shown). The expression levels of
the V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1 rearranged
human light chain regions from the endogenous .kappa. light chain
locus were elevated in comparison to an endogenous .kappa. light
chain locus containing a complete replacement of mouse V.kappa. and
J.kappa. gene segments with human V.kappa. and J.kappa. gene
segments (FIGS. 5A, 5B and 5C). The expression levels of the
VpreBJ.lamda.5 rearranged human light chain region demonstrated
similar high expression from the endogenous .kappa. light chain
locus in both heterozygous and homozygous mice (data not shown).
This demonstrates that in direct competition with the mouse
.lamda., .kappa., or both endogenous light chain loci, a single
rearranged human V.sub.L/J.sub.L sequence can yield better than
wild type level expression from the endogenous .kappa. light chain
locus and give rise to normal splenic and blood B cell frequency.
Further, the presence of an engineered .kappa. light chain locus
having either a human V.kappa.1-39J.kappa.5 or human
V.kappa.3-20J.kappa.1 sequence was well tolerated by the mice and
appear to function in wild type fashion by representing a
substantial portion of the light chain repertoire in the humoral
component of the immune response (FIGS. 6A and 6B).
Example 4
Breeding of Mice Expressing a Single Rearranged Human Germline
Light Chain
[0273] This Example describes several other genetically modified
mouse strains that can be bred to any one of the common light chain
mice described herein to create multiple genetically modified mouse
strains harboring multiple genetically modified immunoglobulin
loci.
[0274] Endogenous Ig.lamda. Knockout (KO).
[0275] To optimize the usage of the engineered light chain locus,
mice bearing one of the rearranged human germline light chain
regions are bred to another mouse containing a deletion in the
endogenous .lamda. light chain locus. In this manner, the progeny
obtained will express, as their only light chain, the rearranged
human germline light chain region as described in Example 2.
Breeding is performed by standard techniques recognized in the art
and, alternatively, by a commercial breeder (e.g., The Jackson
Laboratory). Mouse strains bearing an engineered light chain locus
and a deletion of the endogenous .lamda. light chain locus are
screened for presence of the unique light chain region and absence
of endogenous mouse .lamda. light chains.
[0276] Humanized Endogenous Heavy Chain Locus.
[0277] Mice bearing an engineered human germline light chain locus
are bred with mice that contain a replacement of the endogenous
mouse heavy chain variable gene locus with the human heavy chain
variable gene locus (see U.S. Pat. No. 6,596,541; the
VELOCIMMUNE.RTM. mouse, Regeneron Pharmaceuticals, Inc.). The
VELOCIMMUNE.RTM. mouse comprises a genome comprising human heavy
chain variable regions operably linked to endogenous mouse constant
region loci such that the mouse produces antibodies comprising a
human heavy chain variable region and a mouse heavy chain constant
region in response to antigenic stimulation. The DNA encoding the
variable regions of the heavy chains of the antibodies is isolated
and operably linked to DNA encoding the human heavy chain constant
regions. The DNA is then expressed in a cell capable of expressing
the fully human heavy chain of the antibody.
[0278] Mice bearing a replacement of the endogenous mouse V.sub.H
locus with the human VH locus and a single rearranged human
germline V.sub.L region at the endogenous .kappa. light chain locus
are obtained. Reverse chimeric antibodies containing somatically
mutated heavy chains (human V.sub.H and mouse C.sub.H) with a
single human light chain (human V.sub.L and mouse C.sub.L) are
obtained upon immunization with an antigen of interest. V.sub.H and
V.sub.L nucleotide sequences of B cells expressing the antibodies
are identified and fully human antibodies are made by fusion the
V.sub.H and V.sub.L nucleotide sequences to human C.sub.H and
C.sub.L nucleotide sequences in a suitable expression system.
Example 5
Generation of Antibodies from Mice Expressing Human Heavy Chains
and a Rearranged Human Germline Light Chain Region
[0279] After breeding mice that contain the engineered human light
chain region to various desired strains containing modifications
and deletions of other endogenous Ig loci (as described in Example
4), selected mice can be immunized with an antigen of interest.
[0280] Generally, a VELOCIMMUNE.RTM. mouse containing one of the
single rearranged human germline light chain regions is challenged
with an antigen, and lymphatic cells (such as B-cells) are
recovered from serum of the animals. The lymphatic cells are fused
with a myeloma cell line to prepare immortal hybridoma cell lines,
and such hybridoma cell lines are screened and selected to identify
hybridoma cell lines that produce antibodies containing human heavy
chain variables and a rearranged human germline light chains which
are specific to the antigen used for immunization. DNA encoding the
variable regions of the heavy chains and the light chain are
isolated and linked to desirable isotypic constant regions of the
heavy chain and light chain. Due to the presence of the endogenous
mouse sequences and any additional cis-acting elements present in
the endogenous locus, the single light chain of each antibody may
be somatically mutated. This adds additional diversity to the
antigen-specific repertoire comprising a single light chain and
diverse heavy chain sequences. The resulting cloned antibody
sequences are subsequently expressed in a cell, such as a CHO cell.
Alternatively, DNA encoding the antigen-specific chimeric
antibodies or the variable domains of the light and heavy chains
are identified directly from antigen-specific lymphocytes.
[0281] Initially, high affinity chimeric antibodies are isolated
having a human variable region and a mouse constant region. As
described above, the antibodies are characterized and selected for
desirable characteristics, including affinity, selectivity,
epitope, etc. The mouse constant regions are replaced with a
desired human constant region to generate the fully human antibody
containing a somatically mutated human heavy chain and a single
light chain derived from a rearranged human germline light chain
region of the invention. Suitable human constant regions include,
for example wild type or modified IgG1 or IgG4.
[0282] Separate cohorts of VELOCIMMUNE.RTM. mice containing a
replacement of the endogenous mouse heavy chain locus with human
V.sub.H, D.sub.H, and J.sub.H gene segments and a replacement of
the endogenous mouse .kappa. light chain locus with either the
engineered germline V.kappa.1-39J.kappa.5 human light chain region
or the engineered germline V.kappa.3-20J.kappa.1 human light chain
region (described above) were immunized with a human cell-surface
receptor protein (Antigen E). Antigen E is administered directly
onto the hind footpad of mice with six consecutive injections every
3-4 days. Two to three micrograms of Antigen E are mixed with 10
.mu.g of CpG oligonucleotide (Cat # tlrl-modn--ODN1826
oligonucleotide; InVivogen, San Diego, Calif.) and 25 .mu.g of
Adju-Phos (Aluminum phosphate gel adjuvant, Cat# H-71639-250;
Brenntag Biosector, Frederikssund, Denmark) prior to injection. A
total of six injections are given prior to the final antigen
recall, which is given 3-5 days prior to sacrifice. Bleeds after
the 4th and 6th injection are collected and the antibody immune
response is monitored by a standard antigen-specific
immunoassay.
[0283] When a desired immune response is achieved splenocytes are
harvested and fused with mouse myeloma cells to preserve their
viability and form hybridoma cell lines. The hybridoma cell lines
are screened and selected to identify cell lines that produce
Antigen E-specific common light chain antibodies. Using this
technique several anti-Antigen E-specific common light chain
antibodies (i.e., antibodies possessing human heavy chain variable
domains, the same human light chain variable domain, and mouse
constant domains) are obtained.
[0284] Alternatively, anti-Antigen E common light chain antibodies
are isolated directly from antigen-positive B cells without fusion
to myeloma cells, as described in U.S. 2007/0280945A1, herein
specifically incorporated by reference in its entirety. Using this
method, several fully human anti-Antigen E common light chain
antibodies (i.e., antibodies possessing human heavy chain variable
domains, either an engineered human V.kappa.1-39J.kappa.5 light
chain or an engineered human V.kappa.3-20J.kappa.1 light chain
region, and human constant domains) were obtained.
[0285] The biological properties of the exemplary anti-Antigen E
common light chain antibodies generated in accordance with the
methods of this Example are described in detail in the sections set
forth below.
Example 6
Heavy Chain Gene Segment Usage in Antigen-Specific Common Light
Chain Antibodies
[0286] To analyze the structure of the human anti-Antigen E common
light chain antibodies produced, nucleic acids encoding heavy chain
antibody variable regions were cloned and sequenced. From the
nucleic acid sequences and predicted amino acid sequences of the
antibodies, gene usage was identified for the heavy chain variable
region (HCVR) of selected common light chain antibodies obtained
from immunized VELOCIMMUNE.RTM. mice containing either the
engineered human V.kappa.1-39J.kappa.5 light chain or engineered
human V.kappa.3-20J.kappa.1 light chain region. Results are shown
in Tables 5 and 6, which demonstrate that mice according to the
invention generate antigen-specific common light chain antibodies
from a variety of human heavy chain gene segments, due to a variety
of rearrangements, when employing either a mouse that expresses a
light chain from only a human V.kappa.1-39- or a human
V.kappa.3-20-derived light chain. Human V.sub.H gene segments of
the 2, 3, 4, and 5 families rearranged with a variety of human
D.sub.H segments and human J.sub.H segments to yield
antigen-specific antibodies.
TABLE-US-00005 TABLE 5 V.kappa.1-39J.kappa.5 Common Light Chain
Antibodies HCVR Antibody V.sub.H D.sub.H J.sub.H 2952 2-5 6-6 1
5978 2-5 6-6 1 5981 2-5 3-22 1 6027 3-13 6-6 5 3022 3-23 3-10 4
3028 3-23 3-3 4 5999 3-23 6-6 4 6009 3-23 2-8 4 6011 3-23 7-27 4
5980 3-30 1-1 4 3014 3-30 1-7 4 3015 3-30 1-7 4 3023 3-30 1-7 4
3024 3-30 1-7 4 3032 3-30 1-7 4 6024 3-30 1-7 4 6025 3-30 1-7 4
6031 3-30 1-7 4 6007 3-30 3-3 4 2982 3-30 3-22 5 6001 3-30 3-22 5
6005 3-30 3-22 5 6035 3-30 5-5 2 3013 3-30 5-12 4 3042 3-30 5-12 4
2955 3-30 6-6 1 3043 3-30 6-6 3 3018 3-30 6-6 4 2949 3-30 6-6 5
2950 3-30 6-6 5 2954 3-30 6-6 5 2978 3-30 6-6 5 3016 3-30 6-6 5
3017 3-30 6-6 5 3033 3-30 6-6 5 3041 3-30 6-6 5 5979 3-30 6-6 5
5998 3-30 6-6 5 6004 3-30 6-6 5 6010 3-30 6-6 5 6019 3-30 6-6 5
6021 3-30 6-6 5 6022 3-30 6-6 5 6023 3-30 6-6 5 6030 3-30 6-6 5
6032 3-30 6-6 5 2985 3-30 6-13 4 2997 3-30 6-13 4 3011 3-30 6-13 4
3047 3-30 6-13 4 5982 3-30 6-13 4 6002 3-30 6-13 4 6003 3-30 6-13 4
6012 3-30 6-13 4 6013 3-30 6-13 4 6014 3-30 6-13 4 6015 3-30 6-13 4
6016 3-30 6-13 4 6017 3-30 6-13 4 6020 3-30 6-13 4 6034 3-30 6-13 4
2948 3-30 7-27 4 2987 3-30 7-27 4 2996 3-30 7-27 4 3005 3-30 7-27 4
3012 3-30 7-27 4 3020 3-30 7-27 4 3021 3-30 7-27 4 3025 3-30 7-27 4
3030 3-30 7-27 4 3036 3-30 7-27 4 5997 3-30 7-27 4 6033 3-30 7-27 4
3004 3-30 7-27 5 6028 3-30 7-27 6 3010 4-59 3-16 3 3019 4-59 3-16 3
6018 4-59 3-16 3 6026 4-59 3-16 3 6029 4-59 3-16 3 6036 4-59 3-16 3
6037 4-59 3-16 3 2964 4-59 3-22 3 3027 4-59 3-16 4 3046 5-51 5-5 3
6000 1-69 6-13 4 6006 1-69 6-6 5 6008 1-69 6-13 4
TABLE-US-00006 TABLE 6 V.kappa.3-20J.kappa.1 Common Light Chain
Antibodies HCVR Antibody V.sub.H D.sub.H J.sub.H 5989 3-30 3-3 3
5994 3-33 1-7 4 5985 3-33 2-15 4 5987 3-33 2-15 4 5995 3-33 2-15 4
2968 4-39 1-26 3 5988 4-39 1-26 3 5990 4-39 1-26 3 5992 4-39 1-26 3
2975 5-51 6-13 5 2972 5-51 3-16 6 5986 5-51 3-16 6 5993 5-51 3-16 6
5996 5-51 3-16 6 5984 3-53 1-1 4
Example 7
Determination of Blocking Ability of Antigen-Specific Common Light
Chain Antibodies by LUMINEX.TM. Assay
[0287] Ninety-eight human common light chain antibodies raised
against Antigen E were tested for their ability to block binding of
Antigen E's natural ligand (Ligand Y) to Antigen E in a bead-based
assay.
[0288] The extracellular domain (ECD) of Antigen E was conjugated
to two myc epitope tags and a 6.times. histidine tag (Antigen
E-mmH) and amine-coupled to carboxylated microspheres at a
concentration of 20 .mu.g/mL in MES buffer. The mixture was
incubated for two hours at room temperature followed by bead
deactivation with 1M Tris pH 8.0 followed by washing in PBS with
0.05% (v/v) Tween-20. The beads were then blocked with PBS (Irvine
Scientific, Santa Ana, Calif.) containing 2% (w/v) BSA
(Sigma-Aldrich Corp., St. Louis, Mo.). In a 96-well filter plate,
supernatants containing Antigen E-specific common light chain
antibodies were diluted 1:15 in buffer. A negative control
containing a mock supernatant with the same media components as for
the antibody supernatant was prepared. Antigen E-labeled beads were
added to the supernatants and incubated overnight at 4.degree. C.
Biotinylated-Ligand Y protein was added to a final concentration of
0.06 nM and incubated for two hours at room temperature. Detection
of biotinylated-Ligand Y bound to Antigen E-myc-myc-6His labeled
beads was determined with R-Phycoerythrin conjugated to
Streptavidin (Moss Inc, Pasadena, Md.) followed by measurement in a
LUMINEX.TM. flow cytometry-based analyzer. Background Mean
Fluorescence Intensity (MFI) of a sample without Ligand Y was
subtracted from all samples. Percent blocking was calculated by
division of the background-subtracted MFI of each sample by the
adjusted negative control value, multiplying by 100 and subtracting
the resulting value from 100.
[0289] In a similar experiment, the same 98 human common light
chain antibodies raised against Antigen E were tested for their
ability to block binding of Antigen E to Ligand Y-labeled
beads.
[0290] Briefly, Ligand Y was amine-coupled to carboxylated
microspheres at a concentration of 20 .mu.g/mL diluted in MES
buffer. The mixture and incubated two hours at room temperature
followed by deactivation of beads with 1M Tris pH 8 then washing in
PBS with 0.05% (v/v) Tween-20. The beads were then blocked with PBS
(Irvine Scientific, Santa Ana, Calif.) containing 2% (w/v) BSA
(Sigma-Aldrich Corp., St. Louis, Mo.). In a 96-well filter plate,
supernatants containing Antigen E-specific common light chain
antibodies were diluted 1:15 in buffer. A negative control
containing a mock supernatant with the same media components as for
the antibody supernatant was prepared. A biotinylated-Antigen E-mmH
was added to a final concentration of 0.42 nM and incubated
overnight at 4.degree. C. Ligand Y-labeled beads were then added to
the antibody/Antigen E mixture and incubated for two hours at room
temperature. Detection of biotinylated-Antigen E-mmH bound to
Ligand Y-beads was determined with R-Phycoerythrin conjugated to
Streptavidin (Moss Inc, Pasadena, Md.) followed by measurement in a
LUMINEX.TM. flow cytometry-based analyzer. Background Mean
Fluorescence Intensity (MFI) of a sample without Antigen E was
subtracted from all samples. Percent blocking was calculated by
division of the background-subtracted MFI of each sample by the
adjusted negative control value, multiplying by 100 and subtracting
the resulting value from 100.
[0291] Tables 7 and 8 show the percent blocking for all 98
anti-Antigen E common light chain antibodies tested in both
LUMINEX.TM. assays. ND: not determined under current experimental
conditions.
TABLE-US-00007 TABLE 7 V.kappa.1-39J.kappa.5 Common Light Chain
Antibodies % Blocking of % Blocking of Antibody Antigen E-Labeled
Beads Antigen E In Solution 2948 81.1 47.8 2948G 38.6 ND 2949 97.6
78.8 2949G 97.1 73.7 2950 96.2 81.9 2950G 89.8 31.4 2952 96.1 74.3
2952G 93.5 39.9 2954 93.7 70.1 2954G 91.7 30.1 2955 75.8 30.0 2955G
71.8 ND 2964 92.1 31.4 2964G 94.6 43.0 2978 98.0 95.1 2978G 13.9
94.1 2982 92.8 78.5 2982G 41.9 52.4 2985 39.5 31.2 2985G 2.0 5.0
2987 81.7 67.8 2987G 26.6 29.3 2996 87.3 55.3 2996G 95.9 38.4 2997
93.4 70.6 2997G 9.7 7.5 3004 79.0 48.4 3004G 60.3 40.7 3005 97.4
93.5 3005G 77.5 75.6 3010 98.0 82.6 3010G 97.9 81.0 3011 87.4 42.8
3011G 83.5 41.7 3012 91.0 60.8 3012G 52.4 16.8 3013 80.3 65.8 3013G
17.5 15.4 3014 63.4 20.7 3014G 74.4 28.5 3015 89.1 55.7 3015G 58.8
17.3 3016 97.1 81.6 3016G 93.1 66.4 3017 94.8 70.2 3017G 87.9 40.8
3018 85.4 54.0 3018G 26.1 12.7 3019 99.3 92.4 3019G 99.3 88.1 3020
96.7 90.3 3020G 85.2 41.5 3021 74.5 26.1 3021G 81.1 27.4 3022 65.2
17.6 3022G 67.2 9.1 3023 71.4 28.5 3023G 73.8 29.7 3024 73.9 32.6
3024G 89.0 10.0 3025 70.7 15.6 3025G 76.7 24.3 3027 96.2 61.6 3027G
98.6 75.3 3028 92.4 29.0 3028G 87.3 28.8 3030 6.0 10.6 3030G 41.3
14.2 3032 76.5 31.4 3032G 17.7 11.0 3033 98.2 86.1 3033G 93.6 64.0
3036 74.7 32.7 3036G 90.1 51.2 3041 95.3 75.9 3041G 92.4 51.6 3042
88.1 73.3 3042G 60.9 25.2 3043 90.8 65.8 3043G 92.8 60.3
TABLE-US-00008 TABLE 8 V.kappa.3-20J.kappa.1 Common Light Chain
Antibodies % Blocking of % Blocking of Antibody Antigen E-Labeled
Beads Antigen E In Solution 2968 97.1 73.3 2968G 67.1 14.6 2969
51.7 20.3 2969G 37.2 16.5 2970 92.2 34.2 2970G 92.7 27.2 2971 23.4
11.6 2971G 18.8 18.9 2972 67.1 38.8 2972G 64.5 39.2 2973 77.7 27.0
2973G 51.1 20.7 2974 57.8 12.4 2974G 69.9 17.6 2975 49.4 18.2 2975G
32.0 19.5 2976 1.0 1.0 2976G 50.4 20.4
[0292] In the first LUMINEX.TM. experiment described above, 80
common light chain antibodies containing the V.kappa.1-39J.kappa.5
engineered light chain were tested for their ability to block
Ligand Y binding to Antigen E-labeled beads. Of these 80 common
light chain antibodies, 68 demonstrated >50% blocking, while 12
demonstrated <50% blocking (6 at 25-50% blocking and 6 at
<25% blocking). For the 18 common light chain antibodies
containing the V.kappa.3-20J.kappa.1 engineered light chain, 12
demonstrated >50% blocking, while 6 demonstrated <50%
blocking (3 at 25-50% blocking and 3 at <25% blocking) of Ligand
Y binding to Antigen E-labeled beads.
[0293] In the second LUMINEX.TM. experiment described above, the
same 80 common light chain antibodies containing the
V.kappa.1-39J.kappa.5 engineered light chain were tested for their
ability to block binding of Antigen E to Ligand Y-labeled beads. Of
these 80 common light chain antibodies, 36 demonstrated >50%
blocking, while 44 demonstrated <50% blocking (27 at 25-50%
blocking and 17 at <25% blocking). For the 18 common light chain
antibodies containing the V.kappa.3-20J.kappa.1 engineered light
chain, 1 demonstrated >50% blocking, while 17 demonstrated
<50% blocking (5 at 25-50% blocking and 12 at <25% blocking)
of Antigen E binding to Ligand Y-labeled beads.
[0294] The data of Tables 7 and 8 establish that the rearrangements
described in Tables 5 and 6 generated anti-Antigen E-specific
common light chain antibodies that blocked binding of Ligand Y to
its cognate receptor Antigen E with varying degrees of efficacy,
which is consistent with the anti-Antigen E common light chain
antibodies of Tables 5 and 6 comprising antibodies with overlapping
and non-overlapping epitope specificity with respect to Antigen
E.
Example 8
Determination of Blocking Ability of Antigen-Specific Common Light
Chain Antibodies by ELISA
[0295] Human common light chain antibodies raised against Antigen E
were tested for their ability to block Antigen E binding to a
Ligand Y-coated surface in an ELISA assay.
[0296] Ligand Y was coated onto 96-well plates at a concentration
of 2 .mu.g/mL diluted in PBS and incubated overnight followed by
washing four times in PBS with 0.05% Tween-20. The plate was then
blocked with PBS (Irvine Scientific, Santa Ana, Calif.) containing
0.5% (w/v) BSA (Sigma-Aldrich Corp., St. Louis, Mo.) for one hour
at room temperature. In a separate plate, supernatants containing
anti-Antigen E common light chain antibodies were diluted 1:10 in
buffer. A mock supernatant with the same components of the
antibodies was used as a negative control. Antigen E-mmH (described
above) was added to a final concentration of 0.150 nM and incubated
for one hour at room temperature. The antibody/Antigen E-mmH
mixture was then added to the plate containing Ligand Y and
incubated for one hour at room temperature. Detection of Antigen
E-mmH bound to Ligand Y was determined with Horse-Radish Peroxidase
(HRP) conjugated to anti-Penta-His antibody (Qiagen, Valencia,
Calif.) and developed by standard colorimetric response using
tetramethylbenzidine (TMB) substrate (BD Biosciences, San Jose,
Calif.) neutralized by sulfuric acid. Absorbance was read at OD450
for 0.1 sec. Background absorbance of a sample without Antigen E
was subtracted from all samples. Percent blocking was calculated by
division of the background-subtracted MFI of each sample by the
adjusted negative control value, multiplying by 100 and subtracting
the resulting value from 100.
[0297] Tables 9 and 10 show the percent blocking for all 98
anti-Antigen E common light chain antibodies tested in the ELISA
assay. ND: not determined under current experimental
conditions.
TABLE-US-00009 TABLE 9 V.kappa.1-39J.kappa.5 Common Light Chain
Antibodies % Blocking of Antibody Antigen E In Solution 2948 21.8
2948G 22.9 2949 79.5 2949G 71.5 2950 80.4 2950G 30.9 2952 66.9
2952G 47.3 2954 55.9 2954G 44.7 2955 12.1 2955G 25.6 2964 34.8
2964G 47.7 2978 90.0 2978G 90.2 2982 59.0 2982G 20.4 2985 10.5
2985G ND 2987 31.4 2987G ND 2996 29.3 2996G ND 2997 48.7 2997G ND
3004 16.7 3004G 3.5 3005 87.2 3005G 54.3 3010 74.5 3010G 84.6 3011
19.4 3011G ND 3012 45.0 3012G 12.6 3013 39.0 3013G 9.6 3014 5.2
3014G 17.1 3015 23.7 3015G 10.2 3016 78.1 3016G 37.4 3017 61.6
3017G 25.2 3018 40.6 3018G 14.5 3019 94.6 3019G 92.3 3020 80.8
3020G ND 3021 7.6 3021G 20.7 3022 2.4 3022G 15.0 3023 9.1 3023G
19.2 3024 7.5 3024G 15.2 3025 ND 3025G 13.9 3027 61.4 3027G 82.7
3028 40.3 3028G 12.3 3030 ND 3030G 9.5 3032 ND 3032G 13.1 3033 77.1
3033G 32.9 3036 17.6 3036G 24.6 3041 59.3 3041G 30.7 3042 39.9
3042G 16.1 3043 57.4 3043G 46.1
TABLE-US-00010 TABLE 10 V.kappa.3-20J.kappa.1 Common Light Chain
Antibodies % Blocking of Antibody Antigen E In Solution 2968 68.9
2968G 15.2 2969 10.1 2969G 23.6 2970 34.3 2970G 41.3 2971 6.3 2971G
27.1 2972 9.6 2972G 35.7 2973 20.7 2973G 23.1 2974 ND 2974G 22.0
2975 8.7 2975G 19.2 2976 4.6 2976G 26.7
[0298] As described in this Example, of the 80 common light chain
antibodies containing the V.kappa.1-39J.kappa.5 engineered light
chain tested for their ability to block Antigen E binding to a
Ligand Y-coated surface, 22 demonstrated >50% blocking, while 58
demonstrated <50% blocking (20 at 25-50% blocking and 38 at
<25% blocking). For the 18 common light chain antibodies
containing the V.kappa.3-20J.kappa.1 engineered light chain, one
demonstrated >50% blocking, while 17 demonstrated <50%
blocking (5 at 25-50% blocking and 12 at <25% blocking) of
Antigen E binding to a Ligand Y-coated surface.
[0299] These results are also consistent with the Antigen
E-specific common light chain antibody pool comprising antibodies
with overlapping and non-overlapping epitope specificity with
respect to Antigen E.
Example 9
BIACORE.TM. Affinity Determination for Antigen-Specific Common
Light Chain Antibodies
[0300] Equilibrium dissociation constants (K.sub.D) for selected
antibody supernatants were determined by SPR (Surface Plasmon
Resonance) using a BIACORE.TM. T100 instrument (GE Healthcare). All
data was obtained using HBS-EP (10 mM Hepes, 150 mM NaCl, 0.3 mM
EDTA, 0.05% Surfactant P20, pH 7.4) as both the running and sample
buffers, at 25.degree. C. Antibodies were captured from crude
supernatant samples on a CM5 sensor chip surface previously
derivatized with a high density of anti-human Fc antibodies using
standard amine coupling chemistry. During the capture step,
supernatants were injected across the anti-human Fc surface at a
flow rate of 3 .mu.L/min, for a total of 3 minutes. The capture
step was followed by an injection of either running buffer or
analyte at a concentration of 100 nM for 2 minutes at a flow rate
of 35 .mu.L/min. Dissociation of antigen from the captured antibody
was monitored for 6 minutes. The captured antibody was removed by a
brief injection of 10 mM glycine, pH 1.5. All sensorgrams were
double referenced by subtracting sensorgrams from buffer injections
from the analyte sensorgrams, thereby removing artifacts caused by
dissociation of the antibody from the capture surface. Binding data
for each antibody was fit to a 1:1 binding model with mass
transport using BIAcore T100 Evaluation software v2.1. Results are
shown in Tables 11 and 12.
TABLE-US-00011 TABLE 11 V.kappa.1-39J.kappa.5 Common Light Chain
Antibodies 100 nM Antigen E Antibody K.sub.D (nM) T.sub.1/2 (min)
2948 8.83 28 2948G 95.0 1 2949 3.57 18 2949G 6.37 9 2950 4.91 17
2950G 13.6 5 2952 6.25 7 2952G 7.16 4 2954 2.37 24 2954G 5.30 9
2955 14.4 6 2955G 12.0 4 2964 14.8 6 2964G 13.0 9 2978 1.91 49
2978G 1.80 58 2982 6.41 19 2982G 16.3 9 2985 64.4 9 2985G 2.44 8
2987 21.0 11 2987G 37.6 4 2996 10.8 9 2996G 24.0 2 2997 7.75 19
2997G 151 1 3004 46.5 14 3004G 1.93 91 3005 2.35 108 3005G 6.96 27
3010 4.13 26 3010G 2.10 49 3011 59.1 5 3011G 41.7 5 3012 9.71 20
3012G 89.9 2 3013 20.2 20 3013G 13.2 4 3014 213 4 3014G 36.8 3 3015
29.1 11 3015G 65.9 0 3016 4.99 17 3016G 18.9 4 3017 9.83 8 3017G
55.4 2 3018 11.3 36 3018G 32.5 3 3019 1.54 59 3019G 2.29 42 3020
5.41 39 3020G 41.9 6 3021 50.1 6 3021G 26.8 4 3022 25.7 17 3022G
20.8 12 3023 263 9 3023G 103 5 3024 58.8 7 3024G 7.09 10 3025 35.2
6 3025G 42.5 8 3027 7.15 6 3027G 4.24 18 3028 6.89 37 3028G 7.23 22
3030 46.2 7 3030G 128 3 3032 53.2 9 3032G 13.0 1 3033 4.61 17 3033G
12.0 5 3036 284 12 3036G 18.2 10 3041 6.90 12 3041G 22.9 2 3042
9.46 34 3042G 85.5 3 3043 9.26 29 3043G 13.1 22
TABLE-US-00012 TABLE 12 V.kappa.3-20J.kappa.1 Common Light Chain
Antibodies 100 nM Antigen E Antibody K.sub.D (nM) T.sub.1/2 (min)
2968 5.50 8 2968G 305 0 2969 34.9 2 2969G 181 1 2970G 12.3 3 2971G
32.8 22 2972 6.02 13 2972G 74.6 26 2973 5.35 39 2973G 11.0 44 2974
256 0 2974G 138 0 2975 38.0 2 2975G 134 1 2976 6.73 10 2976G 656
8
[0301] The binding affinities of common light chain antibodies
comprising the rearrangements shown in Tables 5 and 6 vary, with
nearly all exhibiting a K.sub.D in the nanomolar range. The
affinity data is consistent with the common light chain antibodies
resulting from the combinatorial association of rearranged variable
domains described in Tables 5 and 6 being high-affinity, clonally
selected, and somatically mutated. Coupled with data previously
shown, the common light chain antibodies described in Tables 5 and
6 comprise a collection of diverse, high-affinity antibodies that
exhibit specificity for one or more epitopes on Antigen E.
Example 10
Determination of Binding Specificities of Antigen-Specific Common
Light Chain Antibodies by LUMINEX.TM. Assay
[0302] Selected anti-Antigen E common light chain antibodies were
tested for their ability to bind to the ECD of Antigen E and
Antigen E ECD variants, including the cynomolgous monkey ortholog
(Mf Antigen E), which differs from the human protein in
approximately 10% of its amino acid residues; a deletion mutant of
Antigen E lacking the last 10 amino acids from the C-terminal end
of the ECD (Antigen E-ACT); and two mutants containing an alanine
substitution at suspected locations of interaction with Ligand Y
(Antigen E-Ala1 and AntigenE-Ala2). The Antigen E proteins were
produced in CHO cells and each contained a myc-myc-His C-terminal
tag.
[0303] For the binding studies, Antigen E ECD protein or variant
protein (described above) from 1 mL of culture medium was captured
by incubation for 2 hr at room temperature with 1.times.10.sup.6
microsphere (LUMINEX.TM.) beads covalently coated with an anti-myc
monoclonal antibody (MAb 9E10, hybridoma cell line CRL-1729TH;
ATCC, Manassas, Va.). The beads were then washed with PBS before
use. Supernatants containing anti-Antigen E common light chain
antibodies were diluted 1:4 in buffer and added to 96-well filter
plates. A mock supernatant with no antibody was used as negative
control. The beads containing the captured Antigen E proteins were
then added to the antibody samples (3000 beads per well) and
incubated overnight at 4.degree. C. The following day, the sample
beads were washed and the bound common light chain antibody was
detected with a R-phycoerythrin-conjugated anti-human IgG antibody.
The fluorescence intensity of the beads (approximately 100 beads
counted for each antibody sample binding to each Antigen E protein)
was measured with a LUMINEX.TM. flow cytometry-based analyzer, and
the median fluorescence intensity (MFI) for at least 100 counted
beads per bead/antibody interaction was recorded. Results are shown
in Tables 13 and 14.
TABLE-US-00013 TABLE 13 V.kappa.1-39J.kappa.5 Common Light Chain
Antibodies Mean Fluorescence Intensity (MFI) Antigen Antigen
Antigen Antigen Mf Antibody E-ECD E-.DELTA.CT E-Ala1 E-Ala2 Antigen
E 2948 1503 2746 4953 3579 1648 2948G 537 662 2581 2150 863 2949
3706 4345 8169 5678 5142 2949G 3403 3318 7918 5826 5514 2950 3296
4292 7756 5171 4749 2950G 2521 2408 7532 5079 3455 2952 3384 1619
1269 168 911 2952G 3358 1001 108 55 244 2954 2808 3815 7114 5039
3396 2954G 2643 2711 7620 5406 3499 2955 1310 2472 4738 3765 1637
2955G 1324 1802 4910 3755 1623 2964 5108 1125 4185 346 44 2964G
4999 729 4646 534 91 2978 6986 2800 14542 10674 8049 2978G 5464
3295 11652 8026 6452 2982 4955 2388 13200 9490 6772 2982G 3222 2013
8672 6509 4949 2985 1358 832 4986 3892 1669 2985G 43 43 128 244 116
2987 3117 1674 7646 5944 2546 2987G 3068 1537 9202 6004 4744 2996
4666 1917 12875 9046 6459 2996G 2752 1736 8742 6150 4873 2997 5164
2159 12167 8361 5922 2997G 658 356 3392 2325 1020 3004 2794 1397
8542 6268 3083 3004G 2753 1508 8267 5808 4345 3005 5683 2221 12900
9864 5868 3005G 4344 2732 10669 7125 5880 3010 4829 1617 2642 3887
44 3010G 3685 1097 2540 3022 51 3011 2859 2015 7855 5513 3863 3011G
2005 1072 6194 4041 3181 3012 3233 2221 8543 5637 3307 3012G 968
378 3115 2261 1198 3013 2343 1791 6715 4810 2528 3013G 327 144 1333
1225 370 3014 1225 1089 5436 3621 1718 3014G 1585 851 5178 3705
2411 3015 3202 2068 8262 5554 3796 3015G 1243 531 4246 2643 1611
3016 4220 2543 8920 5999 5666 3016G 2519 1277 6344 4288 4091 3017
3545 2553 8700 5547 5098 3017G 1972 1081 5763 3825 3038 3018 2339
1971 6140 4515 2293 3018G 254 118 978 1020 345 3019 5235 1882 7108
4249 54 3019G 4090 1270 4769 3474 214 3020 3883 3107 8591 6602 4420
3020G 2165 1209 6489 4295 2912 3021 1961 1472 6872 4641 2742 3021G
2091 1005 6430 3988 2935 3022 2418 793 7523 2679 36 3022G 2189 831
6182 3051 132 3023 1692 1411 5788 3898 2054 3023G 1770 825 5702
3677 2648 3024 1819 1467 6179 4557 2450 3024G 100 87 268 433 131
3025 1853 1233 6413 4337 2581 3025G 1782 791 5773 3871 2717 3027
4131 1018 582 2510 22 3027G 3492 814 1933 2596 42 3028 4361 2545
9884 5639 975 3028G 2835 1398 7124 3885 597 3030 463 277 1266 1130
391 3030G 943 302 3420 2570 1186 3032 2083 1496 6594 4402 2405
3032G 295 106 814 902 292 3033 4409 2774 8971 6331 5825 3033G 2499
1234 6745 4174 4210 3036 1755 1362 6137 4041 1987 3036G 2313 1073
6387 4243 3173 3041 3674 2655 8629 5837 4082 3041G 2519 1265 6468
4274 3320 3042 2653 2137 7277 5124 3325 3042G 1117 463 4205 2762
1519 3043 3036 2128 7607 5532 3366 3043G 2293 1319 6573 4403
3228
TABLE-US-00014 TABLE 14 V.kappa.3-20J.kappa.1 Common Light Chain
Antibodies Mean Fluorescence Intensity (MFI) Antigen Antigen
Antigen Antigen Mf Antibody E-ECD E-.DELTA.CT E-Ala1 E-Ala2 Antigen
E 2968 6559 3454 14662 3388 29 2968G 2149 375 9109 129 22 2969 2014
1857 7509 5671 3021 2969G 1347 610 6133 4942 2513 2970 5518 1324
14214 607 32 2970G 4683 599 12321 506 31 2971 501 490 2506 2017 754
2971G 578 265 2457 2062 724 2972 2164 2158 8408 6409 3166 2972G
1730 992 6364 4602 2146 2973 3527 1148 3967 44 84 2973G 1294 276
1603 28 44 2974 1766 722 8821 241 19 2974G 2036 228 8172 135 26
2975 1990 1476 8669 6134 2468 2975G 890 315 4194 3987 1376 2976 147
140 996 1079 181 2976G 1365 460 6024 3929 1625
[0304] The anti-Antigen E common light chain antibody supernatants
exhibited high specific binding to the beads linked to Antigen
E-ECD. For these beads, the negative control mock supernatant
resulted in negligible signal (<10 MFI) when combined with the
Antigen E-ECD bead sample, whereas the supernatants containing
anti-Antigen E common light chain antibodies exhibited strong
binding signal (average MFI of 2627 for 98 antibody supernatants;
MFI >500 for 91/98 antibody samples).
[0305] As a measure of the ability of the selected anti-Antigen E
common light chain antibodies to identify different epitopes on the
ECD of Antigen E, the relative binding of the antibodies to the
variants were determined. All four Antigen E variants were captured
to the anti-myc LUMINEX.TM. beads as described above for the native
Antigen E-ECD binding studies, and the relative binding ratios
(MFI.sub.variant/MFI.sub.Antigen E-ECD) were determined. For 98
tested common light chain antibody supernatants shown in Tables 12
and 13, the average ratios (MFI.sub.variant/MFI.sub.Antigen E-ECD)
differed for each variant, likely reflecting different capture
amounts of proteins on the beads (average ratios of 0.61, 2.9, 2.0,
and 1.0 for Antigen E-ACT, Antigen E-Ala1, Antigen E-Ala2, and Mf
Antigen E, respectively). For each protein variant, the binding for
a subset of the 98 tested common light chain antibodies showed
greatly reduced binding, indicating sensitivity to the mutation
that characterized a given variant. For example, 19 of the common
light chain antibody samples bound to the Mf Antigen E with
MFI.sub.variant/MFI.sub.Antigen E-ECD of <8%. Since many in this
group include high or moderately high affinity antibodies (5 with
K.sub.D<5 nM, 15 with K.sub.D<50 nM), it is likely that the
lower signal for this group results from sensitivity to the
sequence (epitope) differences between native Antigen E-ECD and a
given variant rather than from lower affinities.
[0306] These data establish that the common light chain antibodies
described in Tables 5 and 6 represent a diverse group of
Antigen-E-specific common light chain antibodies that specifically
recognize more than one epitope on Antigen E.
Example 11
Light Chain Shuffling in Common Light Chain Antibodies
[0307] Heavy chains of selected antigen-specific common light chain
antibodies were tested for binding to Antigen E after repairing the
heavy chains with either a germline V.kappa.1-39J.kappa.5 or a
germline V.kappa.3-20J.kappa.1 engineered light chain (as described
in Example 1).
[0308] Briefly, 247 heavy chains of Antigen E-specific common light
chain antibodies (V.kappa.1-39J.kappa.5 and V.kappa.3-20J.kappa.1)
were transfected with either a germline V.kappa.1-39 or a germline
V.kappa.3-20 engineered light chain and rescreened for binding to
Antigen E by a LUMINEX.TM. assay (as described in Example 7 and
Example 10). Binding to Antigen E was confirmed by BIACORE.TM. (as
described in Example 9). The results are shown in Table 15.
[0309] As shown in this Example, twenty-eight common light chain
antibodies specific for Antigen E were capable of binding to
Antigen E when repaired with a germline form of the light
chain.
TABLE-US-00015 TABLE 15 Original Repaired No. No. Confirmed Light
Chain Light Chain Tested Binders 1-39 1-39 198 23 3-20 3-20 49
5
Example 12
Heavy Chain Gene Usage and Somatic Hypermutation Frequency in
Common Light Chain Antibodies
[0310] Heavy and light chain sequences (>6000) of antibodies
raised in VELCOIMMUNE.RTM. mice (e.g., U.S. Pat. No. 6,596,541 and
U.S. Pat. No. 7,105,348) were compiled with heavy and light chain
sequences (>600) of common light chain antibodies obtained by a
multi-antigen immunization scheme employing the engineered light
chain mice (described above) to compare heavy chain gene segment
usage and somatic hypermutation frequencies of the antibody
chains.
[0311] Heavy Chain Gene Usage.
[0312] Heavy and light chain sequences obtained from
VELOCIMMUNE.RTM. mice containing a replacement of the endogenous
mouse heavy chain locus with human V.sub.H, D.sub.H, and J.sub.H
gene segments and a replacement of the endogenous mouse .kappa.
light chain locus with either the engineered germline
V.kappa.1-39J.kappa.5 human light chain region or the engineered
germline V.kappa.3-20J.kappa.1 human light chain region (as
described in Example 2) immunized with a human cell-surface
receptor (Antigen E), a heterodimer of two human cell-surface
glycoproteins (Antigen F), a human cytokine receptor (Antigen G)
and a human tumor differentiation antigen (Antigen H) were analyzed
for heavy chain gene segment usage and V.sub.H and J.sub.H gene
segments were recorded. Results are shown in Tables 16-18.
Percentages in Tables 16-18 represent rounded values and in some
cases may not equal 100% when added together.
[0313] Table 16 sets forth the percent heavy chain family usage for
antibodies from VELCOIMMUNE.RTM. mice (VI), antibodies from
VELCOIMMUNE.RTM. mice having a cognate V.kappa.1-39 light chain
(VI-V.kappa.1-39), antibodies from V.kappa.1-39 engineered light
chain mice (V.kappa.1-39), antibodies from VELCOIMMUNE.RTM. mice
having a cognate V.kappa.3-20 light chain (VI-V.kappa.3-20), and
antibodies from V.kappa.3-20 engineered light chain mice
(V.kappa.3-20). Table 17 sets forth the percent V.sub.H and J.sub.H
gene usage for antibodies from VELCOIMMUNE.RTM. mice (VI),
antibodies from VELCOIMMUNE.RTM. mice having a cognate V.kappa.1-39
light chain (VI-V.kappa.1-39), antibodies from V.kappa.1-39
engineered light chain mice (V.kappa.1-39), antibodies from
VELCOIMMUNE.RTM. mice having a cognate V.kappa.3-20 light chain
(VI-V.kappa.3-20), and antibodies from V.kappa.3-20 engineered
light chain mice (V.kappa.3-20). Table 18 sets forth the percent
V.sub.H gene usage for antibodies from V.kappa.1-39 engineered
light chain mice (V.kappa.1-39 Mice) from each immunization group
(Antigens E, F, G and H) and the percent V.sub.H gene usage for
antibodies from V.kappa.3-20 engineered light chain mice
(V.kappa.3-20 Mice) from selected immunization groups (Antigens E
and G).
[0314] As shown in this Example, heavy chain gene usage for
antigens tested in V.kappa.1-39J.kappa.5-engineered light chain
mice was characterized by a preponderance of V.sub.H family III
subgroups (V.sub.H3-7, V.sub.H3-9, V.sub.H3-11, V.sub.H3-13,
V.sub.H3-20, V.sub.H3-23, V.sub.H3-30, V.sub.H3-33 and
V.sub.H3-48). Notable usage of other V.sub.H family subgroups was
characterized by usage of V.sub.H1-18, V.sub.H1-69, V.sub.H2-5,
V.sub.H4-59 and V.sub.H6-1. For antigens tested in
V.kappa.3-20J.kappa.1 engineered light chain mice, heavy chain gene
usage was characterized by a preponderance of V.sub.H family III,
V.sub.H family IV and V.sub.H family V subgroups (V.sub.H3-11,
V.sub.H3-30, V.sub.H3-33, V.sub.H4-39, V.sub.H4-59 and
V.sub.H5-51). Notable usage of other V.sub.H family subgroups was
characterized by usage of V.sub.H1-18, V.sub.H1-69, V.sub.H2-70 and
V.sub.H6-1.
[0315] Somatic Hypermutation Frequency.
[0316] Heavy and light chains from antibodies raised in
VELCOIMMUNE.RTM. mice and the engineered light chain mice
(described above) were aligned to germline sequences according to
the heavy and light chain gene usage demonstrated for each heavy
and/or light chain. Amino acid changes for each framework region
(FW) and complementarity determining region (CDR) for both heavy
and light chain of each sequence were calculated. Results are shown
in Tables 19-22. Percentages in Tables 21-24 represent rounded
values and in some cases may not equal 100% when added
together.
[0317] Table 19 sets forth the number of amino acid (AA) changes
observed in each FW and CDR region of heavy chains of antibodies
from VELCOIMMUNE.RTM. mice, heavy chains of antibodies from
V.kappa.1-39 engineered light chain mice (V.kappa.1-39 Mice) and
heavy chains of antibodies from V.kappa.3-20 engineered light chain
mice (V.kappa.3-20 Mice). Table 20 sets forth the number of amino
acid (AA) changes observed in each FW and CDR region of light
chains of antibodies from VELCOIMMUNE.RTM. mice, the light chain of
antibodies from V.kappa.1-39 engineered mice (V.kappa.1-39 Mice)
and the light chain of antibodies from V.kappa.3-20 engineered mice
(V.kappa.3-20 Mice). Table 21 sets forth the number of amino acid
(AA) changes observed in each FW and CDR region of heavy chains of
antibodies from V.kappa.1-39 engineered light chain mice
(V.kappa.1-39 Mice) for selected immunization groups (Antigens E, F
and H). Table 22 sets forth the number of amino acid (AA) changes
observed in each FW and CDR region of heavy chains of antibodies
from V.kappa.3-20 engineered light chain mice (V.kappa.3-20 Mice)
for selected immunization groups (Antigens E and G).
TABLE-US-00016 TABLE 16 V.sub.H Family VI VI-V.kappa.1-39
V.kappa.1-39 VI-V.kappa.3-20 V.kappa.3-20 1 9.0 14.8 3.3 7.1 4.9 2
2.2 1.8 4.6 0 1.6 3 77.8 69.8 77.3 61.4 29.5 4 8.4 8.3 11.2 27.1
39.3 5 0.9 0 0.7 4.3 23.0 6 1.7 5.3 3.0 0 1.6
TABLE-US-00017 TABLE 17 VI VI-V.kappa.1-39 V.kappa.1-39
VI-V.kappa.3-20 V.kappa.3-20 V.sub.H Gene 1-2 3.9 8.3 0 2.9 0 1-3 0
0 0 0 0 1-8 1.3 0.6 0 1.4 0 1-18 3.0 0.6 1.3 2.1 1.6 1-24 0.4 3.6 0
0.7 0 1-46 0.1 0 0 0 0 1-58 0 0 0 0 0 1-69 0.3 1.8 2.0 0 3.3 2-5
1.9 0 4.6 0 0 2-26 0.2 1.8 0.0 0 0 2-70 0.1 0 0 0 1.6 3-7 3.0 14.8
0 1.4 0 3-9 8.5 3.6 29.6 16.4 0 3-11 5.4 10.7 0 7.1 1.6 3-13 3.2
1.8 0.7 2.1 0 3-15 4.0 4.7 0.3 0.7 0 3-20 1.0 0.6 0.3 5.0 0 3-21
0.8 0.6 0 2.1 0 3-23 20.4 8.9 3.3 8.6 0 3-30 17.6 4.1 35.2 12.9 1.6
3-33 12.6 14.8 0 5.0 26.2 3-43 0.2 0.6 0 0 0 3-48 0.8 1.2 7.2 0 0
3-53 0.3 3.6 0.3 0 0 3-64 0 0 0.3 0 0 3-72 0 0 0 0 0 3-73 0 0 0 0 0
4-31 2.7 0 0.7 8.6 0 4-34 1.8 0.6 0.3 14.3 0 4-39 1.6 0.6 3.0 2.1
14.8 4-59 2.3 7.1 7.2 2.1 24.6 5-51 0.9 0 0.7 4.3 23.0 6-1 1.7 5.3
3.0 0 1.6 J.sub.H Gene 1 1.5 1.2 7.1 0 0 2 4.5 2.4 0.7 5.0 26.9 3
10.5 16.6 13.1 13.6 26.9 4 44.0 34.3 32.3 50.7 9.6 5 9.6 10.1 16.8
7.9 1.9 6 29.7 35.5 30.0 22.9 34.6
TABLE-US-00018 TABLE 18 V.kappa.1-39 Mice V.kappa.3-20 Mice Antigen
Antigen Antigen Antigen Antigen Antigen V.sub.H Gene E F G H E G
1-2 0 0 0 0 0 0 1-3 0 0 0 0 0 0 1-8 0 0 0 0 0 0 1-18 0 0 0 8.3 0
3.1 1-24 0 0 0 0 0 0 1-46 0 0 0 0 0 0 1-58 0 0 0 0 0 0 1-69 2.9 0
25.0 0 0 6.3 2-5 8.2 0 0 0 0 0 2-26 0 0 0 0 0 0 2-70 0 0 0 0 0 3.1
3-7 0 0 0 0 0 0 3-9 1.2 98.8 0 14.6 0 0 3-11 0 0 0 0 0 3.1 3-13 0.6
0 25.0 0 0 0 3-15 0 1.2 0 0 0 0 3-20 0 0 25.0 0 0 0 3-21 0 0 0 0 0
0 3-23 4.1 0 25.0 4.2 0 0 3-30 62.9 0 0 0 3.4 0 3-33 0 0 0 0 13.8
37.5 3-43 0 0 0 0 0 0 3-48 0.6 0 0 43.8 0 0 3-53 1.6 0 0 0 0 0 3-64
1.6 0 0 0 0 0 3-72 0 0 0 0 0 0 3-73 0 0 0 0 0 0 4-31 0 0 0 4.2 0 0
4-34 0 0 0 2.1 0 0 4-39 5.3 0 0 0 31.0 0 4-59 11.8 0 0 4.2 3.4 43.8
5-51 1.2 0 0 0 48.3 0 6-1 0 0 0 18.8 0 3.1
TABLE-US-00019 TABLE 19 Heavy Chains of Antibodies from VELCOIMMUNE
.RTM. Mice # AA Changes FW1 CDR1 FW2 CDR2 FW3 CDR3 0 63 32 36 26 12
82 1 23 32 41 31 22 17 2 9 25 17 23 27 1 3 4 10 5 16 13 0 4 0 1 1 3
12 0 >5 1 0 0 1 14 0 Heavy Chains of Antibodies from
V.kappa.1-39 Mice # AA Changes FW1 CDR1 FW2 CDR2 FW3 CDR3 0 65 8 34
30 9 37 1 25 26 35 34 19 54 2 9 44 23 20 33 9 3 1 19 8 12 22 0 4 0
3 0 5 11 0 >5 1 0 0 0 7 0 Heavy Chains of Antibodies from
V.kappa.3-20 Mice #AA Changes FW1 CDR1 FW2 CDR2 FW3 CDR3 0 57 8 54
16 8 93 1 41 43 34 39 21 7 2 2 25 10 18 20 0 3 0 15 2 21 13 0 4 0
10 0 3 20 0 >5 0 0 0 2 18 0
TABLE-US-00020 TABLE 20 Light Chains of Antibodies from VELCOIMMUNE
.RTM. Mice # AA Changes FW1 CDR1 FW2 CDR2 FW3 CDR3 0 65 24 49 60 33
23 1 24 20 34 31 27 38 2 9 27 16 9 18 28 3 1 20 1 0 14 7 4 0 7 0 0
4 3 >5 1 1 0 0 3 0 Light Chains of Antibodies from V.kappa.1-39
Mice # AA Changes FW1 CDR1 FW2 CDR2 FW3 CDR3 0 91 75 80 90 71 63 1
9 19 17 10 21 27 2 0 5 1 1 5 8 3 0 0 1 0 2 1 4 0 0 0 0 2 1 >5 0
0 0 0 0 0 Light Chains of Antibodies from V.kappa.3-20 Mice #AA
Changes FW1 CDR1 FW2 CDR2 FW3 CDR3 0 90 47 93 97 63 57 1 10 27 3 3
20 43 2 0 27 3 0 17 0 3 0 0 0 0 0 0 4 0 0 0 0 0 0 >5 0 0 0 0 0
0
TABLE-US-00021 TABLE 21 Heavy Chains of Anti-Antigen E Antibodies
from V.kappa.1-39 Mice # AA Changes FW1 CDR1 FW2 CDR2 FW3 CDR3 0 75
8 49 41 14 36 1 21 25 33 35 25 52 2 4 43 14 18 28 12 3 0 20 4 5 16
0 4 0 5 0 1 12 0 >5 1 0 0 0 5 0 Heavy Chains of Anti-Antigen F
Antibodies from V.kappa.1-39 Mice # AA Changes FW1 CDR1 FW2 CDR2
FW3 CDR3 0 52 0 6 6 2 15 1 35 24 32 35 15 78 2 11 59 46 22 49 7 3 0
17 16 24 29 0 4 0 0 0 12 4 0 >5 1 0 0 0 1 0 Heavy Chains of
Anti-Antigen H Antibodies from V.kappa.1-39 Mice # AA Changes FW1
CDR1 FW2 CDR2 FW3 CDR3 0 54 21 29 33 4 77 1 17 35 50 27 6 23 2 23
21 15 21 25 0 3 6 21 4 15 27 0 4 0 2 2 2 15 0 >5 0 0 0 2 23
0
TABLE-US-00022 TABLE 22 Heavy Chains of Anti-Antigen E Antibodies
from V.kappa.3-20 Mice # AA Changes FW1 CDR1 FW2 CDR2 FW3 CDR3 0 79
17 62 24 17 90 1 21 28 34 55 31 10 2 0 28 3 21 24 0 3 0 14 0 0 10 0
4 0 14 0 0 3 0 >5 0 0 0 0 14 0 Heavy Chains of Anti-Antigen G
Antibodies from V.kappa.3-20 Mice # AA Changes FW1 CDR1 FW2 CDR2
FW3 CDR3 0 38 0 47 9 0 97 1 59 56 34 25 13 3 2 3 22 16 16 16 0 3 0
16 3 41 16 0 4 0 6 0 6 34 0 >5 0 0 0 3 22 0
Example 13
Binding Affinity of Bispecific Antibodies Having Universal Light
Chains
[0318] Fully human bispecific antibodies were constructed from
cloned human heavy chain variable regions of selected monospecific
anti-Antigen E common light chain antibodies (described in Example
5) using standard recombinant DNA techniques known in the art.
Table 23 sets forth the pairing of human heavy chains (HC-1 and
HC-2) from selected parental monospecific antibodies, each pair
employed with a germline rearranged human V.kappa.1-39/J.kappa.1
light chain for construction of each bispecific antibody.
[0319] Binding of bispecific or parental monospecific anti-Antigen
E antibodies to the extracellular domain (ECD) of Antigen E was
determined using a real-time surface plasmon resonance biosensor
assay on a BIACORE.TM. 2000 instrument (GE Healthcare). A CM5
BIACORE.TM. sensor surface derivatized with anti-c-myc-specific
monoclonal antibody (Clone#9E10) using EDC-NHS chemistry was used
to capture the C-terminal myc-myc-hexahistidine tagged ECD of
Antigen E (AntigenE-mmh). Around 190 RUs of AntigenE-mmh was
captured on the BIACORE.TM. sensor surface, followed by the
injection of 300 nM and 50 nM concentrations of different
bispecific or parental monospecific anti-Antigen E antibodies at a
flow rate of 50 .mu.l/min. The experiment was performed at
25.degree. C. in HBST running buffer (0.01 M HEPES pH 7.4, 0.15M
NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20). The amount of antibody
binding to AntigenE-mmh surface at 300 nM concentration was
recorded three seconds before the end of antibody injection and
plotted.
[0320] Table 24 and FIG. 8 set forth the binding responses
(BIACORE.TM. units; RU) observed for each bispecific antibody
(BsAb) and monospecific parental antibody (PAb-1, PAb-2). Since
each antibody was injected under saturating conditions over an
identical AntigenE-mmh surface, the binding response reflects the
binding stoichiometry for each antibody binding to the antigen
capture surface.
[0321] As shown in this Example, the observed binding response for
each bispecific antibody was approximately 2-fold greater than the
binding response for each parental monospecific antibody (Table 24
and FIG. 8), demonstrating functional construction of bispecific
antibodies using heavy chains of antigen-specific monoclonal
antibodies and a common light chain where each Fab arm in the
bispecific antibody molecule binds simultaneously to distinct
epitopes on the extracellular domain of a cell surface receptor
(Antigen E; see FIG. 7B, bottom left).
TABLE-US-00023 TABLE 23 Bispecific Antibody Parent HC-1 Parent HC-2
3108 2952 2978 3109 2978 3022 3111 2952 3005 3112 3022 3005
TABLE-US-00024 TABLE 24 Binding Response (RU) Bispecific Antibody
PAb-1 PAb-2 BsAb 3108 236 229 485 3109 236 197 408 3111 202 229 435
3112 202 197 345
Sequence CWU 1
1
3313155DNAArtificial SequenceSynthetic 1ggcgcgccgt agctttgaat
tttaaacatc tatttgacaa gaaatgcata gttccttctc 60tttaaaataa tgtaatgttt
ctttcaagaa taagcttggt ttgatgcctc tctccccaac 120atgatagaag
tgtagcataa atctatgaaa aattccattt ccctgtgcct acaacaacta
180cctgggattg aaaacttctt cccttgctct agtcctttct tctacaccta
cttccacatc 240atctgtgact caaaacaata cttgtcagga aagatcccgg
aaagagcaaa aaagacttcc 300ttagaggtgt cagagattcc tatgccacta
tctgtcatct ctagaagggg ttgtgagtat 360gaggaagagc agagcttgta
aattttctac ttgctttgac ttccactgta tttcctaaca 420acaacaacca
cagcaacacc cataacatca caggacaaac ttctagtact tccaaggctt
480tagtctcagt aaatcttctc tacctccatc acagcagcta gaaggtttga
tactcataca 540aatagtactg tagctttctg ttcataattg gaaaaataga
caagacccaa tgtaatacag 600gctttccttc agccagttag cgttcagttt
ttggatcacc attgcacaca tatacccagc 660atatgtctaa tatatatgta
gaaatccgtg aagcaagagt tataatagct tgtgttttct 720attgtattgt
attttcctct tatatcatct tcttcttcgt tcattaaaaa aaaaccgttc
780aagtaggtct aaattaatta ttggatcata agtagataaa atattttatt
tcataacaca 840ttgacccgat gaatatgttt ctttgccaga catagtcctc
atttccaagg taacaagcct 900gaaaaaatta tactggagca agtcaacagg
taatgatggt agcttttcct tattgtcctg 960gggcaagaat aagacaaaag
ataacagggt agaataaaga ttgtgtaaga aagaaggaca 1020gcaacaggac
atgggaacct tttatagagt aacattttga taatggatga tgagaattaa
1080tgagttagac agggatgggt gggaatgatt gaaggtgtga gtactttagc
acagattaag 1140accaaatcat taggatttaa agagttgtgt agagttagtg
aaggaaaagc cttagaatta 1200aatttggctg cggataaaac attcttggat
tagactgaag actcttttct gtgctaagta 1260agtatattta tgataatgat
gatgactgta gtgctgaata tttaataaat aaaaacaaaa 1320ttaattgccg
catacataat gtcctgaata ctattgtaaa tgttttatct tatttccttt
1380aaactgtcta cagcactata aggtaggtac cagtattgtc acagttacac
agatatggaa 1440accgagacac agggaagtta agttacttga tcaatttcaa
gcaatcggca agccatggag 1500catctatgtc agggctgcca ggacatgtga
ctgtaaacag aagtttttca ctttttaact 1560caaagagggt atgtggctgg
gttaatggaa agcttcagga ccctcagaaa acattactaa 1620caagcaaatg
aaaggtgtat ctggaagatt aagttttaac agactcttca tttccatcga
1680tccaataatg cacttaggga gatgactggg catattgagg ataggaagag
agaagtgaaa 1740acacagcttt ttatattgtt cttaacaggc ttgtgccaaa
catcttctgg gtggatttag 1800gtgattgagg agaagaaaga cacaggagcg
aaattctctg agcacaaggg aggagttcta 1860cactcagact gagccaacag
acttttctgg cctgacaacc agggcggcgc aggatgctca 1920gtgcagagag
gaagaagcag gtggtctttg cagctgaaag ctcagctgat ttgcatatgg
1980agtcattata caacatccca gaattcttta agggcagctg ccaggaagct
aagaagcatc 2040ctctcttcta gctctcagag atggagacag acacactcct
gctatgggtg ctgctgctct 2100gggttccagg tgagggtaca gataagtgtt
atgagcaacc tctgtggcca ttatgatgct 2160ccatgcctct ctgttcttga
tcactataat tagggcattt gtcactggtt ttaagtttcc 2220ccagtcccct
gaattttcca ttttctcaga gtgatgtcca aaattattct taaaaattta
2280aatgaaaagg tcctctgctg tgaaggcttt taaagatata taaaaataat
ctttgtgttt 2340atcattccag gtgccagatg tgacatccag atgacccagt
ctccatcctc cctgtctgca 2400tctgtaggag acagagtcac catcacttgc
cgggcaagtc agagcattag cagctattta 2460aattggtatc agcagaaacc
agggaaagcc cctaagctcc tgatctatgc tgcatccagt 2520ttgcaaagtg
gggtcccatc aaggttcagt ggcagtggat ctgggacaga tttcactctc
2580accatcagca gtctgcaacc tgaagatttt gcaacttact actgtcaaca
gagttacagt 2640acccctccga tcaccttcgg ccaagggaca cgactggaga
ttaaacgtaa gtaatttttc 2700actattgtct tctgaaattt gggtctgatg
gccagtattg acttttagag gcttaaatag 2760gagtttggta aagattggta
aatgagggca tttaagattt gccatgggtt gcaaaagtta 2820aactcagctt
caaaaatgga tttggagaaa aaaagattaa attgctctaa actgaatgac
2880acaaagtaaa aaaaaaaagt gtaactaaaa aggaaccctt gtatttctaa
ggagcaaaag 2940taaatttatt tttgttcact cttgccaaat attgtattgg
ttgttgctga ttatgcatga 3000tacagaaaag tggaaaaata cattttttag
tctttctccc ttttgtttga taaattattt 3060tgtcagacaa caataaaaat
caatagcacg ccctaagatc tagatgcatg ctcgagtgcc 3120atttcattac
ctctttctcc gcacccgaca tagat 3155228DNAArtificial SequenceSynthetic
2aggtgagggt acagataagt gttatgag 28327DNAArtificial
SequenceSynthetic 3tgacaaatgc cctaattata gtgatca 27421DNAArtificial
SequenceSynthetic 4gggcaagtca gagcattagc a 21521DNAArtificial
SequenceSynthetic 5tgcaaactgg atgcagcata g 21619DNAArtificial
SequenceSynthetic 6ggtggagagg ctattcggc 19717DNAArtificial
SequenceSynthetic 7gaacacggcg gcatcag 17823DNAArtificial
SequenceSynthetic 8tgggcacaac agacaatcgg ctg 23929DNAArtificial
SequenceSynthetic 9ccattatgat gctccatgcc tctctgttc
291026DNAArtificial SequenceSynthetic 10atcagcagaa accagggaaa
gcccct 26113166DNAArtificial SequenceSynthetic 11ggcgcgccgt
agctttgaat tttaaacatc tatttgacaa gaaatgcata gttccttctc 60tttaaaataa
tgtaatgttt ctttcaagaa taagcttggt ttgatgcctc tctccccaac
120atgatagaag tgtagcataa atctatgaaa aattccattt ccctgtgcct
acaacaacta 180cctgggattg aaaacttctt cccttgctct agtcctttct
tctacaccta cttccacatc 240atctgtgact caaaacaata cttgtcagga
aagatcccgg aaagagcaaa aaagacttcc 300ttagaggtgt cagagattcc
tatgccacta tctgtcatct ctagaagggg ttgtgagtat 360gaggaagagc
agagcttgta aattttctac ttgctttgac ttccactgta tttcctaaca
420acaacaacca cagcaacacc cataacatca caggacaaac ttctagtact
tccaaggctt 480tagtctcagt aaatcttctc tacctccatc acagcagcta
gaaggtttga tactcataca 540aatagtactg tagctttctg ttcataattg
gaaaaataga caagacccaa tgtaatacag 600gctttccttc agccagttag
cgttcagttt ttggatcacc attgcacaca tatacccagc 660atatgtctaa
tatatatgta gaaatccgtg aagcaagagt tataatagct tgtgttttct
720attgtattgt attttcctct tatatcatct tcttcttcgt tcattaaaaa
aaaaccgttc 780aagtaggtct aaattaatta ttggatcata agtagataaa
atattttatt tcataacaca 840ttgacccgat gaatatgttt ctttgccaga
catagtcctc atttccaagg taacaagcct 900gaaaaaatta tactggagca
agtcaacagg taatgatggt agcttttcct tattgtcctg 960gggcaagaat
aagacaaaag ataacagggt agaataaaga ttgtgtaaga aagaaggaca
1020gcaacaggac atgggaacct tttatagagt aacattttga taatggatga
tgagaattaa 1080tgagttagac agggatgggt gggaatgatt gaaggtgtga
gtactttagc acagattaag 1140accaaatcat taggatttaa agagttgtgt
agagttagtg aaggaaaagc cttagaatta 1200aatttggctg cggataaaac
attcttggat tagactgaag actcttttct gtgctaagta 1260agtatattta
tgataatgat gatgactgta gtgctgaata tttaataaat aaaaacaaaa
1320ttaattgccg catacataat gtcctgaata ctattgtaaa tgttttatct
tatttccttt 1380aaactgtcta cagcactata aggtaggtac cagtattgtc
acagttacac agatatggaa 1440accgagacac agggaagtta agttacttga
tcaatttcaa gcaatcggca agccatggag 1500catctatgtc agggctgcca
ggacatgtga ctgtaaacag aagtttttca ctttttaact 1560caaagagggt
atgtggctgg gttaatggaa agcttcagga ccctcagaaa acattactaa
1620caagcaaatg aaaggtgtat ctggaagatt aagttttaac agactcttca
tttccatcga 1680tccaataatg cacttaggga gatgactggg catattgagg
ataggaagag agaagtgaaa 1740acacagcttt ttatattgtt cttaacaggc
ttgtgccaaa catcttctgg gtggatttag 1800gtgattgagg agaagaaaga
cacaggagcg aaattctctg agcacaaggg aggagttcta 1860cactcagact
gagccaacag acttttctgg cctgacaacc agggcggcgc aggatgctca
1920gtgcagagag gaagaagcag gtggtctttg cagctgaaag ctcagctgat
ttgcatatgg 1980agtcattata caacatccca gaattcttta agggcagctg
ccaggaagct aagaagcatc 2040ctctcttcta gctctcagag atggagacag
acacactcct gctatgggtg ctgctgctct 2100gggttccagg tgagggtaca
gataagtgtt atgagcaacc tctgtggcca ttatgatgct 2160ccatgcctct
ctgttcttga tcactataat tagggcattt gtcactggtt ttaagtttcc
2220ccagtcccct gaattttcca ttttctcaga gtgatgtcca aaattattct
taaaaattta 2280aatgaaaagg tcctctgctg tgaaggcttt taaagatata
taaaaataat ctttgtgttt 2340atcattccag gtgccagatg tataccaccg
gagaaattgt gttgacgcag tctccaggca 2400ccctgtcttt gtctccaggg
gaaagagcca ccctctcctg cagggccagt cagagtgtta 2460gcagcagcta
cttagcctgg taccagcaga aacctggcca ggctcccagg ctcctcatct
2520atggtgcatc cagcagggcc actggcatcc cagacaggtt cagtggcagt
gggtctggga 2580cagacttcac tctcaccatc agcagactgg agcctgaaga
ttttgcagtg tattactgtc 2640agcagtatgg tagctcacct tggacgttcg
gccaagggac caaggtggaa atcaaacgta 2700agtaattttt cactattgtc
ttctgaaatt tgggtctgat ggccagtatt gacttttaga 2760ggcttaaata
ggagtttggt aaagattggt aaatgagggc atttaagatt tgccatgggt
2820tgcaaaagtt aaactcagct tcaaaaatgg atttggagaa aaaaagatta
aattgctcta 2880aactgaatga cacaaagtaa aaaaaaaaag tgtaactaaa
aaggaaccct tgtatttcta 2940aggagcaaaa gtaaatttat ttttgttcac
tcttgccaaa tattgtattg gttgttgctg 3000attatgcatg atacagaaaa
gtggaaaaat acatttttta gtctttctcc cttttgtttg 3060ataaattatt
ttgtcagaca acaataaaaa tcaatagcac gccctaagat ctagatgcat
3120gctcgagtgc catttcatta cctctttctc cgcacccgac atagat
31661219DNAArtificial SequenceSynthetic 12tccaggcacc ctgtctttg
191326DNAArtificial SequenceSynthetic 13aagtagctgc tgctaacact
ctgact 261424DNAArtificial SequenceSynthetic 14aaagagccac
cctctcctgc aggg 24153187DNAArtificial SequenceSynthetic
15ggcgcgccgt agctttgaat tttaaacatc tatttgacaa gaaatgcata gttccttctc
60tttaaaataa tgtaatgttt ctttcaagaa taagcttggt ttgatgcctc tctccccaac
120atgatagaag tgtagcataa atctatgaaa aattccattt ccctgtgcct
acaacaacta 180cctgggattg aaaacttctt cccttgctct agtcctttct
tctacaccta cttccacatc 240atctgtgact caaaacaata cttgtcagga
aagatcccgg aaagagcaaa aaagacttcc 300ttagaggtgt cagagattcc
tatgccacta tctgtcatct ctagaagggg ttgtgagtat 360gaggaagagc
agagcttgta aattttctac ttgctttgac ttccactgta tttcctaaca
420acaacaacca cagcaacacc cataacatca caggacaaac ttctagtact
tccaaggctt 480tagtctcagt aaatcttctc tacctccatc acagcagcta
gaaggtttga tactcataca 540aatagtactg tagctttctg ttcataattg
gaaaaataga caagacccaa tgtaatacag 600gctttccttc agccagttag
cgttcagttt ttggatcacc attgcacaca tatacccagc 660atatgtctaa
tatatatgta gaaatccgtg aagcaagagt tataatagct tgtgttttct
720attgtattgt attttcctct tatatcatct tcttcttcgt tcattaaaaa
aaaaccgttc 780aagtaggtct aaattaatta ttggatcata agtagataaa
atattttatt tcataacaca 840ttgacccgat gaatatgttt ctttgccaga
catagtcctc atttccaagg taacaagcct 900gaaaaaatta tactggagca
agtcaacagg taatgatggt agcttttcct tattgtcctg 960gggcaagaat
aagacaaaag ataacagggt agaataaaga ttgtgtaaga aagaaggaca
1020gcaacaggac atgggaacct tttatagagt aacattttga taatggatga
tgagaattaa 1080tgagttagac agggatgggt gggaatgatt gaaggtgtga
gtactttagc acagattaag 1140accaaatcat taggatttaa agagttgtgt
agagttagtg aaggaaaagc cttagaatta 1200aatttggctg cggataaaac
attcttggat tagactgaag actcttttct gtgctaagta 1260agtatattta
tgataatgat gatgactgta gtgctgaata tttaataaat aaaaacaaaa
1320ttaattgccg catacataat gtcctgaata ctattgtaaa tgttttatct
tatttccttt 1380aaactgtcta cagcactata aggtaggtac cagtattgtc
acagttacac agatatggaa 1440accgagacac agggaagtta agttacttga
tcaatttcaa gcaatcggca agccatggag 1500catctatgtc agggctgcca
ggacatgtga ctgtaaacag aagtttttca ctttttaact 1560caaagagggt
atgtggctgg gttaatggaa agcttcagga ccctcagaaa acattactaa
1620caagcaaatg aaaggtgtat ctggaagatt aagttttaac agactcttca
tttccatcga 1680tccaataatg cacttaggga gatgactggg catattgagg
ataggaagag agaagtgaaa 1740acacagcttt ttatattgtt cttaacaggc
ttgtgccaaa catcttctgg gtggatttag 1800gtgattgagg agaagaaaga
cacaggagcg aaattctctg agcacaaggg aggagttcta 1860cactcagact
gagccaacag acttttctgg cctgacaacc agggcggcgc aggatgctca
1920gtgcagagag gaagaagcag gtggtctttg cagctgaaag ctcagctgat
ttgcatatgg 1980agtcattata caacatccca gaattcttta agggcagctg
ccaggaagct aagaagcatc 2040ctctcttcta gctctcagag atggagacag
acacactcct gctatgggtg ctgctgctct 2100gggttccagg tgagggtaca
gataagtgtt atgagcaacc tctgtggcca ttatgatgct 2160ccatgcctct
ctgttcttga tcactataat tagggcattt gtcactggtt ttaagtttcc
2220ccagtcccct gaattttcca ttttctcaga gtgatgtcca aaattattct
taaaaattta 2280aatgaaaagg tcctctgctg tgaaggcttt taaagatata
taaaaataat ctttgtgttt 2340atcattccag gtgccagatg tgttgtggtc
ctcagccggt gctgcatcag ccgccggcca 2400tgtcctcggc ccttggaacc
acaatccgcc tcacctgcac cctgaggaac gaccatgaca 2460tcggtgtgta
cagcgtctac tggtaccagc agaggccggg ccaccctccc aggttcctgc
2520tgagatattt ctcacaatca gacaagagcc agggccccca ggtcccccct
cgcttctctg 2580gatccaaaga tgtggccagg aacagggggt atttgagcat
ctctgagctg cagcctgagg 2640acgaggctat gtattactgt gctatgcata
actcagtgac gcatgtgttt ggcagcggga 2700cccagctcac cgttttaagt
aagtaatttt tcactattgt cttctgaaat ttgggtctga 2760tggccagtat
tgacttttag aggcttaaat aggagtttgg taaagattgg taaatgaggg
2820catttaagat ttgccatggg ttgcaaaagt taaactcagc ttcaaaaatg
gatttggaga 2880aaaaaagatt aaattgctct aaactgaatg acacaaagta
aaaaaaaaaa gtgtaactaa 2940aaaggaaccc ttgtatttct aaggagcaaa
agtaaattta tttttgttca ctcttgccaa 3000atattgtatt ggttgttgct
gattatgcat gatacagaaa agtggaaaaa tacatttttt 3060agtctttctc
ccttttgttt gataaattat tttgtcagac aacaataaaa atcaatagca
3120cgccctaaga tctagatgca tgctcgagtg ccatttcatt acctctttct
ccgcacccga 3180catagat 31871617DNAArtificial SequenceSynthetic
16tgtcctcggc ccttgga 171720DNAArtificial SequenceSynthetic
17ccgatgtcat ggtcgttcct 201823DNAArtificial SequenceSynthetic
18acaatccgcc tcacctgcac cct 231923DNAArtificial Sequencesynthetic
19agcagtctgc aacctgaaga ttt 232024DNAArtificial Sequencesynthetic
20gtttaatctc cagtcgtgtc cctt 242115DNAArtificial Sequencesynthetic
21cctccgatca ccttc 152220DNAArtificial Sequencesynthetic
22aaaccaggga aagcccctaa 202318DNAArtificial Sequencesynthetic
23atgggacccc actttgca 182419DNAArtificial Sequencesynthetic
24ctcctgatct atgctgcat 192521DNAArtificial Sequencesynthetic
25cagcagactg gagcctgaag a 212621DNAArtificial Sequencesynthetic
26tgatttccac cttggtccct t 212718DNAArtificial Sequencesynthetic
27tagctcacct tggacgtt 182822DNAArtificial Sequencesynthetic
28ctcctcatct atggtgcatc ca 222920DNAArtificial Sequencesynthetic
29gacccactgc cactgaacct 203013DNAArtificial Sequencesynthetic
30ccactggcat ccc 133119DNAArtificial Sequencesynthetic 31tgagcagcac
cctcacgtt 193223DNAArtificial Sequencesynthetic 32gtggcctcac
aggtatagct gtt 233318DNAArtificial Sequencesynthetic 33accaaggacg
agtatgaa 18
* * * * *